Intellectual Developmental Disorder, X-Linked, Syndromic 37

Genetic MONDO:0958322 Pathograph 28 Show in embeddings browser Neurodevelopmental Disorder X-linked Disorder Multiple Congenital Anomaly Syndrome

X-linked syndromic intellectual developmental disorder 37 (MRXS37; OMIM 301118; MONDO:0958322) is a recently delineated neurodevelopmental syndrome caused by germline variants in ZFX at Xp22.11. ZFX encodes a ubiquitously expressed Krueppel-type C2H2 zinc-finger transcription factor that acts as a transcriptional ACTIVATOR, binding a short motif a few hundred base pairs DOWNSTREAM of the transcription start site at the majority of active CpG island promoters, where it promotes productive elongation. The entity was defined in 2024 by a multi-centre cohort of 18 individuals (14 males, 4 females) from 16 unrelated families carrying 11 distinct germline ZFX variants. The core presentation is developmental delay and intellectual disability of variable severity with behavioural abnormalities and hypotonia, set on a recurrent and clinically recognisable facial gestalt (thickened and medially broadened eyebrows, altered facial shape, external eye anomalies, a smooth and/or long philtrum, and ear anomalies) together with a variable burden of congenital anomalies. Two features make this disorder mechanistically distinctive. First, ZFX is one of the small number of human X-linked genes that ESCAPE X inactivation, established since 1989. Both X alleles are therefore normally expressed in females, so a heterozygous female sustains a genuine dosage reduction in every cell rather than the mosaic of wild-type and mutant cells seen for X-inactivated genes. Consistent with this, females are genuinely affected as well as males rather than being obligate silent carriers - although expressivity in females is wide, from apparently unaffected transmitting mothers to syndromic multi-organ presentations, and males are in general more severely affected. This entry therefore annotates the neutral HPO `X-linked inheritance` term rather than asserting X-linked dominant or X-linked recessive. Second, the disorder carries an endocrine/neoplastic arm that is unusual among neurodevelopmental genes. Hyperparathyroidism was found in four founding-cohort families, all of which carried MISSENSE alleles. That observation aligns with the independent finding that recurrent SOMATIC ZFX missense mutations at an arginine hotspot (R786/R787) in the C-terminal zinc-finger region are selected in sporadic parathyroid adenomas, and it is why this entry models two partially separate mechanistic arms rather than one. The allele-class correlation must not be overstated, and this entry deliberately does not state it as a rule. The founding cohort reports hyperparathyroidism in four missense families; it does not report its absence in truncating families, so "found in missense families" is not the same claim as "restricted to missense alleles". A later endocrine series (PMID:40779536) weakens a strict version further: of its three germline ZFX carriers with primary hyperparathyroidism, one carries an IN-FRAME INSERTION rather than a missense allele, and of the two missense carriers one is p.(Arg536Cys), which does not lie in the C-terminal zinc fingers. Both of those are variants of uncertain significance, which is the honest caveat - but the correlation as published is a tendency observed in small numbers, not an established genotype-phenotype rule. See the `zfx_missense_endocrine_gap` discussion. SCOPE / EVIDENCE-MATURITY NOTE - this is a young entity. As of this curation there is no GeneReviews chapter, no Orphanet ORPHA code, no published prevalence estimate, no natural-history study, and no clinical trial; the whole literature is a founding cohort plus a handful of case reports and an endocrine case series. Frequencies are therefore omitted for most phenotypes rather than estimated, and the genotype-phenotype split below is curated as a competing-hypothesis pair, not as settled fact.

Ask OpenScientist

Ask a research question about Intellectual Developmental Disorder, X-Linked, Syndromic 37. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

1
Inheritance
9
Pathophys.
34
Phenotypes
2
Hypotheses
4
Gaps
28
Pathograph
1
Genes
4
Medical Actions
2
Differentials
4
Models
15
References
2
Deep Research
🏷

Classifications

Harrison's Part
NEUROLOGIC GENETICS ENVIRONMENT DISEASE ENDOCRINOLOGY METABOLISM
👪

Inheritance

1
X-linked inheritance HP:0001417
The neutral HPO X-linked term is used deliberately, and neither X-linked dominant nor X-linked recessive is asserted. The reason is that ZFX escapes X inactivation. Both X alleles are normally expressed in females, so a heterozygous female is not a mosaic of wild-type and mutant cells whose phenotype depends on skewing - she has a uniform partial reduction in ZFX activity. Consequently females are genuinely affected rather than obligate silent carriers, which is what the reported female cases show, including a de novo frameshift in a syndromically affected 20-year-old woman. Expressivity in females is nevertheless wide, from apparently unaffected transmitting mothers through to multi-organ syndromic presentations, and males are in general more severely affected than females. The founding cohort included both de novo and inherited variants. Because the number of reported individuals is still small and no penetrance study exists, no numeric penetrance estimate is curated here. Counselling implication drawn by the reporting authors: endocrine testing should be offered even to clinically unaffected females carrying missense variants, because the hyperparathyroidism risk tracks the allele rather than the neurodevelopmental phenotype.
X-linked inheritance Penetrance: INCOMPLETE Expressivity: VARIABLE
Show evidence (4 references)
PMID:2500252 SUPPORT In Vitro
"Transcription analysis of human-rodent hybrid cell lines containing "inactive" human X chromosomes suggests that ZFX escapes X inactivation."
The escape-from-X-inactivation premise that rules out a standard manifesting-carrier framing for heterozygous females.
PMID:41074764 SUPPORT Human Clinical
"Female carriers of pathogenic ZFX variants demonstrate highly variable expressivity, ranging from apparently unaffected individuals to syndromic presentations."
Sources the variable-expressivity and incomplete-penetrance annotation in females.
PMID:41074764 SUPPORT Human Clinical
"Clinical care should include cardiac and endocrine monitoring, with endocrine testing offered to unaffected females carrying missense variants."
Sources the counselling recommendation stated in the description.
+ 1 more reference
◈

Mechanistic Hypotheses

2
Haploinsufficiency / loss of ZFX transcriptional dosage
haploinsufficiency_model CANONICAL
Evidence balance 1 support
Truncating alleles, and by extension the neurodevelopmental phenotype generally, act by reducing the amount of functional ZFX available to activate its CpG island promoter targets, with the elongation defect and the self-renewal defect as the proximate consequences. This is the default model and the one consistent with the cell-line knockdown and knockout data.
Pathograph links
Germline ZFX Truncating Variant -> Impaired ZFX-Dependent Transcriptional Activation at CpG Island Promoters DIRECT Reduced functional ZFX protein lowers occupancy and transactivation at the CpG island promoters that ZFX normally licenses.
Impaired ZFX-Dependent Transcriptional Activation at CpG Island Promoters -> Disrupted Craniofacial Patterning and Congenital Anomaly Formation INDIRECT UNKNOWN INTERMEDIATES The facial gestalt and the congenital-anomaly burden follow from the same transcriptional defect as the neurodevelopmental arm. Indirect with unknown intermediates, and deliberately parented here rather than on the self-renewal node: no study has examined cranial neural crest, pharyngeal-arch patterning, or any other craniofacial developmental programme in ZFX deficiency, so no intermediate can be named and a progenitor route cannot be asserted.
Impaired Stem and Progenitor Cell Self-Renewal -> Disrupted Neurodevelopment INDIRECT UNKNOWN INTERMEDIATES A progenitor-maintenance deficit during development is the proposed route from the transcriptional defect to the neurodevelopmental phenotype. Indirect with unknown intermediates: no neural-progenitor data exist, which is recorded in the zfx_neural_progenitor_gap discussion.
Show evidence (1 reference)
PMID:29429977 SUPPORT In Vitro
"Many genes with promoters bound by ZFX were down-regulated upon ZFX knockdown, supporting the hypothesis that ZFX acts as a transcriptional activator."
The measured result behind the dosage-loss model: reducing ZFX down-regulates the promoters it binds, which is what a haploinsufficiency model predicts.
Altered DNA-binding specificity / gained activity of zinc-finger missense alleles
altered_dna_binding_specificity_model EMERGING
Evidence balance 1 support
Zinc-finger missense alleles are not simple nulls but change which targets are activated and by how much, and this altered activity - rather than reduced dosage - is what predisposes to parathyroid chief cell proliferation. The supporting arguments are that the founding cohort's functional assay showed differential rather than abolished target expression, that hyperparathyroidism has been reported only with missense alleles, and that the somatic parathyroid hotspot is a recurrent missense change without loss of heterozygosity. The direction of effect is explicitly unresolved: the founding paper says "a gain or loss of transcriptional activity" and does not choose.
Pathograph links
Germline ZFX Zinc-Finger Missense Variant -> Parathyroid Chief Cell Proliferation and Adenoma Formation INDIRECT UNKNOWN INTERMEDIATES The endocrine arm. Every founding-cohort family with hyperparathyroidism carried a missense allele, mirroring the recurrent somatic missense hotspot selected in sporadic parathyroid adenomas. The steps between the variant and chief-cell proliferation are not established, hence an indirect edge with unknown intermediates.
Show evidence (1 reference)
PMID:38325380 SUPPORT In Vitro
"DNA-binding domain variants elicited differential expression of a small set of target genes relative to wild-type ZFX in cultured cells, suggesting a gain or loss of transcriptional activity."
The functional observation this hypothesis rests on. PARTIAL because the same sentence declines to resolve the direction, and only a small set of targets was affected.
?

Discussions and Knowledge Gaps

4
Can mouse Zfx models be used to reason about ZFX dosage in human female carriers, given that mouse Zfx is subject to X inactivation while human ZFX escapes it?
HUMAN MODEL MISMATCH zfx_mouse_xci_mismatch
Attached to
pathophysiology#Escape of ZFX from X Inactivation
This is a species difference in the exact variable the human disease mechanism turns on. In humans, ZFX escapes X inactivation, so a heterozygous female has a uniform partial reduction of ZFX in every cell - which is the proposed reason females are genuinely affected rather than silent carriers. In mouse, Zfx is inactivated, so a heterozygous female mouse is a cellular mosaic of wild-type and mutant cells and her phenotype depends on skewing. A heterozygous Zfx mouse therefore does not model a heterozygous ZFX human, and a mild or absent phenotype in such a mouse would be uninformative about human female dosage sensitivity rather than evidence against it. The mouse data used in this entry are from homozygous/conditional deletion in stem cell compartments, where the question does not arise; the mismatch bites for any future heterozygous mouse model.
Proposed experiments
Allele-specific ZFX expression in patient-derived female cells
allele_specific_zfx_expression_female_cells
Measure allele-specific ZFX transcript and protein levels in cells from heterozygous females across the expressivity range, to test whether residual ZFX dosage - rather than X-inactivation skewing, which should not apply to an escape gene - tracks clinical severity.
Humanised or escape-competent mouse model
escape_competent_mouse_model
Assess whether a mouse model engineered so that Zfx escapes inactivation reproduces female dosage sensitivity, isolating escape status as the variable.
Show evidence (2 references)
PMID:2052543 SUPPORT Model Organism
"These results indicate that the mouse Zfx gene is subject to X inactivation."
Establishes the mouse side of the mismatch.
PMID:2500252 SUPPORT In Vitro
"Transcription analysis of human-rodent hybrid cell lines containing "inactive" human X chromosomes suggests that ZFX escapes X inactivation."
Establishes the human side of the mismatch.
Does ZFX loss actually impair neural progenitor self-renewal in the developing human brain, or is the progenitor route to the neurodevelopmental phenotype an inference from embryonic and haematopoietic stem cells?
KNOWLEDGE GAP zfx_neural_progenitor_gap
Attached to
pathophysiology#Impaired Stem and Progenitor Cell Self-Renewal
Every direct measurement of a ZFX self-renewal requirement comes from embryonic stem cells (mouse and human) or adult haematopoietic stem cells. No study has assayed neural progenitors, and no patient-derived neural tissue or organoid model of MRXS37 has been reported. The step from "ZFX maintains stem cell self-renewal" to "ZFX loss disrupts cortical development" is therefore currently an extrapolation across cell type, and the entry marks the causal edge into the neurodevelopmental node PARTIAL for that reason. The alternative that has not been excluded is that the relevant defect is not progenitor depletion at all but a post-mitotic transcriptional deficit in differentiating neurons.
Proposed experiments
Patient-derived iPSC cortical organoids
patient_ipsc_cortical_organoids
Differentiate iPSCs carrying truncating and zinc-finger missense ZFX alleles into cortical organoids and measure neural progenitor proliferation, apoptosis and cell-cycle exit against isogenic controls, distinguishing a progenitor-maintenance defect from a differentiation defect.
ZFX target-gene mapping in human neural progenitors
zfx_target_mapping_neural_progenitors
ChIP-seq and nascent-transcription profiling of ZFX in human neural progenitor cells, to test whether the promoter-proximal pausing mechanism established in cancer cell lines operates on neurodevelopmental target genes.
Show evidence (2 references)
PMID:17448993 SUPPORT Model Organism
"These studies identify Zfx as a shared transcriptional regulator of ESC and HSC, suggesting a common genetic basis of self-renewal in embryonic and adult SC."
Shows the scope of what has actually been demonstrated - embryonic and haematopoietic stem cells - which is precisely the boundary this gap sits at. Marked PARTIAL because it supports the general self-renewal role but says nothing about neural progenitors.
PMID:22879936 SUPPORT In Vitro
"ZFX-overexpressing hESCs resisted spontaneous differentiation but could be directed to differentiate into endodermal and neural cell fates when provided with the appropriate cues."
The closest existing result to a neural readout, and it shows neural differentiation is preserved rather than assaying neural progenitor self-renewal - so the gap stands.
By what developmental route does impaired ZFX transcriptional activation produce the recurrent facial gestalt and the congenital-anomaly burden?
KNOWLEDGE GAP zfx_craniofacial_route_gap
Attached to
pathophysiology#Disrupted Craniofacial Patterning and Congenital Anomaly Formation
The genotype-to-gestalt association is not in doubt - it is the disease definition, and the founding cohort reports the facial features in every subject. What is entirely unexamined is the mechanism. No study has looked at cranial neural crest specification or migration, pharyngeal-arch patterning, or any other craniofacial developmental programme in ZFX deficiency, in any model system. The incoming causal edge is therefore drawn as INDIRECT_UNKNOWN_INTERMEDIATES with PARTIAL evidence: the association is evidenced, the route is not. This is the craniofacial twin of `zfx_neural_progenitor_gap`, and the two may or may not share an intermediate - a common progenitor-maintenance deficit would explain both, but nothing currently rules out a craniofacial-specific transcriptional programme instead.
Proposed experiments
Cranial neural crest differentiation from patient iPSCs
zfx_cranial_neural_crest_differentiation
Differentiate patient-derived and isogenic-control iPSCs down a cranial neural crest lineage and compare specification efficiency, migration and survival, to test whether the gestalt originates in a neural-crest defect at all.
Craniofacial morphometry and facial-primordia target profiling in a ZFX-deficient model
zfx_craniofacial_model_morphometry
Quantitative craniofacial morphometry in a ZFX-deficient model organism, with ZFX target-gene profiling in the developing facial primordia, to identify which ZFX-dependent promoters operate in that tissue.
Do zinc-finger missense alleles cause hyperparathyroidism through gained or altered transcriptional activity, or is the missense-only association an artefact of small numbers?
KNOWLEDGE GAP zfx_missense_endocrine_gap
Attached to
pathophysiology#Germline ZFX Zinc-Finger Missense Variant
The genotype-phenotype claim rests on hyperparathyroidism having been reported in four missense families and in no truncating case. With eighteen founding subjects plus a handful of later reports, and with hyperparathyroidism being an age-dependent finding in a largely paediatric cohort, the absence of endocrine disease among truncating carriers may reflect ascertainment and follow-up rather than biology. The functional data do not settle it either: the founding paper reports "differential expression of a small set of target genes" and explicitly declines to say whether this is gain or loss of activity. Resolving this matters clinically, because it determines whether endocrine surveillance should be offered to all ZFX carriers or only to missense carriers, which is how the current recommendation is written.
Proposed experiments
Prospective endocrine surveillance across allele classes
prospective_endocrine_surveillance_by_allele_class
Longitudinal serum calcium and PTH in an unselected ZFX cohort stratified by allele class, with sufficient follow-up into adulthood to test whether truncating carriers are genuinely spared.
Direction-resolving functional assay in parathyroid-relevant cells
direction_resolving_functional_assay
Compare genome-wide binding and target activation of wild-type ZFX, zinc-finger missense alleles, and null in a parathyroid or endocrine-competent cell model, to determine whether the missense alleles gain targets, lose targets, or redistribute.
Show evidence (2 references)
PMID:38325380 SUPPORT In Vitro
"DNA-binding domain variants elicited differential expression of a small set of target genes relative to wild-type ZFX in cultured cells, suggesting a gain or loss of transcriptional activity."
The functional result that leaves the direction of effect open in the authors' own words, which is the substance of this gap.
PMID:38325380 SUPPORT Human Clinical
"Exome or genome sequencing revealed 11 variants in 18 subjects (14 males and 4 females) from 16 unrelated families."
Sources the cohort size that makes the missense-only association of hyperparathyroidism statistically fragile.
⚙

Pathophysiology

9
Germline ZFX Truncating Variant
Frameshift and nonsense variants distributed across ZFX, accounting for seven of the eleven variants in the founding cohort. These alleles are presumed to act by loss of function, reducing functional ZFX dosage. In a hemizygous male no functional allele remains; in a heterozygous female, because ZFX escapes X inactivation, the remaining wild-type allele is expressed in every cell but cannot be up-regulated to compensate, giving a genuine partial dosage reduction rather than cellular mosaicism.
Haploinsufficiency / loss of ZFX transcriptional dosage
Genetic context allele_type: LOSS_OF_FUNCTION_VARIANT variant_origin: GERMLINE functional_impact_category: LOSS_OF_FUNCTION
Downstream
Impaired ZFX-Dependent Transcriptional Activation at CpG Island Promoters Reduced functional ZFX protein lowers occupancy and transactivation at the CpG island promoters that ZFX normally licenses. Haploinsufficiency / loss of ZFX transcriptional dosage
Show evidence (1 reference)
PMID:38325380 SUPPORT Human Clinical
"Four missense variants were identified in 11 subjects, with seven truncation variants in the remaining individuals."
Establishes the truncating allele class and its share of the founding cohort's variant spectrum.
Germline ZFX Zinc-Finger Missense Variant
Missense variants affecting the C2H2 zinc-finger DNA-binding region of ZFX, which in the founding cohort accounted for four variants but eleven of the eighteen subjects. This allele class is separated from the truncating class because its reported functional consequence is altered rather than simply absent transcriptional output, and because every founding-cohort family with hyperparathyroidism carried a missense allele. It is NOT curated as the only allele class that can produce hyperparathyroidism: a later series reports an in-frame insertion carrier with primary hyperparathyroidism, and the founding cohort never asserts absence of the endocrine phenotype in truncating carriers. The functionally critical fingers are the C-terminal ones: zinc fingers 11-13 are necessary and sufficient for DNA binding, and the somatic parathyroid-adenoma hotspot (R786/R787) lies in the same C-terminal zinc-finger region.
Altered DNA-binding specificity / gained activity of zinc-finger missense alleles
Genetic context allele_type: MISSENSE_VARIANT variant_origin: GERMLINE
DNA-binding transcription factor activity GO:0003700 Gene Ontology (GO) Relation: this pathophysiological event involves this molecular function This pathophysiological event involves dysregulated DNA-binding transcription factor activity (GO:0003700). GO:0003700 is a molecular function from the Gene Ontology. ↕ DYSREGULATED
Downstream
Impaired ZFX-Dependent Transcriptional Activation at CpG Island Promoters DNA-binding-domain missense alleles change the transcriptional output at ZFX target promoters relative to wild-type protein.
Parathyroid Chief Cell Proliferation and Adenoma Formation The endocrine arm. Every founding-cohort family with hyperparathyroidism carried a missense allele, mirroring the recurrent somatic missense hotspot selected in sporadic parathyroid adenomas. The steps between the variant and chief-cell proliferation are not established, hence an indirect edge with unknown intermediates. Altered DNA-binding specificity / gained activity of zinc-finger missense alleles
Show evidence (1 reference)
PMID:32406922 SUPPORT In Vitro
"We found that zinc fingers 11-13 are necessary and sufficient for DNA binding and, in combination with the N terminal region, constitute a functional transactivator."
Maps DNA-binding function to the C-terminal zinc fingers, which is the region in which the disease-associated missense alleles and the somatic parathyroid hotspot both fall.
Escape of ZFX from X Inactivation
ZFX is one of the few human X-linked genes that escape X inactivation, so it is transcribed from both the active and the inactive X in females. This is a constitutive property of the locus rather than a disease event, and it is modelled here because it is what determines the dosage consequence of a heterozygous allele: a female carrier has a uniform partial reduction in ZFX activity in every cell rather than a mosaic of wild-type and mutant cells, which is why females are genuinely affected rather than silent carriers.
Downstream
Impaired ZFX-Dependent Transcriptional Activation at CpG Island Promoters MODULATING, not causing. Note the schema's `causal_link_type` encodes only directness, so it is deliberately left unset here rather than asserting a directness that would misdescribe this edge. Escape from X inactivation is a constitutive normal property of the locus and produces no disease on its own; what it does is set how a heterozygous allele translates into dosage. Because the second allele cannot be recruited by skewed inactivation, heterozygosity in a female produces a uniform partial reduction in ZFX activity rather than a mosaic.
Show evidence (3 references)
PMID:2500252 SUPPORT In Vitro
"Transcription analysis of human-rodent hybrid cell lines containing "inactive" human X chromosomes suggests that ZFX escapes X inactivation."
The original demonstration that human ZFX escapes X inactivation.
PMID:1970799 SUPPORT Other
"ZFX is one of a few genes on the human X chromosome that are known to escape X inactivation."
Independent confirmation of escape status and of the Xp21.3/Xp22.1 localisation. Classified OTHER because the supporting work is linkage and physical mapping rather than a clinical, animal, cell-based, or in silico study.
PMID:39940742 SUPPORT In Vitro
"Forty-five escape genes were differentially expressed between the WT and TS cell lines. Among these, five genes (ATP7A, PHKA1, EBP, ZFX, and SMC1A) were suggested to be implicated in the TS phenotype."
Contemporary confirmation that ZFX is treated as an X-inactivation escape gene. Marked PARTIAL because the paper says these genes were "suggested to be implicated" in the Turner phenotype - a hypothesis about a different disorder - so it corroborates escape status but not any claim about ZFX dosage consequences here.
Impaired ZFX-Dependent Transcriptional Activation at CpG Island Promoters
The convergent molecular node. ZFX binds a short motif roughly 200-250 bp downstream of the transcription start site at the majority of active CpG island promoters - an unusual, architecturally defined binding position inside the transcribed region rather than upstream - and acts there as an activator. Genes whose promoters ZFX occupies are expressed at higher levels, and knockdown reduces their expression. Both the truncating and the missense allele classes converge on degraded or mis-specified output from this promoter-proximal activator function.
Haploinsufficiency / loss of ZFX transcriptional dosage
positive regulation of transcription by RNA polymerase II GO:0045944 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased positive regulation of transcription by RNA polymerase II (GO:0045944). GO:0045944 is a biological process from the Gene Ontology. ↓ DECREASED
RNA polymerase II cis-regulatory region sequence-specific DNA binding GO:0000978 Gene Ontology (GO) Relation: this pathophysiological event involves this molecular function This pathophysiological event involves decreased RNA polymerase II cis-regulatory region sequence-specific DNA binding (GO:0000978). GO:0000978 is a molecular function from the Gene Ontology. ↓ DECREASED
Experimental models
ZFX and ZNF711 CRISPR knockout HEK293T cells CELL LINE Quantifies the transcriptomic consequence of losing ZFX and localises DNA-binding function to zinc fingers 11-13.
Downstream
Increased RNA Polymerase II Promoter-Proximal Pausing Because ZFX binds within the transcribed region just downstream of the TSS, reduced ZFX acts on elongation: polymerase accumulates in the paused state at ZFX-regulated promoters instead of proceeding into productive elongation.
Disrupted Craniofacial Patterning and Congenital Anomaly Formation The facial gestalt and the congenital-anomaly burden follow from the same transcriptional defect as the neurodevelopmental arm. Indirect with unknown intermediates, and deliberately parented here rather than on the self-renewal node: no study has examined cranial neural crest, pharyngeal-arch patterning, or any other craniofacial developmental programme in ZFX deficiency, so no intermediate can be named and a progenitor route cannot be asserted. Haploinsufficiency / loss of ZFX transcriptional dosage
Impaired Stem and Progenitor Cell Self-Renewal Among the programmes ZFX activates is a self-renewal transcriptional module shared by embryonic and adult stem cells, so degraded ZFX output manifests cellularly as a self-renewal defect.
Show evidence (3 references)
PMID:29429977 SUPPORT In Vitro
"Many genes with promoters bound by ZFX were down-regulated upon ZFX knockdown, supporting the hypothesis that ZFX acts as a transcriptional activator."
Establishes ZFX as an activator whose loss reduces target gene expression, which is the premise of this node.
PMID:29429977 SUPPORT In Vitro
"We identified roughly 9000 ZFX binding sites and found that most of the sites are in CpG island promoters."
Genome-wide localisation of ZFX to CpG island promoters, which defines the regulatory territory affected.
PMID:38726870 SUPPORT In Vitro
"The ZFX transcriptional activator binds to CpG island promoters, with a major peak at ∼200-250 bp downstream from transcription start sites."
Specifies the unusual promoter-downstream binding position that makes the elongation mechanism plausible.
Increased RNA Polymerase II Promoter-Proximal Pausing
Reduced ZFX at target promoters increases Pol II pausing and decreases histone H4 acetylation, the two coupled readouts of the proposed mechanism: ZFX recruits H4 acetylation activity and thereby releases polymerase into productive elongation. This is the best-resolved step in the ZFX mechanism and is derived entirely from cell-line work, not from patient tissue.
transcription elongation by RNA polymerase II GO:0006368 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased transcription elongation by RNA polymerase II (GO:0006368). GO:0006368 is a biological process from the Gene Ontology. ↓ DECREASED
Downstream
Impaired Stem and Progenitor Cell Self-Renewal Failure to release paused polymerase at ZFX-dependent promoters lowers output of the self-renewal programme those promoters drive.
Show evidence (2 references)
PMID:38726870 SUPPORT In Vitro
"We used GRO-seq to show that loss or reduction of ZFX increased Pol2 pausing at ZFX-regulated promoters."
The measured result - nascent-transcription profiling showing increased pausing on ZFX reduction - which is the state this node asserts.
PMID:38726870 SUPPORT In Vitro
"Our studies support a model in which ZFX enhances elongation at target promoters by recruiting H4 acetylation complexes and reducing pausing."
Sources the coupled H4-acetylation arm of this node, and the authors' mechanistic interpretation of the pausing result.
Impaired Stem and Progenitor Cell Self-Renewal
In model systems, loss of ZFX selectively impairs self-renewal while leaving differentiation capacity intact, with increased apoptosis and stem-cell-specific up-regulation of stress-inducible genes. The requirement is conserved to human embryonic stem cells, where ZFX behaves as a rheostat setting the balance between self-renewal and differentiation. Extension of this to neural progenitors in the developing human brain is INFERENCE, not observation - no patient-tissue or neural-progenitor data exist for MRXS37, which is recorded as a knowledge gap below. The cell types annotated on this node are therefore deliberately the ones actually assayed, embryonic and haematopoietic stem cells, and NOT neural stem cells, so that the pathograph and anything exported from it do not assert a neural-progenitor claim this entry's own prose declines to make.
Haploinsufficiency / loss of ZFX transcriptional dosage
embryonic stem cell CL:0002322 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves embryonic stem cell (CL:0002322). CL:0002322 is a cell type from the Cell Ontology. hematopoietic stem cell CL:0000037 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves hematopoietic stem cell (CL:0000037). CL:0000037 is a cell type from the Cell Ontology.
stem cell population maintenance GO:0019827 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased stem cell population maintenance (GO:0019827). GO:0019827 is a biological process from the Gene Ontology. ↓ DECREASED cell population proliferation GO:0008283 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased cell population proliferation (GO:0008283). GO:0008283 is a biological process from the Gene Ontology. ↓ DECREASED
Experimental models
ZFX knockdown and overexpression in human embryonic stem cells CELL LINE ZFX knockdown impairs clonal growth and serial replating in human ESCs; overexpression resists spontaneous differentiation.
Animal models
Zfx knockout mouse Mouse recapitulates Establishes the selective self-renewal requirement for Zfx that this pathophysiology node asserts.
Downstream
Disrupted Neurodevelopment A progenitor-maintenance deficit during development is the proposed route from the transcriptional defect to the neurodevelopmental phenotype. Indirect with unknown intermediates: no neural-progenitor data exist, which is recorded in the zfx_neural_progenitor_gap discussion. Haploinsufficiency / loss of ZFX transcriptional dosage
Show evidence (4 references)
PMID:17448993 SUPPORT Model Organism
"The deletion of transcription factor Zfx impaired the self-renewal but not the differentiation capacity of murine ESC; conversely, Zfx overexpression facilitated ESC self-renewal by opposing differentiation."
Establishes the selective self-renewal requirement, with differentiation spared, that defines this node.
PMID:17448993 SUPPORT Model Organism
"Zfx-deficient ESC and HSC showed increased apoptosis and SC-specific upregulation of stress-inducible genes."
The cellular consequence - apoptosis and a stress response - of losing Zfx.
PMID:22879936 SUPPORT In Vitro
"Thus, ZFX acts as a molecular rheostat regulating the balance between self-renewal and differentiation in hESCs, revealing the close evolutionary conservation of the self-renewal mechanisms in murine and human ESCs."
Confirms the requirement in HUMAN cells, which is what licenses using the murine self-renewal result for a human disorder.
+ 1 more reference
Disrupted Neurodevelopment
The neurodevelopmental consequence: global developmental delay and intellectual disability of variable severity, behavioural abnormalities and hypotonia. Structural brain findings reported in individual cases include reduced white matter with a thin corpus callosum and inferior cerebellar vermian hypoplasia. Kept separate from the craniofacial and congenital-anomaly node because they are distinct developmental programmes with distinct evidence, even though both follow from the same upstream transcriptional defect.
nervous system development GO:0007399 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves abnormal nervous system development (GO:0007399). GO:0007399 is a biological process from the Gene Ontology. ⚠ ABNORMAL
brain UBERON:0000955 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in brain (UBERON:0000955). UBERON:0000955 is an anatomical location from the Uberon multi-species anatomy ontology.
Animal models
zfx loss-of-function zebrafish Zebrafish partially recapitulates Reproduces an altered behavioural phenotype, supporting a conserved neurobehavioural role for ZFX.
Downstream
Global developmental delay Disrupted brain development presents clinically as global developmental delay.
Intellectual disability Disrupted brain development presents clinically as intellectual disability.
Hypotonia Hypotonia is part of the neurodevelopmental presentation.
Atypical behavior Behavioural abnormalities are a core component of the neurodevelopmental presentation.
Show evidence (2 references)
PMID:38325380 SUPPORT Human Clinical
"Clinical findings included developmental delay/intellectual disability, behavioral abnormalities, hypotonia, and congenital anomalies."
The core clinical statement of the founding cohort.
PMID:38325380 SUPPORT Human Clinical
"Our clinical and experimental data support that variants in ZFX are associated with an X-linked intellectual disability syndrome characterized by a recurrent facial gestalt, neurocognitive and behavioral abnormalities, and an increased risk for congenital anomalies and hyperparathyroidism."
The authors' own summary of the entity this node represents.
Disrupted Craniofacial Patterning and Congenital Anomaly Formation
The extra-neural developmental consequence: a recurrent and clinically recognisable facial gestalt present in every reported subject of the founding cohort - thickened and medially broadened eyebrows, altered facial shape, external eye anomalies, a smooth and/or long philtrum and ear anomalies - together with a variable burden of congenital anomalies. This node deliberately carries no mechanistic annotation beyond the clinical observation: no study has examined cranial neural crest, pharyngeal-arch patterning, or any other craniofacial developmental programme in ZFX deficiency, so the route from the transcriptional defect to the gestalt is entirely unexamined. That unexamined route is recorded as the `zfx_craniofacial_route_gap` discussion; it is a reason to draw the incoming edge as INDIRECT_UNKNOWN_INTERMEDIATES, not a reason to omit it - that ZFX variants produce this gestalt is the disease definition, and only the mechanism is unknown.
Downstream
Abnormal facial shape The recurrent facial gestalt is the clinical expression of this node.
Thick eyebrow Eyebrow thickening with medial broadening is a component of the gestalt.
Abnormal pinna morphology Ear anomalies are a component of the gestalt.
Abnormality of the eye External eye anomalies are a component of the gestalt.
Congenital heart defect Congenital heart defects are part of the reported congenital-anomaly burden; no developmental intermediate is established.
Show evidence (2 references)
PMID:38325380 SUPPORT Human Clinical
"Overlapping and recurrent facial features were identified in all subjects, including thickening and medial broadening of eyebrows, variations in the shape of the face, external eye abnormalities, smooth and/or long philtrum, and ear abnormalities."
Enumerates the components of the facial gestalt and states it was present in every subject.
PMID:38325380 SUPPORT Human Clinical
"Clinical findings included developmental delay/intellectual disability, behavioral abnormalities, hypotonia, and congenital anomalies."
Sources the congenital-anomaly burden. Marked PARTIAL because the abstract names "congenital anomalies" as a category without enumerating the organ systems involved.
Parathyroid Chief Cell Proliferation and Adenoma Formation
The endocrine arm, reached from the zinc-finger missense allele class rather than from the truncating class. Germline missense carriers develop primary hyperparathyroidism, in some cases with a resectable parathyroid lesion and normalisation of PTH and calcium after parathyroidectomy. The supporting rationale is that recurrent SOMATIC ZFX missense mutations at a two-arginine hotspot (R786/R787) in a C-terminal zinc finger are positively selected in sporadic parathyroid adenomas, without loss of heterozygosity - the signature of a proto-oncogene rather than a tumour suppressor. Note this is convergence of two allele sets on one protein region, not a demonstration that the germline alleles act by the same biochemical route.
chief cell of parathyroid gland CL:0000446 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves chief cell of parathyroid gland (CL:0000446). CL:0000446 is a cell type from the Cell Ontology.
cell population proliferation GO:0008283 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased cell population proliferation (GO:0008283). GO:0008283 is a biological process from the Gene Ontology. ↑ INCREASED
parathyroid gland UBERON:0001132 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in parathyroid gland (UBERON:0001132). UBERON:0001132 is an anatomical location from the Uberon multi-species anatomy ontology.
Downstream
Hyperparathyroidism Autonomous proliferation of parathyroid chief cells is what produces inappropriate parathyroid hormone secretion.
Elevated circulating parathyroid hormone level The biochemical expression of the lesion, and the earliest signal reported - an isolated PTH elevation with normal calcium.
Hypercalcemia Excess parathyroid hormone raises serum calcium through its established actions on bone, kidney and intestinal calcium handling.
Hypophosphatemia Excess parathyroid hormone lowers serum phosphate via reduced renal tubular phosphate reabsorption.
Osteoporosis Long-standing parathyroid hormone excess drives bone resorption, giving the reduced bone density seen after years of untreated disease.
Show evidence (4 references)
PMID:25594030 SUPPORT Human Clinical
"The ZFX mutations we identified were strikingly specific, focused in each tumor on one encoded residue in a hotspot of two consecutive highly conserved arginine residues (R786/787; arginine to glutamine, threonine or leucine) in a zinc finger domain near the C-terminus of the protein."
Defines the somatic hotspot in the same C-terminal zinc-finger region that harbours the germline missense alleles.
PMID:25594030 SUPPORT Human Clinical
"the absence of loss of heterozygosity, and the absence of these mutations among over 4000 ZFX alleles in the dbSNP137 database, strongly suggest a novel role for ZFX as a human proto-oncogene."
Establishes the proto-oncogene (not tumour-suppressor) framing, which is why this arm is modelled as gained proliferative activity rather than as loss of a brake.
PMID:39056049 SUPPORT Human Clinical
"Genetic testing showed a likely pathogenic de novo heterozygous germline missense variant p.R764W in the ZFX gene that encodes a zinc-finger transcription factor previously shown to harbor somatic missense variants in a subset of sporadic parathyroid tumors."
A germline zinc-finger missense allele in a patient with surgically confirmed primary hyperparathyroidism.
+ 1 more reference
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Intellectual Developmental Disorder, X-Linked, Syndromic 37 Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

34
Cardiovascular 1
Congenital heart defect Abnormal heart morphology HP:0001627 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Abnormal heart morphology (HP:0001627). HP:0001627 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:41074764 SUPPORT Human Clinical
"was later diagnosed with congenital heart defects, autism spectrum disorder, mild intellectual disability, and absence seizures"
Direct report of congenital heart defects.
Digestive 1
Inguinal hernia HP:0000023 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Inguinal hernia (HP:0000023). HP:0000023 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:41077274 SUPPORT Human Clinical
"including facial features, hypotonia, diminished white matter and thin corpus callosum, inguinal and umbilical herniation, and ophthalmological abnormalities"
The phenotype list for this family; inguinal herniation is named in the "inguinal and umbilical herniation" clause.
Ear 2
Abnormal pinna morphology HP:0000377 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Abnormal pinna morphology (HP:0000377). HP:0000377 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:38325380 SUPPORT Human Clinical
"external eye abnormalities, smooth and/or long philtrum, and ear abnormalities"
Direct description of ear anomalies.
Sensorineural hearing impairment HP:0000407 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Sensorineural hearing impairment (HP:0000407). HP:0000407 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:41074764 SUPPORT Human Clinical
"She further developed sensorineural hearing loss, skin hyperpigmentation, and ophthalmoplegia."
Direct report of sensorineural hearing loss.
PMID:40779536 SUPPORT Human Clinical
"Additionally, she presented other characteristics seen in patients with pathogenic variants in the ZFX gene, such as hearing loss and multiple cutaneous nevi."
Independent report of hearing loss as a recognised ZFX-associated feature, here in a germline missense carrier.
Endocrine 2
Hyperparathyroidism HP:0000843 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Hyperparathyroidism (HP:0000843). HP:0000843 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:38325380 SUPPORT Human Clinical
"Hyperparathyroidism was found in four families with missense variants, and enrichment of different tumor types was observed."
Founding-cohort report of hyperparathyroidism restricted to missense families.
PMID:40779536 SUPPORT Human Clinical
"We present the clinical and molecular characterization of three patients diagnosed with primary hyperparathyroidism (PHPT) who have germline variants in the ZFX gene."
Independent case series of germline ZFX variants in primary hyperparathyroidism.
Elevated circulating parathyroid hormone level HP:0003165 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Elevated circulating parathyroid hormone level (HP:0003165). HP:0003165 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:41077274 SUPPORT Human Clinical
"An elevated PTH was noted, with normocalcemia, a possible early sign of hyperparathyroidism."
Direct report of isolated PTH elevation with normal calcium.
Head and Neck 3
Abnormal facial shape VERY_FREQUENT HP:0001999 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Abnormal facial shape (HP:0001999). HP:0001999 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:38325380 SUPPORT Human Clinical
"Overlapping and recurrent facial features were identified in all subjects, including thickening and medial broadening of eyebrows, variations in the shape of the face, external eye abnormalities, smooth and/or long philtrum, and ear abnormalities."
Supports both the phenotype and the VERY_FREQUENT band: the founding cohort states the facial features were present "in all subjects".
Long philtrum HP:0000343 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Long philtrum (HP:0000343). HP:0000343 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:38325380 SUPPORT Human Clinical
"Overlapping and recurrent facial features were identified in all subjects, including thickening and medial broadening of eyebrows, variations in the shape of the face, external eye abnormalities, smooth and/or long philtrum, and ear abnormalities."
The gestalt sentence; the philtral feature is the "smooth and/or long philtrum" clause within it.
Long palpebral fissure HP:0000637 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Long palpebral fissure (HP:0000637). HP:0000637 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:41074764 SUPPORT Human Clinical
"long palpebral fissures, ophthalmoplegia, skin hyperpigmentation, and a short uvula, expanding the known clinical spectrum"
Direct report of long palpebral fissures.
Integument 2
Hyperpigmentation of the skin HP:0000953 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Hyperpigmentation of the skin (HP:0000953). HP:0000953 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:41074764 SUPPORT Human Clinical
"She further developed sensorineural hearing loss, skin hyperpigmentation, and ophthalmoplegia."
Direct report of skin hyperpigmentation.
Cafe-au-lait spot HP:0000957 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Cafe-au-lait spot (HP:0000957). HP:0000957 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:39056049 SUPPORT Human Clinical
"Dysmorphic facies, multiple cutaneous melanocytic nevi, café au lait macules, long fingers, and scoliosis were observed."
Direct report of cafe-au-lait macules.
Metabolism 2
Hypercalcemia HP:0003072 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Hypercalcemia (HP:0003072). HP:0003072 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:39056049 SUPPORT Human Clinical
"Laboratory evaluation showed an elevated parathyroid hormone (PTH) level, hypercalcemia, and hypophosphatemia, all consistent with PHPT."
Direct report of hypercalcaemia in a germline ZFX missense carrier.
Hypophosphatemia HP:0002148 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Hypophosphatemia (HP:0002148). HP:0002148 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:39056049 SUPPORT Human Clinical
"Laboratory evaluation showed an elevated parathyroid hormone (PTH) level, hypercalcemia, and hypophosphatemia, all consistent with PHPT."
Direct report of hypophosphataemia.
Musculoskeletal 3
Hypotonia HP:0001252 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Hypotonia (HP:0001252). HP:0001252 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:38325380 SUPPORT Human Clinical
"Clinical findings included developmental delay/intellectual disability, behavioral abnormalities, hypotonia, and congenital anomalies."
Hypotonia named among the core findings of the founding cohort.
PMID:41077274 SUPPORT Human Clinical
"including facial features, hypotonia, diminished white matter and thin corpus callosum, inguinal and umbilical herniation, and ophthalmological abnormalities"
Independent confirmation of hypotonia.
Scoliosis HP:0002650 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Scoliosis (HP:0002650). HP:0002650 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:39056049 SUPPORT Human Clinical
"Dysmorphic facies, multiple cutaneous melanocytic nevi, café au lait macules, long fingers, and scoliosis were observed."
Direct report of scoliosis.
Osteoporosis HP:0000939 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Osteoporosis (HP:0000939). HP:0000939 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:39056049 SUPPORT Human Clinical
"A 51-year-old woman with a history of primary hyperparathyroidism (PHPT) with prior parathyroidectomy, osteoporosis, and learning disability was referred for hypercalcemia discovered after a fall."
Direct report of osteoporosis in a germline ZFX missense carrier.
Nervous System 8
Global developmental delay HP:0001263 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Global developmental delay (HP:0001263). HP:0001263 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:38325380 SUPPORT Human Clinical
"Clinical findings included developmental delay/intellectual disability, behavioral abnormalities, hypotonia, and congenital anomalies."
Founding-cohort statement of developmental delay as a core finding.
PMID:41077274 SUPPORT Human Clinical
"The phenotype of the patient includes a global neurodevelopmental delay and several additional features greatly overlapping with the phenotype in previously described patients"
Independent confirmation in a subsequently reported family.
Intellectual disability HP:0001249 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Intellectual disability (HP:0001249). HP:0001249 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:38325380 SUPPORT Human Clinical
"Our clinical and experimental data support that variants in ZFX are associated with an X-linked intellectual disability syndrome characterized by a recurrent facial gestalt, neurocognitive and behavioral abnormalities, and an increased risk for congenital anomalies and hyperparathyroidism."
Defines the entity as an intellectual disability syndrome.
PMID:41074764 SUPPORT Human Clinical
"was later diagnosed with congenital heart defects, autism spectrum disorder, mild intellectual disability, and absence seizures"
Documents intellectual disability in an affected heterozygous female.
Delayed speech and language development HP:0000750 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Delayed speech and language development (HP:0000750). HP:0000750 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:41074764 SUPPORT Human Clinical
"She exhibited motor and speech delays with hypotonia in early childhood"
Direct report of speech delay.
Motor delay HP:0001270 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Motor delay (HP:0001270). HP:0001270 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:41074764 SUPPORT Human Clinical
"She exhibited motor and speech delays with hypotonia in early childhood"
Direct report of motor delay.
Atypical behavior HP:0000708 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Atypical behavior (HP:0000708). HP:0000708 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:38325380 SUPPORT Human Clinical
"Clinical findings included developmental delay/intellectual disability, behavioral abnormalities, hypotonia, and congenital anomalies."
Behavioural abnormality named among the core findings.
Autistic behavior HP:0000729 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Autistic behavior (HP:0000729). HP:0000729 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:41074764 SUPPORT Human Clinical
"was later diagnosed with congenital heart defects, autism spectrum disorder, mild intellectual disability, and absence seizures"
Direct report of an autism spectrum diagnosis.
Absence seizures Generalized non-motor (absence) seizure HP:0002121 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Generalized non-motor (absence) seizure (HP:0002121). HP:0002121 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:41074764 SUPPORT Human Clinical
"was later diagnosed with congenital heart defects, autism spectrum disorder, mild intellectual disability, and absence seizures"
Direct report of absence seizures.
Cerebellar vermis hypoplasia HP:0001320 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Cerebellar vermis hypoplasia (HP:0001320). HP:0001320 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:41074764 SUPPORT Human Clinical
"Novel phenotypic features included inferior cerebellar vermian hypoplasia, hypoplastic right vertebral artery, aberrant subclavian artery, long palpebral fissures, ophthalmoplegia, skin hyperpigmentation, and a short uvula"
Direct report of inferior cerebellar vermian hypoplasia.
Neoplasm 1
Neoplasm HP:0002664 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Neoplasm (HP:0002664). HP:0002664 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:38325380 SUPPORT Human Clinical
"Hyperparathyroidism was found in four families with missense variants, and enrichment of different tumor types was observed."
Marked PARTIAL: the cohort reports tumour-type enrichment but gives no denominator, comparison population, or risk estimate in the abstract.
Other 9
Thick eyebrow HP:0000574 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Thick eyebrow (HP:0000574). HP:0000574 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:38325380 SUPPORT Human Clinical
"including thickening and medial broadening of eyebrows"
Direct description of eyebrow thickening.
Smooth philtrum HP:0000319 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Smooth philtrum (HP:0000319). HP:0000319 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:38325380 SUPPORT Human Clinical
"Overlapping and recurrent facial features were identified in all subjects, including thickening and medial broadening of eyebrows, variations in the shape of the face, external eye abnormalities, smooth and/or long philtrum, and ear abnormalities."
The gestalt sentence; the philtral feature is the "smooth and/or long philtrum" clause within it.
Abnormality of the eye VERY_FREQUENT HP:0000478 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Abnormality of the eye (HP:0000478). HP:0000478 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:38325380 SUPPORT Human Clinical
"Overlapping and recurrent facial features were identified in all subjects, including thickening and medial broadening of eyebrows, variations in the shape of the face, external eye abnormalities, smooth and/or long philtrum, and ear abnormalities."
Supports both the phenotype and the VERY_FREQUENT band - external eye abnormalities are listed among features found "in all subjects".
Ophthalmoplegia HP:0000602 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Ophthalmoplegia (HP:0000602). HP:0000602 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:41074764 SUPPORT Human Clinical
"She further developed sensorineural hearing loss, skin hyperpigmentation, and ophthalmoplegia."
Direct report of ophthalmoplegia.
Thin corpus callosum HP:0033725 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Thin corpus callosum (HP:0033725). HP:0033725 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:41077274 SUPPORT Human Clinical
"including facial features, hypotonia, diminished white matter and thin corpus callosum, inguinal and umbilical herniation, and ophthalmological abnormalities"
Direct report of a thin corpus callosum.
Cerebral white matter hypoplasia HP:0012430 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Cerebral white matter hypoplasia (HP:0012430). HP:0012430 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:41077274 SUPPORT Human Clinical
"diminished white matter and thin corpus callosum"
Direct report of diminished white matter.
Umbilical hernia HP:0001537 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Umbilical hernia (HP:0001537). HP:0001537 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:41077274 SUPPORT Human Clinical
"including facial features, hypotonia, diminished white matter and thin corpus callosum, inguinal and umbilical herniation, and ophthalmological abnormalities"
The phenotype list for this family; umbilical herniation is named in the "inguinal and umbilical herniation" clause.
Short uvula HP:0010812 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Short uvula (HP:0010812). HP:0010812 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:41074764 SUPPORT Human Clinical
"ophthalmoplegia, skin hyperpigmentation, and a short uvula, expanding the known clinical spectrum"
Direct report of a short uvula.
Melanocytic nevus HP:0000995 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Melanocytic nevus (HP:0000995). HP:0000995 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:39056049 SUPPORT Human Clinical
"Dysmorphic facies, multiple cutaneous melanocytic nevi, café au lait macules, long fingers, and scoliosis were observed."
Direct report of multiple cutaneous melanocytic nevi.
PMID:40779536 SUPPORT Human Clinical
"ZFX may be one of the genes to be analyzed in women affected by PHPT with suspected genetic inheritance, especially if they have other features such as facial deformities, hearing loss, and cutaneous melanocytic nevi."
Names cutaneous melanocytic nevi as one of the ZFX-associated features that should prompt testing.
🧬

Genetic Associations

1
ZFX (Causative)
Gene: ZFX hgnc:12869 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is ZFX (hgnc:12869). hgnc:12869 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: CAUSATIVE variant_origin: GERMLINE
Show evidence (5 references)
PMID:38325380 SUPPORT Human Clinical
"Here, we present clinical and molecular characterization of 18 individuals with germline ZFX variants."
The gene-discovery cohort establishing the ZFX-MRXS37 relationship.
PMID:38325380 SUPPORT Human Clinical
"Exome or genome sequencing revealed 11 variants in 18 subjects (14 males and 4 females) from 16 unrelated families."
Sources the variant count, cohort composition, and family count.
PMID:38325380 SUPPORT Human Clinical
"ZFX on Xp22.11 encodes a transcription factor that has been linked to diverse processes including oncogenesis and development, but germline variants have not been characterized in association with disease."
Sources the locus and the novelty of the germline gene-disease relationship.
+ 2 more references
💊

Medical Actions

4
Multidisciplinary Supportive Care
Action: Supportive CareNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Supportive Care (NCIT:C15747). NCIT:C15747 is a clinical intervention from the NCI Thesaurus. NCIT:C15747
No disease-modifying or targeted therapy exists for MRXS37. Management is supportive and multidisciplinary, as for other syndromic intellectual disabilities, and is directed at the individual's developmental, behavioural, sensory, cardiac and endocrine findings.
Cardiac and Endocrine Surveillance
Action: Supportive CareNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Supportive Care (NCIT:C15747). NCIT:C15747 is a clinical intervention from the NCI Thesaurus. NCIT:C15747
Structured surveillance is the one management step the literature states explicitly for this disorder: cardiac monitoring, plus endocrine monitoring (serum calcium and PTH) extended to clinically unaffected females carrying missense variants, on the basis that the hyperparathyroidism risk tracks the missense allele class rather than the neurodevelopmental phenotype.
Show evidence (1 reference)
PMID:41074764 SUPPORT Human Clinical
"Clinical care should include cardiac and endocrine monitoring, with endocrine testing offered to unaffected females carrying missense variants."
The explicit surveillance recommendation from the reporting authors.
Parathyroidectomy
Action: ParathyroidectomyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Parathyroidectomy (NCIT:C51593). NCIT:C51593 is a clinical intervention from the NCI Thesaurus. NCIT:C51593
Surgical parathyroidectomy for symptomatic primary hyperparathyroidism, as performed in a germline ZFX missense carrier with normalisation of PTH, calcium and phosphorus afterwards. This treats the endocrine complication; it does not modify the neurodevelopmental disorder.
Mechanism Target:
INHIBITS Parathyroid Chief Cell Proliferation and Adenoma Formation — Resection of the hyperfunctioning parathyroid tissue removes the proliferating chief-cell lesion driving the hypercalcaemia.
Show evidence (1 reference)
PMID:39056049 SUPPORT Human Clinical
"The patient underwent right inferior parathyroidectomy with normalization of PTH, calcium, and phosphorus."
Demonstrates biochemical resolution after resection in a ZFX missense carrier.
Show evidence (1 reference)
PMID:39056049 SUPPORT Human Clinical
"A 51-year-old woman with a history of primary hyperparathyroidism (PHPT) with prior parathyroidectomy, osteoporosis, and learning disability was referred for hypercalcemia discovered after a fall."
Documents parathyroidectomy as the treatment actually used for the endocrine complication in a germline ZFX missense carrier.
Genetic Counseling
Action: Genetic CounselingNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Genetic Counseling (NCIT:C15240). NCIT:C15240 is a clinical intervention from the NCI Thesaurus. NCIT:C15240
Genetic counselling for families, covering the X-linked inheritance, the documented occurrence of both de novo and inherited variants, and the implication that a transmitting mother may be only minimally affected but still at endocrine risk if the allele is missense.
🔬

Diagnosis

2
Exome or genome sequencing
Molecular diagnosis rests on exome or genome sequencing; every reported case to date was ascertained this way. Because ZFX was implicated in disease only in 2024, older targeted X-linked intellectual disability panels may not include it, so a negative panel does not exclude the diagnosis.
Show evidence (2 references)
PMID:38325380 SUPPORT Human Clinical
"Exome or genome sequencing revealed 11 variants in 18 subjects (14 males and 4 females) from 16 unrelated families."
Establishes exome/genome sequencing as the diagnostic modality used.
PMID:41074764 SUPPORT Human Clinical
"We describe a 20-year-old female with a heterozygous ZFX frameshift variant, p.(Met666Valfs*2), identified by genome sequencing"
Genome sequencing as the ascertainment route in a further case.
Serum calcium and parathyroid hormone measurement
Biochemical endocrine screening with serum calcium and PTH is indicated in ZFX variant carriers, and the reporting authors extend this specifically to clinically unaffected females with missense variants. An isolated PTH elevation with normal calcium has been interpreted as a possible early sign.
Show evidence (2 references)
PMID:41074764 SUPPORT Human Clinical
"Clinical care should include cardiac and endocrine monitoring, with endocrine testing offered to unaffected females carrying missense variants."
The recommendation for endocrine testing in carriers.
PMID:41077274 SUPPORT Human Clinical
"An elevated PTH was noted, with normocalcemia, a possible early sign of hyperparathyroidism."
Shows what an early biochemical signal looks like in practice.
🔀

Differential Diagnoses

2

Conditions with similar clinical presentations that must be differentiated from Intellectual Developmental Disorder, X-Linked, Syndromic 37:

Other X-linked syndromic intellectual disability disorders
Overlapping Features MRXS37 sits within a large group of X-linked syndromic intellectual disability disorders and is not clinically separable from them without sequencing. The recurrent facial gestalt is the feature that makes it pattern-recognisable once suspected, and hyperparathyroidism in a person with syndromic intellectual disability is the finding most likely to point specifically at ZFX.
Show evidence (1 reference)
PMID:38325380 SUPPORT Human Clinical
"Pathogenic variants in multiple genes on the X chromosome have been implicated in syndromic and non-syndromic intellectual disability disorders."
States the differential-diagnostic context: ZFX sits among many X-linked genes producing syndromic intellectual disability.
Non-syndromic and syndromic causes of primary hyperparathyroidism
Overlapping Features Ascertainment can run the other way. A woman presenting with primary hyperparathyroidism who also has facial dysmorphism, hearing loss or cutaneous melanocytic nevi should prompt consideration of germline ZFX testing, which is the recommendation drawn by the endocrine case series.
Show evidence (1 reference)
PMID:40779536 SUPPORT Human Clinical
"ZFX may be one of the genes to be analyzed in women affected by PHPT with suspected genetic inheritance, especially if they have other features such as facial deformities, hearing loss, and cutaneous melanocytic nevi."
The reverse-ascertainment recommendation from the endocrine literature.
🧫

Experimental Models

2
ZFX knockdown and overexpression in human embryonic stem cells CELL_LINE
Human embryonic stem cells with ZFX knockdown or overexpression, used to test whether the self-renewal requirement identified in mouse is conserved in human cells. It is, which is what licenses using the murine stem cell data to reason about a human disorder.
Pathograph links
Impaired Stem and Progenitor Cell Self-Renewal recapitulates fidelity: moderate ZFX knockdown impairs clonal growth and serial replating in human ESCs; overexpression resists spontaneous differentiation.
Limitations: Embryonic stem cells are not neural progenitors and not patient-derived, and the perturbation is knockdown rather than a patient allele, so this supports the general requirement rather than the specific disease mechanism.
Show evidence (1 reference)
PMID:22879936 SUPPORT In Vitro
"ZFX knockdown in hESCs hindered clonal growth and decreased colony size after serial replating."
The loss-of-function readout in human cells.
ZFX and ZNF711 CRISPR knockout HEK293T cells CELL_LINE
Bi-allelic CRISPR knockouts of ZFX and/or ZNF711 in female HEK293T cells, used to establish the scale of transcriptome dysregulation caused by loss of these factors and to map the domains required for DNA binding and transactivation.
Pathograph links
Impaired ZFX-Dependent Transcriptional Activation at CpG Island Promoters measures fidelity: moderate Quantifies the transcriptomic consequence of losing ZFX and localises DNA-binding function to zinc fingers 11-13.
Limitations: An immortalised kidney-derived cell line, not a neural or parathyroid context, and complete bi-allelic knockout rather than the partial dosage reduction that a heterozygous patient sustains.
Show evidence (1 reference)
PMID:32406922 SUPPORT In Vitro
"We found that loss of either ZFX or ZNF711 reduced cell growth and that the double knockout cells have major defects in proliferation."
The proliferation phenotype of ZFX loss in human cells.
🐁

Animal Models

2
zfx loss-of-function zebrafish
A zebrafish model of ZFX loss generated alongside the founding human cohort. It is the only in vivo model reported for this disorder and it supports a neurobehavioural consequence of ZFX loss.
Species
Zebrafish
Genotype
zfx loss of function
Publication
PMID:38325380
Pathograph links
Disrupted Neurodevelopment partially recapitulates fidelity: low Reproduces an altered behavioural phenotype, supporting a conserved neurobehavioural role for ZFX.
Limitations: Only a behavioural phenotype is reported. The model does not address the defining human features - intellectual disability, the recurrent facial gestalt, congenital anomalies, or hyperparathyroidism - and behaviour in a larval fish is not a measure of human neurocognition. Fidelity is recorded as LOW for that reason, not because the result is doubted.
Show evidence (1 reference)
PMID:38325380 SUPPORT Model Organism
"Additionally, a zebrafish model of ZFX loss displayed an altered behavioral phenotype, providing additional evidence for the functional significance of ZFX."
The model's reported outcome and the authors' own interpretation of its scope.
Show evidence (1 reference)
PMID:38325380 SUPPORT Model Organism
"a zebrafish model of ZFX loss displayed an altered behavioral phenotype"
Establishes that this zebrafish model exists and what it showed.
Zfx knockout mouse
Not a disease model of MRXS37 but the gene-function model that established ZFX's role in stem cell self-renewal. Deletion impairs self-renewal of embryonic and adult haematopoietic stem cells while sparing differentiation and short-term progenitors.
Species
Mouse
Genotype
Zfx conditional/germline deletion
Publication
PMID:17448993
Pathograph links
Impaired Stem and Progenitor Cell Self-Renewal recapitulates fidelity: moderate Establishes the selective self-renewal requirement for Zfx that this pathophysiology node asserts.
Limitations: Two limitations bound its use for the human disorder. First, this is a gene-function study in stem cell compartments, with no craniofacial, cardiac, endocrine or cognitive phenotyping analogous to the human syndrome, and neural progenitors were not the compartment assayed. Second, mouse Zfx is SUBJECT to X inactivation whereas human ZFX escapes it, so the dosage biology of a heterozygous female differs between species - see the HUMAN_MODEL_MISMATCH discussion.
Show evidence (1 reference)
PMID:17448993 SUPPORT Model Organism
"Furthermore, Zfx deletion abolished the maintenance of adult HSC but did not affect erythromyeloid progenitors or fetal HSC."
The selective, compartment-specific self-renewal requirement demonstrated in mouse.
Show evidence (1 reference)
PMID:17448993 SUPPORT Model Organism
"The deletion of transcription factor Zfx impaired the self-renewal but not the differentiation capacity of murine ESC"
Establishes the murine deletion model and the selective self-renewal phenotype for which it is cited here.
{ }

Source YAML

click to show 
name: Intellectual Developmental Disorder, X-Linked, Syndromic 37
creation_date: '2026-08-19T00:00:00Z'
category: Genetic
classifications:
  harrisons_chapter:
  - classification_value: NEUROLOGIC
  - classification_value: GENETICS_ENVIRONMENT_DISEASE
  - classification_value: ENDOCRINOLOGY_METABOLISM
parents:
- Neurodevelopmental Disorder
- X-linked Disorder
- Multiple Congenital Anomaly Syndrome
disease_term:
  preferred_term: intellectual developmental disorder, X-linked, syndromic 37
  term:
    id: MONDO:0958322
    label: intellectual developmental disorder, X-linked, syndromic 37
synonyms:
- MRXS37
- ZFX-related neurodevelopmental disorder
- ZFX-associated syndromic intellectual disability
- X-linked syndromic intellectual developmental disorder 37
description: >
  X-linked syndromic intellectual developmental disorder 37 (MRXS37; OMIM
  301118; MONDO:0958322) is a recently delineated neurodevelopmental syndrome
  caused by germline variants in ZFX at Xp22.11. ZFX encodes a ubiquitously
  expressed Krueppel-type C2H2 zinc-finger transcription factor that acts as a
  transcriptional ACTIVATOR, binding a short motif a few hundred base pairs
  DOWNSTREAM of the transcription start site at the majority of active CpG
  island promoters, where it promotes productive elongation.

  The entity was defined in 2024 by a multi-centre cohort of 18 individuals
  (14 males, 4 females) from 16 unrelated families carrying 11 distinct
  germline ZFX variants. The core presentation is developmental delay and
  intellectual disability of variable severity with behavioural abnormalities
  and hypotonia, set on a recurrent and clinically recognisable facial gestalt
  (thickened and medially broadened eyebrows, altered facial shape, external
  eye anomalies, a smooth and/or long philtrum, and ear anomalies) together
  with a variable burden of congenital anomalies.

  Two features make this disorder mechanistically distinctive.

  First, ZFX is one of the small number of human X-linked genes that ESCAPE X
  inactivation, established since 1989. Both X alleles are therefore normally
  expressed in females, so a heterozygous female sustains a genuine dosage
  reduction in every cell rather than the mosaic of wild-type and mutant cells
  seen for X-inactivated genes. Consistent with this, females are genuinely
  affected as well as males rather than being obligate silent carriers -
  although expressivity in females is wide, from apparently unaffected
  transmitting mothers to syndromic multi-organ presentations, and males are
  in general more severely affected. This entry therefore annotates the
  neutral HPO `X-linked inheritance` term rather than asserting X-linked
  dominant or X-linked recessive.

  Second, the disorder carries an endocrine/neoplastic arm that is unusual
  among neurodevelopmental genes. Hyperparathyroidism was found in four
  founding-cohort families, all of which carried MISSENSE alleles. That
  observation aligns with the independent finding that recurrent SOMATIC ZFX
  missense mutations at an arginine hotspot (R786/R787) in the C-terminal
  zinc-finger region are selected in sporadic parathyroid adenomas, and it is
  why this entry models two partially separate mechanistic arms rather than
  one.

  The allele-class correlation must not be overstated, and this entry
  deliberately does not state it as a rule. The founding cohort reports
  hyperparathyroidism in four missense families; it does not report its
  absence in truncating families, so "found in missense families" is not the
  same claim as "restricted to missense alleles". A later endocrine series
  (PMID:40779536) weakens a strict version further: of its three germline ZFX
  carriers with primary hyperparathyroidism, one carries an IN-FRAME INSERTION
  rather than a missense allele, and of the two missense carriers one is
  p.(Arg536Cys), which does not lie in the C-terminal zinc fingers. Both of
  those are variants of uncertain significance, which is the honest caveat -
  but the correlation as published is a tendency observed in small numbers,
  not an established genotype-phenotype rule. See the
  `zfx_missense_endocrine_gap` discussion.

  SCOPE / EVIDENCE-MATURITY NOTE - this is a young entity. As of this
  curation there is no GeneReviews chapter, no Orphanet ORPHA code, no
  published prevalence estimate, no natural-history study, and no clinical
  trial; the whole literature is a founding cohort plus a handful of
  case reports and an endocrine case series. Frequencies are therefore
  omitted for most phenotypes rather than estimated, and the
  genotype-phenotype split below is curated as a competing-hypothesis pair,
  not as settled fact.
references:
- reference: PMID:38325380
  title: Variants in ZFX are associated with an X-linked neurodevelopmental disorder with recurrent facial gestalt.
  findings: []
- reference: PMID:41077274
  title: Expansion of the phenotype in ZFX neurodevelopmental disorder in a family.
  findings: []
- reference: PMID:41074764
  title: De Novo Heterozygous ZFX Frameshift Variant in a Female With an X-Linked Neurodevelopmental Disorder.
  findings: []
- reference: PMID:39056049
  title: A Germline ZFX Missense Variant in a Patient With Primary Hyperparathyroidism.
  findings: []
- reference: PMID:40779536
  title: Association of germline variants in the ZFX gene with primary hyperparathyroidism.
  findings: []
- reference: PMID:25594030
  title: Recurrent ZFX mutations in human sporadic parathyroid adenomas.
  findings: []
- reference: PMID:29429977
  title: ZFX acts as a transcriptional activator in multiple types of human tumors by binding downstream from transcription start sites at the majority of CpG island promoters.
  findings: []
- reference: PMID:32406922
  title: Characterization of the ZFX family of transcription factors that bind downstream of the start site of CpG island promoters.
  findings: []
- reference: PMID:38726870
  title: Reduction of ZFX levels decreases histone H4 acetylation and increases Pol2 pausing at target promoters.
  findings: []
- reference: PMID:17448993
  title: Zfx controls the self-renewal of embryonic and hematopoietic stem cells.
  findings: []
- reference: PMID:22879936
  title: ZFX controls the self-renewal of human embryonic stem cells.
  findings: []
- reference: PMID:2500252
  title: ZFX has a gene structure similar to ZFY, the putative human sex determinant, and escapes X inactivation.
  findings: []
- reference: PMID:1970799
  title: Chromosomal localization of ZFX--a human gene that escapes X inactivation--and its murine homologs.
  findings: []
- reference: PMID:2052543
  title: Inactivation of the Zfx gene on the mouse X chromosome.
  findings: []
- reference: PMID:39940742
  title: Expression Patterns of Escape Genes in Turner Syndrome Fibroblasts and Induced Pluripotent Stem Cells.
  findings: []
notes: >
  Curation provenance and identifier caveat. This entry was built from primary
  literature, with two deep-research reports used as lead-generation aids:
  `claude_code` and `openscientist`. The default `falcon`/Edison provider was
  attempted first and FAILED - the API returned HTTP 402 Payment Required and
  produced no report - so there is no falcon artifact for this entry. Both
  reports that did run passed the NEC preflight against MONDO:0958322 (PASS,
  with ZFX mentioned 53 and 59 times respectively and the next-ranked gene in
  low single digits), and both reported 9/9 citations resolved with none
  flagged off topic.

  One identifier error was caught and NOT propagated: the `claude_code` report
  asserted `HGNC:12874` for ZFX. That identifier is ZIC3. ZFX is `hgnc:12869`,
  which is both the causal gene recorded on MONDO:0958322 via RO:0004003 and
  the value the independent `openscientist` report gives. The wrong ID was
  discarded. This is worth recording because it is the DR failure mode that
  snippet validation cannot see - a fabricated ontology identifier is caught
  only by checking it against the ontology.

  One claim present in the `openscientist` report was deliberately NOT adopted:
  that "X-inactivation skewing is the dominant modifier of expression in
  females". That contradicts the escape-from-X-inactivation premise stated
  elsewhere in the same report and reasoned from here - skewing is precisely
  what does not govern an escape gene. A speculative link between ZFX and
  canonical Wnt signalling was also left out; its source is an editorial that
  presents it as "one possible mechanism".

  Several quantitative claims that circulate in secondary summaries of this
  disorder are deliberately NOT curated here because no quotable primary
  source was found for them: the gnomAD pLI value, the exact de-novo fraction
  of the founding cohort, and per-phenotype frequencies. The founding paper's
  abstract states the cohort composition and the qualifier "in all subjects"
  for the facial gestalt, and those are the only frequency-bearing statements
  used.
pathophysiology:
- name: Germline ZFX Truncating Variant
  biological_scale: MOLECULAR
  description: >
    Frameshift and nonsense variants distributed across ZFX, accounting for
    seven of the eleven variants in the founding cohort. These alleles are
    presumed to act by loss of function, reducing functional ZFX dosage. In a
    hemizygous male no functional allele remains; in a heterozygous female,
    because ZFX escapes X inactivation, the remaining wild-type allele is
    expressed in every cell but cannot be up-regulated to compensate, giving a
    genuine partial dosage reduction rather than cellular mosaicism.
  genetic_context:
    allele_type: LOSS_OF_FUNCTION_VARIANT
    variant_origin: GERMLINE
    functional_impact_category: LOSS_OF_FUNCTION
  downstream:
  - target: Impaired ZFX-Dependent Transcriptional Activation at CpG Island Promoters
    causal_link_type: DIRECT
    hypothesis_groups:
    - haploinsufficiency_model
    description: >
      Reduced functional ZFX protein lowers occupancy and transactivation at
      the CpG island promoters that ZFX normally licenses.
    evidence:
    - reference: PMID:29429977
      reference_title: ZFX acts as a transcriptional activator in multiple types of human tumors by binding downstream from transcription start sites at the majority of CpG island promoters.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "Many genes with promoters bound by ZFX were down-regulated upon ZFX knockdown, supporting the hypothesis that ZFX acts as a transcriptional activator."
      explanation: >-
        Reducing ZFX specifically - by siRNA against ZFX alone - lowers
        expression of the promoters it binds, which is exactly the dosage-loss
        step this edge asserts.
    - reference: PMID:32406922
      reference_title: Characterization of the ZFX family of transcription factors that bind downstream of the start site of CpG island promoters.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "RNA-seq analysis revealed that thousands of genes showed altered expression in the double knockout clones, suggesting that these TFs are critical regulators of the transcriptome."
      explanation: >-
        Shows the scale of transcriptome dysregulation when these factors are
        lost. Marked PARTIAL because the clones are ZFX AND ZNF711 double
        knockouts, so the effect cannot be attributed to ZFX alone, and because
        a bi-allelic knockout is not the partial dosage reduction a patient
        sustains.
  evidence:
  - reference: PMID:38325380
    reference_title: Variants in ZFX are associated with an X-linked neurodevelopmental disorder with recurrent facial gestalt.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Four missense variants were identified in 11 subjects, with seven truncation variants in the remaining individuals."
    explanation: >-
      Establishes the truncating allele class and its share of the founding
      cohort's variant spectrum.
- name: Germline ZFX Zinc-Finger Missense Variant
  biological_scale: MOLECULAR
  description: >
    Missense variants affecting the C2H2 zinc-finger DNA-binding region of
    ZFX, which in the founding cohort accounted for four variants but eleven
    of the eighteen subjects. This allele class is separated from the
    truncating class because its reported functional consequence is altered
    rather than simply absent transcriptional output, and because every
    founding-cohort family with hyperparathyroidism carried a missense allele.
    It is NOT curated as the only allele class that can produce
    hyperparathyroidism: a later series reports an in-frame insertion carrier
    with primary hyperparathyroidism, and the founding cohort never asserts
    absence of the endocrine phenotype in truncating carriers. The functionally critical fingers are the
    C-terminal ones: zinc fingers 11-13 are necessary and sufficient for DNA
    binding, and the somatic parathyroid-adenoma hotspot (R786/R787) lies in
    the same C-terminal zinc-finger region.
  molecular_functions:
  - preferred_term: DNA-binding transcription factor activity
    term:
      id: GO:0003700
      label: DNA-binding transcription factor activity
    modifier: DYSREGULATED
  genetic_context:
    allele_type: MISSENSE_VARIANT
    variant_origin: GERMLINE
  downstream:
  - target: Impaired ZFX-Dependent Transcriptional Activation at CpG Island Promoters
    description: >
      DNA-binding-domain missense alleles change the transcriptional output at
      ZFX target promoters relative to wild-type protein.
    evidence:
    - reference: PMID:38325380
      reference_title: Variants in ZFX are associated with an X-linked neurodevelopmental disorder with recurrent facial gestalt.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "In molecular studies, DNA-binding domain variants elicited differential expression of a small set of target genes relative to wild-type ZFX in cultured cells, suggesting a gain or loss of transcriptional activity."
      explanation: >-
        Direct functional demonstration that DBD missense alleles alter target
        gene expression; the authors themselves leave the direction (gain vs
        loss) open.
  - target: Parathyroid Chief Cell Proliferation and Adenoma Formation
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    hypothesis_groups:
    - altered_dna_binding_specificity_model
    description: >
      The endocrine arm. Every founding-cohort family with hyperparathyroidism
      carried a missense allele, mirroring the recurrent somatic missense
      hotspot selected in sporadic parathyroid adenomas. The steps between the
      variant and chief-cell proliferation are not established, hence an
      indirect edge with unknown intermediates.
    evidence:
    - reference: PMID:38325380
      reference_title: Variants in ZFX are associated with an X-linked neurodevelopmental disorder with recurrent facial gestalt.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Hyperparathyroidism was found in four families with missense variants, and enrichment of different tumor types was observed."
      explanation: >-
        Ties hyperparathyroidism to missense-carrying families. Marked PARTIAL
        for two reasons: it reports a clinical endocrine association, not
        chief-cell proliferation or adenoma, which is what this edge's target
        node asserts; and it states where hyperparathyroidism was found, not
        that it is absent in truncating carriers.
  evidence:
  - reference: PMID:32406922
    reference_title: Characterization of the ZFX family of transcription factors that bind downstream of the start site of CpG island promoters.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "We found that zinc fingers 11-13 are necessary and sufficient for DNA binding and, in combination with the N terminal region, constitute a functional transactivator."
    explanation: >-
      Maps DNA-binding function to the C-terminal zinc fingers, which is the
      region in which the disease-associated missense alleles and the somatic
      parathyroid hotspot both fall.
- name: Escape of ZFX from X Inactivation
  biological_scale: MOLECULAR
  description: >
    ZFX is one of the few human X-linked genes that escape X inactivation, so
    it is transcribed from both the active and the inactive X in females. This
    is a constitutive property of the locus rather than a disease event, and
    it is modelled here because it is what determines the dosage consequence
    of a heterozygous allele: a female carrier has a uniform partial reduction
    in ZFX activity in every cell rather than a mosaic of wild-type and mutant
    cells, which is why females are genuinely affected rather than silent
    carriers.
  downstream:
  - target: Impaired ZFX-Dependent Transcriptional Activation at CpG Island Promoters
    description: >
      MODULATING, not causing. Note the schema's `causal_link_type` encodes
      only directness, so it is deliberately left unset here rather than
      asserting a directness that would misdescribe this edge.
      Escape from X inactivation is a constitutive
      normal property of the locus and produces no disease on its own; what it
      does is set how a heterozygous allele translates into dosage. Because the
      second allele cannot be recruited by skewed inactivation, heterozygosity
      in a female produces a uniform partial reduction in ZFX activity rather
      than a mosaic.
    evidence:
    - reference: PMID:41074764
      reference_title: De Novo Heterozygous ZFX Frameshift Variant in a Female With an X-Linked Neurodevelopmental Disorder.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Female carriers of pathogenic ZFX variants demonstrate highly variable expressivity, ranging from apparently unaffected individuals to syndromic presentations."
      explanation: >-
        Documents that heterozygous females are genuinely affected, consistent
        with an escape-gene dosage model. Marked PARTIAL because the paper
        reports the clinical observation, not a measurement of allelic
        expression in the affected tissue.
  evidence:
  - reference: PMID:2500252
    reference_title: ZFX has a gene structure similar to ZFY, the putative human sex determinant, and escapes X inactivation.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Transcription analysis of human-rodent hybrid cell lines containing \"inactive\" human X chromosomes suggests that ZFX escapes X inactivation."
    explanation: The original demonstration that human ZFX escapes X inactivation.
  - reference: PMID:1970799
    reference_title: Chromosomal localization of ZFX--a human gene that escapes X inactivation--and its murine homologs.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "ZFX is one of a few genes on the human X chromosome that are known to escape X inactivation."
    explanation: >-
      Independent confirmation of escape status and of the Xp21.3/Xp22.1
      localisation. Classified OTHER because the supporting work is linkage
      and physical mapping rather than a clinical, animal, cell-based, or in
      silico study.
  - reference: PMID:39940742
    reference_title: Expression Patterns of Escape Genes in Turner Syndrome Fibroblasts and Induced Pluripotent Stem Cells.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Forty-five escape genes were differentially expressed between the WT and TS cell lines. Among these, five genes (ATP7A, PHKA1, EBP, ZFX, and SMC1A) were suggested to be implicated in the TS phenotype."
    explanation: >-
      Contemporary confirmation that ZFX is treated as an X-inactivation escape
      gene. Marked PARTIAL because the paper says these genes were "suggested
      to be implicated" in the Turner phenotype - a hypothesis about a
      different disorder - so it corroborates escape status but not any claim
      about ZFX dosage consequences here.
- name: Impaired ZFX-Dependent Transcriptional Activation at CpG Island Promoters
  biological_scale: MOLECULAR
  description: >
    The convergent molecular node. ZFX binds a short motif roughly 200-250 bp
    downstream of the transcription start site at the majority of active CpG
    island promoters - an unusual, architecturally defined binding position
    inside the transcribed region rather than upstream - and acts there as an
    activator. Genes whose promoters ZFX occupies are expressed at higher
    levels, and knockdown reduces their expression. Both the truncating and
    the missense allele classes converge on degraded or mis-specified output
    from this promoter-proximal activator function.
  biological_processes:
  - preferred_term: positive regulation of transcription by RNA polymerase II
    term:
      id: GO:0045944
      label: positive regulation of transcription by RNA polymerase II
    modifier: DECREASED
  molecular_functions:
  - preferred_term: RNA polymerase II cis-regulatory region sequence-specific DNA binding
    term:
      id: GO:0000978
      label: RNA polymerase II cis-regulatory region sequence-specific DNA binding
    modifier: DECREASED
  downstream:
  - target: Increased RNA Polymerase II Promoter-Proximal Pausing
    description: >
      Because ZFX binds within the transcribed region just downstream of the
      TSS, reduced ZFX acts on elongation: polymerase accumulates in the
      paused state at ZFX-regulated promoters instead of proceeding into
      productive elongation.
    evidence:
    - reference: PMID:38726870
      reference_title: Reduction of ZFX levels decreases histone H4 acetylation and increases Pol2 pausing at target promoters.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "We used GRO-seq to show that loss or reduction of ZFX increased Pol2 pausing at ZFX-regulated promoters."
      explanation: >-
        Nascent-transcription measurement establishing the elongation defect
        as the proximate consequence of reduced ZFX.
  - target: Disrupted Craniofacial Patterning and Congenital Anomaly Formation
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    hypothesis_groups:
    - haploinsufficiency_model
    description: >
      The facial gestalt and the congenital-anomaly burden follow from the same
      transcriptional defect as the neurodevelopmental arm. Indirect with
      unknown intermediates, and deliberately parented here rather than on the
      self-renewal node: no study has examined cranial neural crest,
      pharyngeal-arch patterning, or any other craniofacial developmental
      programme in ZFX deficiency, so no intermediate can be named and a
      progenitor route cannot be asserted.
    evidence:
    - reference: PMID:38325380
      reference_title: Variants in ZFX are associated with an X-linked neurodevelopmental disorder with recurrent facial gestalt.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Our clinical and experimental data support that variants in ZFX are associated with an X-linked intellectual disability syndrome characterized by a recurrent facial gestalt, neurocognitive and behavioral abnormalities, and an increased risk for congenital anomalies and hyperparathyroidism."
      explanation: >-
        Establishes the genotype-to-gestalt association, which is part of the
        disease definition rather than an inference. Marked PARTIAL because it
        evidences THAT ZFX variants produce the gestalt, not the developmental
        route from the transcriptional defect to it.
  - target: Impaired Stem and Progenitor Cell Self-Renewal
    description: >
      Among the programmes ZFX activates is a self-renewal transcriptional
      module shared by embryonic and adult stem cells, so degraded ZFX output
      manifests cellularly as a self-renewal defect.
    evidence:
    - reference: PMID:17448993
      reference_title: Zfx controls the self-renewal of embryonic and hematopoietic stem cells.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "Zfx directly activated common target genes in ESC and HSC, as well as ESC-specific target genes including ESC self-renewal regulators Tbx3 and Tcl1."
      explanation: >-
        Links ZFX's direct transcriptional activation to the self-renewal
        programme, connecting the molecular node to the cellular one.
  evidence:
  - reference: PMID:29429977
    reference_title: ZFX acts as a transcriptional activator in multiple types of human tumors by binding downstream from transcription start sites at the majority of CpG island promoters.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Many genes with promoters bound by ZFX were down-regulated upon ZFX knockdown, supporting the hypothesis that ZFX acts as a transcriptional activator."
    explanation: >-
      Establishes ZFX as an activator whose loss reduces target gene
      expression, which is the premise of this node.
  - reference: PMID:29429977
    reference_title: ZFX acts as a transcriptional activator in multiple types of human tumors by binding downstream from transcription start sites at the majority of CpG island promoters.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "We identified roughly 9000 ZFX binding sites and found that most of the sites are in CpG island promoters."
    explanation: >-
      Genome-wide localisation of ZFX to CpG island promoters, which defines
      the regulatory territory affected.
  - reference: PMID:38726870
    reference_title: Reduction of ZFX levels decreases histone H4 acetylation and increases Pol2 pausing at target promoters.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "The ZFX transcriptional activator binds to CpG island promoters, with a major peak at ∼200-250 bp downstream from transcription start sites."
    explanation: >-
      Specifies the unusual promoter-downstream binding position that makes
      the elongation mechanism plausible.
- name: Increased RNA Polymerase II Promoter-Proximal Pausing
  biological_scale: MOLECULAR
  description: >
    Reduced ZFX at target promoters increases Pol II pausing and decreases
    histone H4 acetylation, the two coupled readouts of the proposed
    mechanism: ZFX recruits H4 acetylation activity and thereby releases
    polymerase into productive elongation. This is the best-resolved step in
    the ZFX mechanism and is derived entirely from cell-line work, not from
    patient tissue.
  biological_processes:
  - preferred_term: transcription elongation by RNA polymerase II
    term:
      id: GO:0006368
      label: transcription elongation by RNA polymerase II
    modifier: DECREASED
  downstream:
  - target: Impaired Stem and Progenitor Cell Self-Renewal
    description: >
      Failure to release paused polymerase at ZFX-dependent promoters lowers
      output of the self-renewal programme those promoters drive.
    evidence:
    - reference: PMID:38726870
      reference_title: Reduction of ZFX levels decreases histone H4 acetylation and increases Pol2 pausing at target promoters.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "Our studies support a model in which ZFX enhances elongation at target promoters by recruiting H4 acetylation complexes and reducing pausing."
      explanation: >-
        States the elongation model, including the H4-acetylation recruitment
        step. Marked PARTIAL because the paper establishes the elongation
        defect but does not itself measure a self-renewal outcome; that link
        comes from the stem-cell literature.
  evidence:
  - reference: PMID:38726870
    reference_title: Reduction of ZFX levels decreases histone H4 acetylation and increases Pol2 pausing at target promoters.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "We used GRO-seq to show that loss or reduction of ZFX increased Pol2 pausing at ZFX-regulated promoters."
    explanation: >-
      The measured result - nascent-transcription profiling showing increased
      pausing on ZFX reduction - which is the state this node asserts.
  - reference: PMID:38726870
    reference_title: Reduction of ZFX levels decreases histone H4 acetylation and increases Pol2 pausing at target promoters.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Our studies support a model in which ZFX enhances elongation at target promoters by recruiting H4 acetylation complexes and reducing pausing."
    explanation: >-
      Sources the coupled H4-acetylation arm of this node, and the authors'
      mechanistic interpretation of the pausing result.
- name: Impaired Stem and Progenitor Cell Self-Renewal
  biological_scale: CELLULAR
  description: >
    In model systems, loss of ZFX selectively impairs self-renewal while
    leaving differentiation capacity intact, with increased apoptosis and
    stem-cell-specific up-regulation of stress-inducible genes. The
    requirement is conserved to human embryonic stem cells, where ZFX behaves
    as a rheostat setting the balance between self-renewal and
    differentiation. Extension of this to neural progenitors in the developing
    human brain is INFERENCE, not observation - no patient-tissue or
    neural-progenitor data exist for MRXS37, which is recorded as a knowledge
    gap below. The cell types annotated on this node are therefore
    deliberately the ones actually assayed, embryonic and haematopoietic stem
    cells, and NOT neural stem cells, so that the pathograph and anything
    exported from it do not assert a neural-progenitor claim this entry's own
    prose declines to make.
  cell_types:
  - preferred_term: embryonic stem cell
    term:
      id: CL:0002322
      label: embryonic stem cell
  - preferred_term: hematopoietic stem cell
    term:
      id: CL:0000037
      label: hematopoietic stem cell
  biological_processes:
  - preferred_term: stem cell population maintenance
    term:
      id: GO:0019827
      label: stem cell population maintenance
    modifier: DECREASED
  - preferred_term: cell population proliferation
    term:
      id: GO:0008283
      label: cell population proliferation
    modifier: DECREASED
  downstream:
  - target: Disrupted Neurodevelopment
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    hypothesis_groups:
    - haploinsufficiency_model
    description: >
      A progenitor-maintenance deficit during development is the proposed
      route from the transcriptional defect to the neurodevelopmental
      phenotype. Indirect with unknown intermediates: no neural-progenitor data
      exist, which is recorded in the zfx_neural_progenitor_gap discussion.
    evidence:
    - reference: PMID:38325380
      reference_title: Variants in ZFX are associated with an X-linked neurodevelopmental disorder with recurrent facial gestalt.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "Additionally, a zebrafish model of ZFX loss displayed an altered behavioral phenotype, providing additional evidence for the functional significance of ZFX."
      explanation: >-
        The only in vivo evidence tying ZFX loss to a neurobehavioural
        outcome. Marked PARTIAL because the zebrafish assay reports behaviour,
        not progenitor dynamics or craniofacial patterning, so the specific
        progenitor route remains inferred.
  evidence:
  - reference: PMID:17448993
    reference_title: Zfx controls the self-renewal of embryonic and hematopoietic stem cells.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "The deletion of transcription factor Zfx impaired the self-renewal but not the differentiation capacity of murine ESC; conversely, Zfx overexpression facilitated ESC self-renewal by opposing differentiation."
    explanation: >-
      Establishes the selective self-renewal requirement, with differentiation
      spared, that defines this node.
  - reference: PMID:17448993
    reference_title: Zfx controls the self-renewal of embryonic and hematopoietic stem cells.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Zfx-deficient ESC and HSC showed increased apoptosis and SC-specific upregulation of stress-inducible genes."
    explanation: The cellular consequence - apoptosis and a stress response - of losing Zfx.
  - reference: PMID:22879936
    reference_title: ZFX controls the self-renewal of human embryonic stem cells.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Thus, ZFX acts as a molecular rheostat regulating the balance between self-renewal and differentiation in hESCs, revealing the close evolutionary conservation of the self-renewal mechanisms in murine and human ESCs."
    explanation: >-
      Confirms the requirement in HUMAN cells, which is what licenses using the
      murine self-renewal result for a human disorder.
  - reference: PMID:22879936
    reference_title: ZFX controls the self-renewal of human embryonic stem cells.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "ZFX knockdown in hESCs hindered clonal growth and decreased colony size after serial replating."
    explanation: The direct loss-of-function readout in human embryonic stem cells.
- name: Disrupted Neurodevelopment
  biological_scale: ORGANISM
  description: >
    The neurodevelopmental consequence: global developmental delay and
    intellectual disability of variable severity, behavioural abnormalities
    and hypotonia. Structural brain findings reported in individual cases
    include reduced white matter with a thin corpus callosum and inferior
    cerebellar vermian hypoplasia. Kept separate from the craniofacial and
    congenital-anomaly node because they are distinct developmental
    programmes with distinct evidence, even though both follow from the same
    upstream transcriptional defect.
  biological_processes:
  - preferred_term: nervous system development
    term:
      id: GO:0007399
      label: nervous system development
    modifier: ABNORMAL
  locations:
  - preferred_term: brain
    term:
      id: UBERON:0000955
      label: brain
  downstream:
  - target: Global developmental delay
    causal_link_type: DIRECT
    description: Disrupted brain development presents clinically as global developmental delay.
    evidence:
    - reference: PMID:38325380
      reference_title: Variants in ZFX are associated with an X-linked neurodevelopmental disorder with recurrent facial gestalt.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Clinical findings included developmental delay/intellectual disability, behavioral abnormalities, hypotonia, and congenital anomalies."
      explanation: Developmental delay is named among the founding cohort's core clinical findings.
  - target: Intellectual disability
    causal_link_type: DIRECT
    description: Disrupted brain development presents clinically as intellectual disability.
    evidence:
    - reference: PMID:38325380
      reference_title: Variants in ZFX are associated with an X-linked neurodevelopmental disorder with recurrent facial gestalt.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Clinical findings included developmental delay/intellectual disability, behavioral abnormalities, hypotonia, and congenital anomalies."
      explanation: Intellectual disability is named among the founding cohort's core clinical findings.
  - target: Hypotonia
    causal_link_type: DIRECT
    description: Hypotonia is part of the neurodevelopmental presentation.
    evidence:
    - reference: PMID:38325380
      reference_title: Variants in ZFX are associated with an X-linked neurodevelopmental disorder with recurrent facial gestalt.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Clinical findings included developmental delay/intellectual disability, behavioral abnormalities, hypotonia, and congenital anomalies."
      explanation: Hypotonia is named among the founding cohort's core clinical findings.
  - target: Atypical behavior
    causal_link_type: DIRECT
    description: Behavioural abnormalities are a core component of the neurodevelopmental presentation.
    evidence:
    - reference: PMID:38325380
      reference_title: Variants in ZFX are associated with an X-linked neurodevelopmental disorder with recurrent facial gestalt.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Clinical findings included developmental delay/intellectual disability, behavioral abnormalities, hypotonia, and congenital anomalies."
      explanation: Behavioural abnormalities are named among the founding cohort's core clinical findings.
  evidence:
  - reference: PMID:38325380
    reference_title: Variants in ZFX are associated with an X-linked neurodevelopmental disorder with recurrent facial gestalt.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Clinical findings included developmental delay/intellectual disability, behavioral abnormalities, hypotonia, and congenital anomalies."
    explanation: The core clinical statement of the founding cohort.
  - reference: PMID:38325380
    reference_title: Variants in ZFX are associated with an X-linked neurodevelopmental disorder with recurrent facial gestalt.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Our clinical and experimental data support that variants in ZFX are associated with an X-linked intellectual disability syndrome characterized by a recurrent facial gestalt, neurocognitive and behavioral abnormalities, and an increased risk for congenital anomalies and hyperparathyroidism."
    explanation: The authors' own summary of the entity this node represents.
- name: Disrupted Craniofacial Patterning and Congenital Anomaly Formation
  biological_scale: ORGANISM
  description: >
    The extra-neural developmental consequence: a recurrent and clinically
    recognisable facial gestalt present in every reported subject of the
    founding cohort - thickened and medially broadened eyebrows, altered
    facial shape, external eye anomalies, a smooth and/or long philtrum and
    ear anomalies - together with a variable burden of congenital anomalies.
    This node deliberately carries no mechanistic annotation beyond the
    clinical observation: no study has examined cranial neural crest,
    pharyngeal-arch patterning, or any other craniofacial developmental
    programme in ZFX deficiency, so the route from the transcriptional defect
    to the gestalt is entirely unexamined. That unexamined route is recorded
    as the `zfx_craniofacial_route_gap` discussion; it is a reason to draw the
    incoming edge as INDIRECT_UNKNOWN_INTERMEDIATES, not a reason to omit it -
    that ZFX variants produce this gestalt is the disease definition, and only
    the mechanism is unknown.
  downstream:
  - target: Abnormal facial shape
    causal_link_type: DIRECT
    description: The recurrent facial gestalt is the clinical expression of this node.
    evidence:
    - reference: PMID:38325380
      reference_title: Variants in ZFX are associated with an X-linked neurodevelopmental disorder with recurrent facial gestalt.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Overlapping and recurrent facial features were identified in all subjects, including thickening and medial broadening of eyebrows, variations in the shape of the face, external eye abnormalities, smooth and/or long philtrum, and ear abnormalities."
      explanation: The gestalt statement itself, reported in all subjects.
  - target: Thick eyebrow
    causal_link_type: DIRECT
    description: Eyebrow thickening with medial broadening is a component of the gestalt.
    evidence:
    - reference: PMID:38325380
      reference_title: Variants in ZFX are associated with an X-linked neurodevelopmental disorder with recurrent facial gestalt.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Overlapping and recurrent facial features were identified in all subjects, including thickening and medial broadening of eyebrows, variations in the shape of the face, external eye abnormalities, smooth and/or long philtrum, and ear abnormalities."
      explanation: Eyebrow thickening is listed as a component of the gestalt.
  - target: Abnormal pinna morphology
    causal_link_type: DIRECT
    description: Ear anomalies are a component of the gestalt.
    evidence:
    - reference: PMID:38325380
      reference_title: Variants in ZFX are associated with an X-linked neurodevelopmental disorder with recurrent facial gestalt.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Overlapping and recurrent facial features were identified in all subjects, including thickening and medial broadening of eyebrows, variations in the shape of the face, external eye abnormalities, smooth and/or long philtrum, and ear abnormalities."
      explanation: Ear abnormalities are listed as a component of the gestalt.
  - target: Abnormality of the eye
    causal_link_type: DIRECT
    description: External eye anomalies are a component of the gestalt.
    evidence:
    - reference: PMID:38325380
      reference_title: Variants in ZFX are associated with an X-linked neurodevelopmental disorder with recurrent facial gestalt.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Overlapping and recurrent facial features were identified in all subjects, including thickening and medial broadening of eyebrows, variations in the shape of the face, external eye abnormalities, smooth and/or long philtrum, and ear abnormalities."
      explanation: External eye abnormalities are listed as a component of the gestalt.
  - target: Congenital heart defect
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >
      Congenital heart defects are part of the reported congenital-anomaly
      burden; no developmental intermediate is established.
    evidence:
    - reference: PMID:41074764
      reference_title: De Novo Heterozygous ZFX Frameshift Variant in a Female With an X-Linked Neurodevelopmental Disorder.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "was later diagnosed with congenital heart defects, autism spectrum disorder, mild intellectual disability, and absence seizures"
      explanation: A reported congenital heart defect in an affected ZFX variant carrier.
  evidence:
  - reference: PMID:38325380
    reference_title: Variants in ZFX are associated with an X-linked neurodevelopmental disorder with recurrent facial gestalt.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Overlapping and recurrent facial features were identified in all subjects, including thickening and medial broadening of eyebrows, variations in the shape of the face, external eye abnormalities, smooth and/or long philtrum, and ear abnormalities."
    explanation: >-
      Enumerates the components of the facial gestalt and states it was present
      in every subject.
  - reference: PMID:38325380
    reference_title: Variants in ZFX are associated with an X-linked neurodevelopmental disorder with recurrent facial gestalt.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Clinical findings included developmental delay/intellectual disability, behavioral abnormalities, hypotonia, and congenital anomalies."
    explanation: >-
      Sources the congenital-anomaly burden. Marked PARTIAL because the
      abstract names "congenital anomalies" as a category without enumerating
      the organ systems involved.
- name: Parathyroid Chief Cell Proliferation and Adenoma Formation
  biological_scale: TISSUE
  description: >
    The endocrine arm, reached from the zinc-finger missense allele class
    rather than from the truncating class. Germline missense carriers develop
    primary hyperparathyroidism, in some cases with a resectable parathyroid
    lesion and normalisation of PTH and calcium after parathyroidectomy. The
    supporting rationale is that recurrent SOMATIC ZFX missense mutations at a
    two-arginine hotspot (R786/R787) in a C-terminal zinc finger are
    positively selected in sporadic parathyroid adenomas, without loss of
    heterozygosity - the signature of a proto-oncogene rather than a tumour
    suppressor. Note this is convergence of two allele sets on one protein
    region, not a demonstration that the germline alleles act by the same
    biochemical route.
  cell_types:
  - preferred_term: chief cell of parathyroid gland
    term:
      id: CL:0000446
      label: chief cell of parathyroid gland
  locations:
  - preferred_term: parathyroid gland
    term:
      id: UBERON:0001132
      label: parathyroid gland
  biological_processes:
  - preferred_term: cell population proliferation
    term:
      id: GO:0008283
      label: cell population proliferation
    modifier: INCREASED
  downstream:
  - target: Hyperparathyroidism
    causal_link_type: DIRECT
    description: >
      Autonomous proliferation of parathyroid chief cells is what produces
      inappropriate parathyroid hormone secretion.
    evidence:
    - reference: PMID:39056049
      reference_title: A Germline ZFX Missense Variant in a Patient With Primary Hyperparathyroidism.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Laboratory evaluation showed an elevated parathyroid hormone (PTH) level, hypercalcemia, and hypophosphatemia, all consistent with PHPT."
      explanation: Documents the elevated PTH that this edge asserts follows from the lesion.
  - target: Elevated circulating parathyroid hormone level
    causal_link_type: DIRECT
    description: >
      The biochemical expression of the lesion, and the earliest signal
      reported - an isolated PTH elevation with normal calcium.
    evidence:
    - reference: PMID:41077274
      reference_title: Expansion of the phenotype in ZFX neurodevelopmental disorder in a family.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "An elevated PTH was noted, with normocalcemia, a possible early sign of hyperparathyroidism."
      explanation: The earliest biochemical signal reported, preceding hypercalcaemia.
  - target: Hypercalcemia
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: >
      Excess parathyroid hormone raises serum calcium through its established
      actions on bone, kidney and intestinal calcium handling.
    evidence:
    - reference: PMID:39056049
      reference_title: A Germline ZFX Missense Variant in a Patient With Primary Hyperparathyroidism.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Laboratory evaluation showed an elevated parathyroid hormone (PTH) level, hypercalcemia, and hypophosphatemia, all consistent with PHPT."
      explanation: Documents hypercalcaemia co-occurring with the PTH elevation in a ZFX carrier.
  - target: Hypophosphatemia
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: >
      Excess parathyroid hormone lowers serum phosphate via reduced renal
      tubular phosphate reabsorption.
    evidence:
    - reference: PMID:39056049
      reference_title: A Germline ZFX Missense Variant in a Patient With Primary Hyperparathyroidism.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Laboratory evaluation showed an elevated parathyroid hormone (PTH) level, hypercalcemia, and hypophosphatemia, all consistent with PHPT."
      explanation: Documents hypophosphataemia co-occurring with the PTH elevation in a ZFX carrier.
  - target: Osteoporosis
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: >
      Long-standing parathyroid hormone excess drives bone resorption, giving
      the reduced bone density seen after years of untreated disease.
    evidence:
    - reference: PMID:39056049
      reference_title: A Germline ZFX Missense Variant in a Patient With Primary Hyperparathyroidism.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "A 51-year-old woman with a history of primary hyperparathyroidism (PHPT) with prior parathyroidectomy, osteoporosis, and learning disability was referred for hypercalcemia discovered after a fall."
      explanation: >-
        Documents osteoporosis co-occurring with long-standing primary
        hyperparathyroidism in a ZFX carrier. Marked PARTIAL because the case
        report establishes co-occurrence, not that the ZFX-associated PTH
        excess caused this individual's bone loss.
  evidence:
  - reference: PMID:25594030
    reference_title: Recurrent ZFX mutations in human sporadic parathyroid adenomas.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The ZFX mutations we identified were strikingly specific, focused in each tumor on one encoded residue in a hotspot of two consecutive highly conserved arginine residues (R786/787; arginine to glutamine, threonine or leucine) in a zinc finger domain near the C-terminus of the protein."
    explanation: >-
      Defines the somatic hotspot in the same C-terminal zinc-finger region
      that harbours the germline missense alleles.
  - reference: PMID:25594030
    reference_title: Recurrent ZFX mutations in human sporadic parathyroid adenomas.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "the absence of loss of heterozygosity, and the absence of these mutations among over 4000 ZFX alleles in the dbSNP137 database, strongly suggest a novel role for ZFX as a human proto-oncogene."
    explanation: >-
      Establishes the proto-oncogene (not tumour-suppressor) framing, which is
      why this arm is modelled as gained proliferative activity rather than as
      loss of a brake.
  - reference: PMID:39056049
    reference_title: A Germline ZFX Missense Variant in a Patient With Primary Hyperparathyroidism.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Genetic testing showed a likely pathogenic de novo heterozygous germline missense variant p.R764W in the ZFX gene that encodes a zinc-finger transcription factor previously shown to harbor somatic missense variants in a subset of sporadic parathyroid tumors."
    explanation: >-
      A germline zinc-finger missense allele in a patient with surgically
      confirmed primary hyperparathyroidism.
  - reference: PMID:40779536
    reference_title: Association of germline variants in the ZFX gene with primary hyperparathyroidism.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We present the clinical and molecular characterization of three patients diagnosed with primary hyperparathyroidism (PHPT) who have germline variants in the ZFX gene."
    explanation: >-
      Independent case series confirming germline ZFX variants in primary
      hyperparathyroidism.
mechanistic_hypotheses:
- hypothesis_group_id: haploinsufficiency_model
  hypothesis_label: Haploinsufficiency / loss of ZFX transcriptional dosage
  status: CANONICAL
  description: >
    Truncating alleles, and by extension the neurodevelopmental phenotype
    generally, act by reducing the amount of functional ZFX available to
    activate its CpG island promoter targets, with the elongation defect and
    the self-renewal defect as the proximate consequences. This is the
    default model and the one consistent with the cell-line knockdown and
    knockout data.
  evidence:
  - reference: PMID:29429977
    reference_title: ZFX acts as a transcriptional activator in multiple types of human tumors by binding downstream from transcription start sites at the majority of CpG island promoters.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Many genes with promoters bound by ZFX were down-regulated upon ZFX knockdown, supporting the hypothesis that ZFX acts as a transcriptional activator."
    explanation: >-
      The measured result behind the dosage-loss model: reducing ZFX
      down-regulates the promoters it binds, which is what a haploinsufficiency
      model predicts.
- hypothesis_group_id: altered_dna_binding_specificity_model
  hypothesis_label: Altered DNA-binding specificity / gained activity of zinc-finger missense alleles
  status: EMERGING
  description: >
    Zinc-finger missense alleles are not simple nulls but change which targets
    are activated and by how much, and this altered activity - rather than
    reduced dosage - is what predisposes to parathyroid chief cell
    proliferation. The supporting arguments are that the founding cohort's
    functional assay showed differential rather than abolished target
    expression, that hyperparathyroidism has been reported only with missense
    alleles, and that the somatic parathyroid hotspot is a recurrent missense
    change without loss of heterozygosity. The direction of effect is
    explicitly unresolved: the founding paper says "a gain or loss of
    transcriptional activity" and does not choose.
  evidence:
  - reference: PMID:38325380
    reference_title: Variants in ZFX are associated with an X-linked neurodevelopmental disorder with recurrent facial gestalt.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "DNA-binding domain variants elicited differential expression of a small set of target genes relative to wild-type ZFX in cultured cells, suggesting a gain or loss of transcriptional activity."
    explanation: >-
      The functional observation this hypothesis rests on. PARTIAL because the
      same sentence declines to resolve the direction, and only a small set of
      targets was affected.
phenotypes:
- category: Neurologic
  name: Global developmental delay
  description: >
    Global developmental delay is a core feature, typically presenting with
    motor and speech delay in early childhood.
  phenotype_term:
    preferred_term: Global developmental delay
    term:
      id: HP:0001263
      label: Global developmental delay
  evidence:
  - reference: PMID:38325380
    reference_title: Variants in ZFX are associated with an X-linked neurodevelopmental disorder with recurrent facial gestalt.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Clinical findings included developmental delay/intellectual disability, behavioral abnormalities, hypotonia, and congenital anomalies."
    explanation: Founding-cohort statement of developmental delay as a core finding.
  - reference: PMID:41077274
    reference_title: Expansion of the phenotype in ZFX neurodevelopmental disorder in a family.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The phenotype of the patient includes a global neurodevelopmental delay and several additional features greatly overlapping with the phenotype in previously described patients"
    explanation: Independent confirmation in a subsequently reported family.
- category: Neurologic
  name: Intellectual disability
  description: >
    Intellectual disability of variable severity; males are in general more
    severely affected than females, and some heterozygous females are
    apparently unaffected.
  phenotype_term:
    preferred_term: Intellectual disability
    term:
      id: HP:0001249
      label: Intellectual disability
  evidence:
  - reference: PMID:38325380
    reference_title: Variants in ZFX are associated with an X-linked neurodevelopmental disorder with recurrent facial gestalt.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Our clinical and experimental data support that variants in ZFX are associated with an X-linked intellectual disability syndrome characterized by a recurrent facial gestalt, neurocognitive and behavioral abnormalities, and an increased risk for congenital anomalies and hyperparathyroidism."
    explanation: Defines the entity as an intellectual disability syndrome.
  - reference: PMID:41074764
    reference_title: De Novo Heterozygous ZFX Frameshift Variant in a Female With an X-Linked Neurodevelopmental Disorder.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "was later diagnosed with congenital heart defects, autism spectrum disorder, mild intellectual disability, and absence seizures"
    explanation: Documents intellectual disability in an affected heterozygous female.
- category: Neurologic
  name: Delayed speech and language development
  description: Speech and language delay accompanying the motor delay.
  phenotype_term:
    preferred_term: Delayed speech and language development
    term:
      id: HP:0000750
      label: Delayed speech and language development
  evidence:
  - reference: PMID:41074764
    reference_title: De Novo Heterozygous ZFX Frameshift Variant in a Female With an X-Linked Neurodevelopmental Disorder.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "She exhibited motor and speech delays with hypotonia in early childhood"
    explanation: Direct report of speech delay.
- category: Neurologic
  name: Motor delay
  description: Delayed acquisition of motor milestones from early childhood.
  phenotype_term:
    preferred_term: Motor delay
    term:
      id: HP:0001270
      label: Motor delay
  evidence:
  - reference: PMID:41074764
    reference_title: De Novo Heterozygous ZFX Frameshift Variant in a Female With an X-Linked Neurodevelopmental Disorder.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "She exhibited motor and speech delays with hypotonia in early childhood"
    explanation: Direct report of motor delay.
- category: Neurologic
  name: Hypotonia
  description: Hypotonia is a recurrent finding, typically evident in infancy and early childhood.
  phenotype_term:
    preferred_term: Hypotonia
    term:
      id: HP:0001252
      label: Hypotonia
  evidence:
  - reference: PMID:38325380
    reference_title: Variants in ZFX are associated with an X-linked neurodevelopmental disorder with recurrent facial gestalt.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Clinical findings included developmental delay/intellectual disability, behavioral abnormalities, hypotonia, and congenital anomalies."
    explanation: Hypotonia named among the core findings of the founding cohort.
  - reference: PMID:41077274
    reference_title: Expansion of the phenotype in ZFX neurodevelopmental disorder in a family.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "including facial features, hypotonia, diminished white matter and thin corpus callosum, inguinal and umbilical herniation, and ophthalmological abnormalities"
    explanation: Independent confirmation of hypotonia.
- category: Behavioral
  name: Atypical behavior
  description: >
    Behavioural abnormalities are a core component of the syndrome. Autistic
    behaviour is documented in an affected individual; the founding cohort
    reports behavioural abnormality at the category level.
  phenotype_term:
    preferred_term: Atypical behavior
    term:
      id: HP:0000708
      label: Atypical behavior
  evidence:
  - reference: PMID:38325380
    reference_title: Variants in ZFX are associated with an X-linked neurodevelopmental disorder with recurrent facial gestalt.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Clinical findings included developmental delay/intellectual disability, behavioral abnormalities, hypotonia, and congenital anomalies."
    explanation: Behavioural abnormality named among the core findings.
- category: Behavioral
  name: Autistic behavior
  description: Autism spectrum disorder diagnosed in an affected individual.
  phenotype_term:
    preferred_term: Autistic behavior
    term:
      id: HP:0000729
      label: Autistic behavior
  evidence:
  - reference: PMID:41074764
    reference_title: De Novo Heterozygous ZFX Frameshift Variant in a Female With an X-Linked Neurodevelopmental Disorder.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "was later diagnosed with congenital heart defects, autism spectrum disorder, mild intellectual disability, and absence seizures"
    explanation: Direct report of an autism spectrum diagnosis.
- category: Neurologic
  name: Absence seizures
  description: Absence seizures reported in an affected heterozygous female.
  phenotype_term:
    preferred_term: Generalized non-motor (absence) seizure
    term:
      id: HP:0002121
      label: Generalized non-motor (absence) seizure
  evidence:
  - reference: PMID:41074764
    reference_title: De Novo Heterozygous ZFX Frameshift Variant in a Female With an X-Linked Neurodevelopmental Disorder.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "was later diagnosed with congenital heart defects, autism spectrum disorder, mild intellectual disability, and absence seizures"
    explanation: Direct report of absence seizures.
- category: Craniofacial
  name: Abnormal facial shape
  description: >
    A recurrent, clinically recognisable facial gestalt was present in every
    subject of the founding cohort, and is the feature that makes the
    disorder pattern-recognisable at the bedside.
  phenotype_term:
    preferred_term: Abnormal facial shape
    term:
      id: HP:0001999
      label: Abnormal facial shape
  frequency: VERY_FREQUENT
  evidence:
  - reference: PMID:38325380
    reference_title: Variants in ZFX are associated with an X-linked neurodevelopmental disorder with recurrent facial gestalt.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Overlapping and recurrent facial features were identified in all subjects, including thickening and medial broadening of eyebrows, variations in the shape of the face, external eye abnormalities, smooth and/or long philtrum, and ear abnormalities."
    explanation: >-
      Supports both the phenotype and the VERY_FREQUENT band: the founding
      cohort states the facial features were present "in all subjects".
- category: Craniofacial
  name: Thick eyebrow
  description: >
    Thickening of the eyebrows with medial broadening is the most
    characteristic single component of the facial gestalt.
  phenotype_term:
    preferred_term: Thick eyebrow
    term:
      id: HP:0000574
      label: Thick eyebrow
  evidence:
  - reference: PMID:38325380
    reference_title: Variants in ZFX are associated with an X-linked neurodevelopmental disorder with recurrent facial gestalt.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "including thickening and medial broadening of eyebrows"
    explanation: Direct description of eyebrow thickening.
- category: Craniofacial
  name: Long philtrum
  description: A smooth and/or long philtrum forms part of the recurrent facial gestalt.
  phenotype_term:
    preferred_term: Long philtrum
    term:
      id: HP:0000343
      label: Long philtrum
  evidence:
  - reference: PMID:38325380
    reference_title: Variants in ZFX are associated with an X-linked neurodevelopmental disorder with recurrent facial gestalt.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Overlapping and recurrent facial features were identified in all subjects, including thickening and medial broadening of eyebrows, variations in the shape of the face, external eye abnormalities, smooth and/or long philtrum, and ear abnormalities."
    explanation: >-
      The gestalt sentence; the philtral feature is the "smooth and/or long
      philtrum" clause within it.
- category: Craniofacial
  name: Smooth philtrum
  description: A smooth philtrum reported alongside, or instead of, a long philtrum.
  phenotype_term:
    preferred_term: Smooth philtrum
    term:
      id: HP:0000319
      label: Smooth philtrum
  evidence:
  - reference: PMID:38325380
    reference_title: Variants in ZFX are associated with an X-linked neurodevelopmental disorder with recurrent facial gestalt.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Overlapping and recurrent facial features were identified in all subjects, including thickening and medial broadening of eyebrows, variations in the shape of the face, external eye abnormalities, smooth and/or long philtrum, and ear abnormalities."
    explanation: >-
      The gestalt sentence; the philtral feature is the "smooth and/or long
      philtrum" clause within it.
- category: Craniofacial
  name: Abnormal pinna morphology
  description: External ear anomalies form part of the recurrent facial gestalt.
  phenotype_term:
    preferred_term: Abnormal pinna morphology
    term:
      id: HP:0000377
      label: Abnormal pinna morphology
  evidence:
  - reference: PMID:38325380
    reference_title: Variants in ZFX are associated with an X-linked neurodevelopmental disorder with recurrent facial gestalt.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "external eye abnormalities, smooth and/or long philtrum, and ear abnormalities"
    explanation: Direct description of ear anomalies.
- category: Ophthalmologic
  name: Abnormality of the eye
  description: >
    External eye abnormalities are one of the components of the recurrent
    facial gestalt that the founding cohort reports in every subject. The
    broad HPO term is used because the cohort abstract does not specify which
    external eye features were seen.
  phenotype_term:
    preferred_term: Abnormality of the eye
    term:
      id: HP:0000478
      label: Abnormality of the eye
  frequency: VERY_FREQUENT
  evidence:
  - reference: PMID:38325380
    reference_title: Variants in ZFX are associated with an X-linked neurodevelopmental disorder with recurrent facial gestalt.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Overlapping and recurrent facial features were identified in all subjects, including thickening and medial broadening of eyebrows, variations in the shape of the face, external eye abnormalities, smooth and/or long philtrum, and ear abnormalities."
    explanation: >-
      Supports both the phenotype and the VERY_FREQUENT band - external eye
      abnormalities are listed among features found "in all subjects".
- category: Ophthalmologic
  name: Ophthalmoplegia
  description: >
    Ophthalmoplegia, reported as a novel finding in one affected female. The
    broader external eye anomalies of the facial gestalt are curated
    separately above.
  phenotype_term:
    preferred_term: Ophthalmoplegia
    term:
      id: HP:0000602
      label: Ophthalmoplegia
  evidence:
  - reference: PMID:41074764
    reference_title: De Novo Heterozygous ZFX Frameshift Variant in a Female With an X-Linked Neurodevelopmental Disorder.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "She further developed sensorineural hearing loss, skin hyperpigmentation, and ophthalmoplegia."
    explanation: Direct report of ophthalmoplegia.
- category: Ophthalmologic
  name: Long palpebral fissure
  description: Long palpebral fissures reported as a novel phenotypic feature.
  phenotype_term:
    preferred_term: Long palpebral fissure
    term:
      id: HP:0000637
      label: Long palpebral fissure
  evidence:
  - reference: PMID:41074764
    reference_title: De Novo Heterozygous ZFX Frameshift Variant in a Female With an X-Linked Neurodevelopmental Disorder.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "long palpebral fissures, ophthalmoplegia, skin hyperpigmentation, and a short uvula, expanding the known clinical spectrum"
    explanation: Direct report of long palpebral fissures.
- category: Auditory
  name: Sensorineural hearing impairment
  description: >
    Sensorineural hearing loss is reported both in the neurodevelopmental
    presentation and in a germline missense carrier presenting with primary
    hyperparathyroidism.
  phenotype_term:
    preferred_term: Sensorineural hearing impairment
    term:
      id: HP:0000407
      label: Sensorineural hearing impairment
  evidence:
  - reference: PMID:41074764
    reference_title: De Novo Heterozygous ZFX Frameshift Variant in a Female With an X-Linked Neurodevelopmental Disorder.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "She further developed sensorineural hearing loss, skin hyperpigmentation, and ophthalmoplegia."
    explanation: Direct report of sensorineural hearing loss.
  - reference: PMID:40779536
    reference_title: Association of germline variants in the ZFX gene with primary hyperparathyroidism.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Additionally, she presented other characteristics seen in patients with pathogenic variants in the ZFX gene, such as hearing loss and multiple cutaneous nevi."
    explanation: >-
      Independent report of hearing loss as a recognised ZFX-associated
      feature, here in a germline missense carrier.
- category: Cardiovascular
  name: Congenital heart defect
  description: >
    Congenital heart defects are part of the congenital-anomaly burden;
    vascular anomalies (a hypoplastic vertebral artery and an aberrant
    subclavian artery) were novel findings in one affected female.
  phenotype_term:
    preferred_term: Abnormal heart morphology
    term:
      id: HP:0001627
      label: Abnormal heart morphology
  evidence:
  - reference: PMID:41074764
    reference_title: De Novo Heterozygous ZFX Frameshift Variant in a Female With an X-Linked Neurodevelopmental Disorder.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "was later diagnosed with congenital heart defects, autism spectrum disorder, mild intellectual disability, and absence seizures"
    explanation: Direct report of congenital heart defects.
- category: Neuroimaging
  name: Thin corpus callosum
  description: A thin corpus callosum with diminished white matter on brain imaging.
  phenotype_term:
    preferred_term: Thin corpus callosum
    term:
      id: HP:0033725
      label: Thin corpus callosum
  evidence:
  - reference: PMID:41077274
    reference_title: Expansion of the phenotype in ZFX neurodevelopmental disorder in a family.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "including facial features, hypotonia, diminished white matter and thin corpus callosum, inguinal and umbilical herniation, and ophthalmological abnormalities"
    explanation: Direct report of a thin corpus callosum.
- category: Neuroimaging
  name: Cerebral white matter hypoplasia
  description: Diminished cerebral white matter accompanying the thin corpus callosum.
  phenotype_term:
    preferred_term: Cerebral white matter hypoplasia
    term:
      id: HP:0012430
      label: Cerebral white matter hypoplasia
  evidence:
  - reference: PMID:41077274
    reference_title: Expansion of the phenotype in ZFX neurodevelopmental disorder in a family.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "diminished white matter and thin corpus callosum"
    explanation: Direct report of diminished white matter.
- category: Neuroimaging
  name: Cerebellar vermis hypoplasia
  description: Inferior cerebellar vermian hypoplasia, reported as a novel feature.
  phenotype_term:
    preferred_term: Cerebellar vermis hypoplasia
    term:
      id: HP:0001320
      label: Cerebellar vermis hypoplasia
  evidence:
  - reference: PMID:41074764
    reference_title: De Novo Heterozygous ZFX Frameshift Variant in a Female With an X-Linked Neurodevelopmental Disorder.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Novel phenotypic features included inferior cerebellar vermian hypoplasia, hypoplastic right vertebral artery, aberrant subclavian artery, long palpebral fissures, ophthalmoplegia, skin hyperpigmentation, and a short uvula"
    explanation: Direct report of inferior cerebellar vermian hypoplasia.
- category: Gastrointestinal
  name: Inguinal hernia
  description: Inguinal herniation reported as part of the congenital-anomaly burden.
  phenotype_term:
    preferred_term: Inguinal hernia
    term:
      id: HP:0000023
      label: Inguinal hernia
  evidence:
  - reference: PMID:41077274
    reference_title: Expansion of the phenotype in ZFX neurodevelopmental disorder in a family.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "including facial features, hypotonia, diminished white matter and thin corpus callosum, inguinal and umbilical herniation, and ophthalmological abnormalities"
    explanation: >-
      The phenotype list for this family; inguinal herniation is named in the
      "inguinal and umbilical herniation" clause.
- category: Gastrointestinal
  name: Umbilical hernia
  description: Umbilical herniation reported as part of the congenital-anomaly burden.
  phenotype_term:
    preferred_term: Umbilical hernia
    term:
      id: HP:0001537
      label: Umbilical hernia
  evidence:
  - reference: PMID:41077274
    reference_title: Expansion of the phenotype in ZFX neurodevelopmental disorder in a family.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "including facial features, hypotonia, diminished white matter and thin corpus callosum, inguinal and umbilical herniation, and ophthalmological abnormalities"
    explanation: >-
      The phenotype list for this family; umbilical herniation is named in the
      "inguinal and umbilical herniation" clause.
- category: Craniofacial
  name: Short uvula
  description: A short uvula reported as a novel phenotypic feature.
  phenotype_term:
    preferred_term: Short uvula
    term:
      id: HP:0010812
      label: Short uvula
  evidence:
  - reference: PMID:41074764
    reference_title: De Novo Heterozygous ZFX Frameshift Variant in a Female With an X-Linked Neurodevelopmental Disorder.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "ophthalmoplegia, skin hyperpigmentation, and a short uvula, expanding the known clinical spectrum"
    explanation: Direct report of a short uvula.
- category: Dermatologic
  name: Hyperpigmentation of the skin
  description: Skin hyperpigmentation reported as a novel phenotypic feature.
  phenotype_term:
    preferred_term: Hyperpigmentation of the skin
    term:
      id: HP:0000953
      label: Hyperpigmentation of the skin
  evidence:
  - reference: PMID:41074764
    reference_title: De Novo Heterozygous ZFX Frameshift Variant in a Female With an X-Linked Neurodevelopmental Disorder.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "She further developed sensorineural hearing loss, skin hyperpigmentation, and ophthalmoplegia."
    explanation: Direct report of skin hyperpigmentation.
- category: Dermatologic
  name: Melanocytic nevus
  description: >
    Multiple cutaneous melanocytic nevi, reported in germline ZFX missense
    carriers ascertained through primary hyperparathyroidism and recognised
    by those authors as a ZFX-associated feature.
  phenotype_term:
    preferred_term: Melanocytic nevus
    term:
      id: HP:0000995
      label: Melanocytic nevus
  evidence:
  - reference: PMID:39056049
    reference_title: A Germline ZFX Missense Variant in a Patient With Primary Hyperparathyroidism.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Dysmorphic facies, multiple cutaneous melanocytic nevi, café au lait macules, long fingers, and scoliosis were observed."
    explanation: Direct report of multiple cutaneous melanocytic nevi.
  - reference: PMID:40779536
    reference_title: Association of germline variants in the ZFX gene with primary hyperparathyroidism.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "ZFX may be one of the genes to be analyzed in women affected by PHPT with suspected genetic inheritance, especially if they have other features such as facial deformities, hearing loss, and cutaneous melanocytic nevi."
    explanation: >-
      Names cutaneous melanocytic nevi as one of the ZFX-associated features
      that should prompt testing.
- category: Dermatologic
  name: Cafe-au-lait spot
  description: Cafe-au-lait macules observed in a germline ZFX missense carrier.
  phenotype_term:
    preferred_term: Cafe-au-lait spot
    term:
      id: HP:0000957
      label: Cafe-au-lait spot
  evidence:
  - reference: PMID:39056049
    reference_title: A Germline ZFX Missense Variant in a Patient With Primary Hyperparathyroidism.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Dysmorphic facies, multiple cutaneous melanocytic nevi, café au lait macules, long fingers, and scoliosis were observed."
    explanation: Direct report of cafe-au-lait macules.
- category: Musculoskeletal
  name: Scoliosis
  description: Scoliosis observed in a germline ZFX missense carrier.
  phenotype_term:
    preferred_term: Scoliosis
    term:
      id: HP:0002650
      label: Scoliosis
  evidence:
  - reference: PMID:39056049
    reference_title: A Germline ZFX Missense Variant in a Patient With Primary Hyperparathyroidism.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Dysmorphic facies, multiple cutaneous melanocytic nevi, café au lait macules, long fingers, and scoliosis were observed."
    explanation: Direct report of scoliosis.
- category: Endocrine
  name: Hyperparathyroidism
  description: >
    Hyperparathyroidism is the signature extra-neural complication and is
    reported specifically in association with the zinc-finger missense allele
    class. Presentations range from frank primary hyperparathyroidism with
    hypercalcaemia requiring parathyroidectomy, to an isolated elevation of
    PTH with normal calcium interpreted as a possible early sign.
  phenotype_term:
    preferred_term: Hyperparathyroidism
    term:
      id: HP:0000843
      label: Hyperparathyroidism
  evidence:
  - reference: PMID:38325380
    reference_title: Variants in ZFX are associated with an X-linked neurodevelopmental disorder with recurrent facial gestalt.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Hyperparathyroidism was found in four families with missense variants, and enrichment of different tumor types was observed."
    explanation: Founding-cohort report of hyperparathyroidism restricted to missense families.
  - reference: PMID:40779536
    reference_title: Association of germline variants in the ZFX gene with primary hyperparathyroidism.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We present the clinical and molecular characterization of three patients diagnosed with primary hyperparathyroidism (PHPT) who have germline variants in the ZFX gene."
    explanation: Independent case series of germline ZFX variants in primary hyperparathyroidism.
- category: Endocrine
  name: Elevated circulating parathyroid hormone level
  description: >
    An elevated PTH with normocalcaemia, interpreted by the reporting authors
    as a possible early sign of hyperparathyroidism, was found in both an
    affected male and his transmitting mother.
  phenotype_term:
    preferred_term: Elevated circulating parathyroid hormone level
    term:
      id: HP:0003165
      label: Elevated circulating parathyroid hormone level
  evidence:
  - reference: PMID:41077274
    reference_title: Expansion of the phenotype in ZFX neurodevelopmental disorder in a family.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "An elevated PTH was noted, with normocalcemia, a possible early sign of hyperparathyroidism."
    explanation: Direct report of isolated PTH elevation with normal calcium.
- category: Endocrine
  name: Hypercalcemia
  description: >
    Hypercalcaemia in the setting of primary hyperparathyroidism, normalising
    after parathyroidectomy.
  phenotype_term:
    preferred_term: Hypercalcemia
    term:
      id: HP:0003072
      label: Hypercalcemia
  evidence:
  - reference: PMID:39056049
    reference_title: A Germline ZFX Missense Variant in a Patient With Primary Hyperparathyroidism.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Laboratory evaluation showed an elevated parathyroid hormone (PTH) level, hypercalcemia, and hypophosphatemia, all consistent with PHPT."
    explanation: Direct report of hypercalcaemia in a germline ZFX missense carrier.
- category: Endocrine
  name: Hypophosphatemia
  description: Hypophosphataemia accompanying primary hyperparathyroidism.
  phenotype_term:
    preferred_term: Hypophosphatemia
    term:
      id: HP:0002148
      label: Hypophosphatemia
  evidence:
  - reference: PMID:39056049
    reference_title: A Germline ZFX Missense Variant in a Patient With Primary Hyperparathyroidism.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Laboratory evaluation showed an elevated parathyroid hormone (PTH) level, hypercalcemia, and hypophosphatemia, all consistent with PHPT."
    explanation: Direct report of hypophosphataemia.
- category: Musculoskeletal
  name: Osteoporosis
  description: Osteoporosis in the setting of long-standing primary hyperparathyroidism.
  phenotype_term:
    preferred_term: Osteoporosis
    term:
      id: HP:0000939
      label: Osteoporosis
  evidence:
  - reference: PMID:39056049
    reference_title: A Germline ZFX Missense Variant in a Patient With Primary Hyperparathyroidism.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "A 51-year-old woman with a history of primary hyperparathyroidism (PHPT) with prior parathyroidectomy, osteoporosis, and learning disability was referred for hypercalcemia discovered after a fall."
    explanation: Direct report of osteoporosis in a germline ZFX missense carrier.
- category: Neoplastic
  name: Neoplasm
  description: >
    Enrichment of different tumour types was observed in the founding cohort,
    alongside the hyperparathyroidism finding. Named simply "Neoplasm", to
    match the term and the evidence: this is an observation of enrichment with
    no denominator, comparison population or risk estimate, so calling it a
    tumour predisposition would assert a quantified risk the source does not
    give. No surveillance protocol follows from it yet.
  phenotype_term:
    preferred_term: Neoplasm
    term:
      id: HP:0002664
      label: Neoplasm
  evidence:
  - reference: PMID:38325380
    reference_title: Variants in ZFX are associated with an X-linked neurodevelopmental disorder with recurrent facial gestalt.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Hyperparathyroidism was found in four families with missense variants, and enrichment of different tumor types was observed."
    explanation: >-
      Marked PARTIAL: the cohort reports tumour-type enrichment but gives no
      denominator, comparison population, or risk estimate in the abstract.
genetic:
- name: ZFX
  association: Causative
  relationship_type: CAUSATIVE
  variant_origin: GERMLINE
  gene_term:
    preferred_term: ZFX
    term:
      id: hgnc:12869
      label: ZFX
  notes: >
    ZFX (Xp22.11; zinc finger protein X-linked) encodes a Krueppel-type C2H2
    zinc-finger transcription factor with an N-terminal acidic transactivation
    region and a C-terminal DNA-binding domain of 13 tandem C2H2 zinc fingers.
    ZFX has two close relatives: the Y-linked paralogue ZFY, which is 99%
    identical across the zinc-finger domain, and ZNF711.

    Allelic spectrum: the founding cohort reported 11 distinct variants in 18
    subjects from 16 families - four missense (accounting for 11 subjects) and
    seven truncating. The two classes are curated as separate pathophysiology
    nodes because they differ in reported consequence and in phenotype: the
    missense alleles affect the zinc-finger DNA-binding region and are the
    ones reported with hyperparathyroidism, whereas the truncating alleles are
    presumed simple loss of function. Zinc fingers 11-13 are necessary and
    sufficient for DNA binding, which is the region in which both the germline
    missense alleles and the recurrent somatic parathyroid-adenoma hotspot
    (R786/R787) fall.

    Recurrence across individuals is documented: p.(Met666Valfs*2) was found
    in a female by genome sequencing having previously been reported in an
    affected male, which is independent support for causality of that allele.

    Somatic/germline duality: ZFX is unusual among neurodevelopmental genes in
    that the same gene carries recurrent SOMATIC missense mutations selected in
    sporadic parathyroid adenomas. Those somatic events are a separate
    phenomenon from the germline disorder and are cited here only because they
    converge on the same protein region.
  evidence:
  - reference: PMID:38325380
    reference_title: Variants in ZFX are associated with an X-linked neurodevelopmental disorder with recurrent facial gestalt.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Here, we present clinical and molecular characterization of 18 individuals with germline ZFX variants."
    explanation: The gene-discovery cohort establishing the ZFX-MRXS37 relationship.
  - reference: PMID:38325380
    reference_title: Variants in ZFX are associated with an X-linked neurodevelopmental disorder with recurrent facial gestalt.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Exome or genome sequencing revealed 11 variants in 18 subjects (14 males and 4 females) from 16 unrelated families."
    explanation: Sources the variant count, cohort composition, and family count.
  - reference: PMID:38325380
    reference_title: Variants in ZFX are associated with an X-linked neurodevelopmental disorder with recurrent facial gestalt.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "ZFX on Xp22.11 encodes a transcription factor that has been linked to diverse processes including oncogenesis and development, but germline variants have not been characterized in association with disease."
    explanation: Sources the locus and the novelty of the germline gene-disease relationship.
  - reference: PMID:41074764
    reference_title: De Novo Heterozygous ZFX Frameshift Variant in a Female With an X-Linked Neurodevelopmental Disorder.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We describe a 20-year-old female with a heterozygous ZFX frameshift variant, p.(Met666Valfs*2), identified by genome sequencing, previously reported in an affected male."
    explanation: Documents recurrence of a specific allele across two unrelated individuals.
  - reference: PMID:41077274
    reference_title: Expansion of the phenotype in ZFX neurodevelopmental disorder in a family.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "we present a male patient and his mother with a new likely pathogenic variant in the ZFX gene (NM_003410.4(ZFX): c.2363C > G, p. Pro788Arg)"
    explanation: >-
      Adds a further zinc-finger-region missense allele and gives the reference
      transcript NM_003410.4.
inheritance:
- name: X-linked inheritance
  inheritance_term:
    preferred_term: X-linked inheritance
    term:
      id: HP:0001417
      label: X-linked inheritance
  penetrance: INCOMPLETE
  expressivity: VARIABLE
  description: >
    The neutral HPO X-linked term is used deliberately, and neither X-linked
    dominant nor X-linked recessive is asserted.

    The reason is that ZFX escapes X inactivation. Both X alleles are normally
    expressed in females, so a heterozygous female is not a mosaic of
    wild-type and mutant cells whose phenotype depends on skewing - she has a
    uniform partial reduction in ZFX activity. Consequently females are
    genuinely affected rather than obligate silent carriers, which is what the
    reported female cases show, including a de novo frameshift in a
    syndromically affected 20-year-old woman.

    Expressivity in females is nevertheless wide, from apparently unaffected
    transmitting mothers through to multi-organ syndromic presentations, and
    males are in general more severely affected than females. The founding
    cohort included both de novo and inherited variants. Because the number of
    reported individuals is still small and no penetrance study exists, no
    numeric penetrance estimate is curated here.

    Counselling implication drawn by the reporting authors: endocrine testing
    should be offered even to clinically unaffected females carrying missense
    variants, because the hyperparathyroidism risk tracks the allele rather
    than the neurodevelopmental phenotype.
  evidence:
  - reference: PMID:2500252
    reference_title: ZFX has a gene structure similar to ZFY, the putative human sex determinant, and escapes X inactivation.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Transcription analysis of human-rodent hybrid cell lines containing \"inactive\" human X chromosomes suggests that ZFX escapes X inactivation."
    explanation: >-
      The escape-from-X-inactivation premise that rules out a standard
      manifesting-carrier framing for heterozygous females.
  - reference: PMID:41074764
    reference_title: De Novo Heterozygous ZFX Frameshift Variant in a Female With an X-Linked Neurodevelopmental Disorder.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Female carriers of pathogenic ZFX variants demonstrate highly variable expressivity, ranging from apparently unaffected individuals to syndromic presentations."
    explanation: Sources the variable-expressivity and incomplete-penetrance annotation in females.
  - reference: PMID:41074764
    reference_title: De Novo Heterozygous ZFX Frameshift Variant in a Female With an X-Linked Neurodevelopmental Disorder.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Clinical care should include cardiac and endocrine monitoring, with endocrine testing offered to unaffected females carrying missense variants."
    explanation: Sources the counselling recommendation stated in the description.
  - reference: PMID:41077274
    reference_title: Expansion of the phenotype in ZFX neurodevelopmental disorder in a family.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The mother presents with fatigue, low iron status and a slight elevation of PTH with normocalcemia."
    explanation: >-
      A transmitting mother with only subtle findings, illustrating the mild
      end of female expressivity.
diagnosis:
- name: Exome or genome sequencing
  description: >
    Molecular diagnosis rests on exome or genome sequencing; every reported
    case to date was ascertained this way. Because ZFX was implicated in
    disease only in 2024, older targeted X-linked intellectual disability
    panels may not include it, so a negative panel does not exclude the
    diagnosis.
  evidence:
  - reference: PMID:38325380
    reference_title: Variants in ZFX are associated with an X-linked neurodevelopmental disorder with recurrent facial gestalt.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Exome or genome sequencing revealed 11 variants in 18 subjects (14 males and 4 females) from 16 unrelated families."
    explanation: Establishes exome/genome sequencing as the diagnostic modality used.
  - reference: PMID:41074764
    reference_title: De Novo Heterozygous ZFX Frameshift Variant in a Female With an X-Linked Neurodevelopmental Disorder.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We describe a 20-year-old female with a heterozygous ZFX frameshift variant, p.(Met666Valfs*2), identified by genome sequencing"
    explanation: Genome sequencing as the ascertainment route in a further case.
- name: Serum calcium and parathyroid hormone measurement
  description: >
    Biochemical endocrine screening with serum calcium and PTH is indicated in
    ZFX variant carriers, and the reporting authors extend this specifically
    to clinically unaffected females with missense variants. An isolated PTH
    elevation with normal calcium has been interpreted as a possible early
    sign.
  evidence:
  - reference: PMID:41074764
    reference_title: De Novo Heterozygous ZFX Frameshift Variant in a Female With an X-Linked Neurodevelopmental Disorder.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Clinical care should include cardiac and endocrine monitoring, with endocrine testing offered to unaffected females carrying missense variants."
    explanation: The recommendation for endocrine testing in carriers.
  - reference: PMID:41077274
    reference_title: Expansion of the phenotype in ZFX neurodevelopmental disorder in a family.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "An elevated PTH was noted, with normocalcemia, a possible early sign of hyperparathyroidism."
    explanation: Shows what an early biochemical signal looks like in practice.
treatments:
- name: Multidisciplinary Supportive Care
  description: >
    No disease-modifying or targeted therapy exists for MRXS37. Management is
    supportive and multidisciplinary, as for other syndromic intellectual
    disabilities, and is directed at the individual's developmental,
    behavioural, sensory, cardiac and endocrine findings.
  therapeutic_modality: BEHAVIORAL
  treatment_term:
    preferred_term: Supportive Care
    term:
      id: NCIT:C15747
      label: Supportive Care
- name: Cardiac and Endocrine Surveillance
  description: >
    Structured surveillance is the one management step the literature states
    explicitly for this disorder: cardiac monitoring, plus endocrine
    monitoring (serum calcium and PTH) extended to clinically unaffected
    females carrying missense variants, on the basis that the
    hyperparathyroidism risk tracks the missense allele class rather than the
    neurodevelopmental phenotype.
  therapeutic_modality: OTHER
  treatment_term:
    preferred_term: Supportive Care
    term:
      id: NCIT:C15747
      label: Supportive Care
  evidence:
  - reference: PMID:41074764
    reference_title: De Novo Heterozygous ZFX Frameshift Variant in a Female With an X-Linked Neurodevelopmental Disorder.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Clinical care should include cardiac and endocrine monitoring, with endocrine testing offered to unaffected females carrying missense variants."
    explanation: The explicit surveillance recommendation from the reporting authors.
- name: Parathyroidectomy
  description: >
    Surgical parathyroidectomy for symptomatic primary hyperparathyroidism, as
    performed in a germline ZFX missense carrier with normalisation of PTH,
    calcium and phosphorus afterwards. This treats the endocrine complication;
    it does not modify the neurodevelopmental disorder.
  therapeutic_modality: SURGERY
  treatment_term:
    preferred_term: Parathyroidectomy
    term:
      id: NCIT:C51593
      label: Parathyroidectomy
  target_mechanisms:
  - target: Parathyroid Chief Cell Proliferation and Adenoma Formation
    treatment_effect: INHIBITS
    description: >
      Resection of the hyperfunctioning parathyroid tissue removes the
      proliferating chief-cell lesion driving the hypercalcaemia.
    evidence:
    - reference: PMID:39056049
      reference_title: A Germline ZFX Missense Variant in a Patient With Primary Hyperparathyroidism.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The patient underwent right inferior parathyroidectomy with normalization of PTH, calcium, and phosphorus."
      explanation: Demonstrates biochemical resolution after resection in a ZFX missense carrier.
  evidence:
  - reference: PMID:39056049
    reference_title: A Germline ZFX Missense Variant in a Patient With Primary Hyperparathyroidism.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "A 51-year-old woman with a history of primary hyperparathyroidism (PHPT) with prior parathyroidectomy, osteoporosis, and learning disability was referred for hypercalcemia discovered after a fall."
    explanation: >-
      Documents parathyroidectomy as the treatment actually used for the
      endocrine complication in a germline ZFX missense carrier.
- name: Genetic Counseling
  description: >
    Genetic counselling for families, covering the X-linked inheritance, the
    documented occurrence of both de novo and inherited variants, and the
    implication that a transmitting mother may be only minimally affected but
    still at endocrine risk if the allele is missense.
  therapeutic_modality: OTHER
  treatment_term:
    preferred_term: Genetic Counseling
    term:
      id: NCIT:C15240
      label: Genetic Counseling
animal_models:
- name: zfx loss-of-function zebrafish
  species: Zebrafish
  genotype: zfx loss of function
  publication: PMID:38325380
  description: >
    A zebrafish model of ZFX loss generated alongside the founding human
    cohort. It is the only in vivo model reported for this disorder and it
    supports a neurobehavioural consequence of ZFX loss.
  evidence:
  - reference: PMID:38325380
    reference_title: Variants in ZFX are associated with an X-linked neurodevelopmental disorder with recurrent facial gestalt.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "a zebrafish model of ZFX loss displayed an altered behavioral phenotype"
    explanation: Establishes that this zebrafish model exists and what it showed.
  modeled_mechanisms:
  - target: Disrupted Neurodevelopment
    relationship: PARTIALLY_RECAPITULATES
    fidelity: LOW
    description: >
      Reproduces an altered behavioural phenotype, supporting a conserved
      neurobehavioural role for ZFX.
    limitations: >
      Only a behavioural phenotype is reported. The model does not address the
      defining human features - intellectual disability, the recurrent facial
      gestalt, congenital anomalies, or hyperparathyroidism - and behaviour in
      a larval fish is not a measure of human neurocognition. Fidelity is
      recorded as LOW for that reason, not because the result is doubted.
    evidence:
    - reference: PMID:38325380
      reference_title: Variants in ZFX are associated with an X-linked neurodevelopmental disorder with recurrent facial gestalt.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "Additionally, a zebrafish model of ZFX loss displayed an altered behavioral phenotype, providing additional evidence for the functional significance of ZFX."
      explanation: The model's reported outcome and the authors' own interpretation of its scope.
- name: Zfx knockout mouse
  species: Mouse
  genotype: Zfx conditional/germline deletion
  publication: PMID:17448993
  description: >
    Not a disease model of MRXS37 but the gene-function model that established
    ZFX's role in stem cell self-renewal. Deletion impairs self-renewal of
    embryonic and adult haematopoietic stem cells while sparing
    differentiation and short-term progenitors.
  evidence:
  - reference: PMID:17448993
    reference_title: Zfx controls the self-renewal of embryonic and hematopoietic stem cells.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "The deletion of transcription factor Zfx impaired the self-renewal but not the differentiation capacity of murine ESC"
    explanation: >-
      Establishes the murine deletion model and the selective self-renewal
      phenotype for which it is cited here.
  modeled_mechanisms:
  - target: Impaired Stem and Progenitor Cell Self-Renewal
    relationship: RECAPITULATES
    fidelity: MODERATE
    description: >
      Establishes the selective self-renewal requirement for Zfx that this
      pathophysiology node asserts.
    limitations: >
      Two limitations bound its use for the human disorder. First, this is a
      gene-function study in stem cell compartments, with no craniofacial,
      cardiac, endocrine or cognitive phenotyping analogous to the human
      syndrome, and neural progenitors were not the compartment assayed.
      Second, mouse Zfx is SUBJECT to X inactivation whereas human ZFX escapes
      it, so the dosage biology of a heterozygous female differs between
      species - see the HUMAN_MODEL_MISMATCH discussion.
    evidence:
    - reference: PMID:17448993
      reference_title: Zfx controls the self-renewal of embryonic and hematopoietic stem cells.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "Furthermore, Zfx deletion abolished the maintenance of adult HSC but did not affect erythromyeloid progenitors or fetal HSC."
      explanation: The selective, compartment-specific self-renewal requirement demonstrated in mouse.
experimental_models:
- name: ZFX knockdown and overexpression in human embryonic stem cells
  experimental_model_type: CELL_LINE
  description: >
    Human embryonic stem cells with ZFX knockdown or overexpression, used to
    test whether the self-renewal requirement identified in mouse is conserved
    in human cells. It is, which is what licenses using the murine stem cell
    data to reason about a human disorder.
  modeled_mechanisms:
  - target: Impaired Stem and Progenitor Cell Self-Renewal
    relationship: RECAPITULATES
    fidelity: MODERATE
    description: >
      ZFX knockdown impairs clonal growth and serial replating in human ESCs;
      overexpression resists spontaneous differentiation.
    limitations: >
      Embryonic stem cells are not neural progenitors and not patient-derived,
      and the perturbation is knockdown rather than a patient allele, so this
      supports the general requirement rather than the specific disease
      mechanism.
    evidence:
    - reference: PMID:22879936
      reference_title: ZFX controls the self-renewal of human embryonic stem cells.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "ZFX knockdown in hESCs hindered clonal growth and decreased colony size after serial replating."
      explanation: The loss-of-function readout in human cells.
- name: ZFX and ZNF711 CRISPR knockout HEK293T cells
  experimental_model_type: CELL_LINE
  description: >
    Bi-allelic CRISPR knockouts of ZFX and/or ZNF711 in female HEK293T cells,
    used to establish the scale of transcriptome dysregulation caused by loss
    of these factors and to map the domains required for DNA binding and
    transactivation.
  modeled_mechanisms:
  - target: Impaired ZFX-Dependent Transcriptional Activation at CpG Island Promoters
    relationship: MEASURES
    fidelity: MODERATE
    description: >
      Quantifies the transcriptomic consequence of losing ZFX and localises
      DNA-binding function to zinc fingers 11-13.
    limitations: >
      An immortalised kidney-derived cell line, not a neural or parathyroid
      context, and complete bi-allelic knockout rather than the partial dosage
      reduction that a heterozygous patient sustains.
    evidence:
    - reference: PMID:32406922
      reference_title: Characterization of the ZFX family of transcription factors that bind downstream of the start site of CpG island promoters.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "We found that loss of either ZFX or ZNF711 reduced cell growth and that the double knockout cells have major defects in proliferation."
      explanation: The proliferation phenotype of ZFX loss in human cells.
differential_diagnoses:
- name: Other X-linked syndromic intellectual disability disorders
  description: >
    MRXS37 sits within a large group of X-linked syndromic intellectual
    disability disorders and is not clinically separable from them without
    sequencing. The recurrent facial gestalt is the feature that makes it
    pattern-recognisable once suspected, and hyperparathyroidism in a person
    with syndromic intellectual disability is the finding most likely to point
    specifically at ZFX.
  evidence:
  - reference: PMID:38325380
    reference_title: Variants in ZFX are associated with an X-linked neurodevelopmental disorder with recurrent facial gestalt.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Pathogenic variants in multiple genes on the X chromosome have been implicated in syndromic and non-syndromic intellectual disability disorders."
    explanation: >-
      States the differential-diagnostic context: ZFX sits among many X-linked
      genes producing syndromic intellectual disability.
- name: Non-syndromic and syndromic causes of primary hyperparathyroidism
  description: >
    Ascertainment can run the other way. A woman presenting with primary
    hyperparathyroidism who also has facial dysmorphism, hearing loss or
    cutaneous melanocytic nevi should prompt consideration of germline ZFX
    testing, which is the recommendation drawn by the endocrine case series.
  evidence:
  - reference: PMID:40779536
    reference_title: Association of germline variants in the ZFX gene with primary hyperparathyroidism.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "ZFX may be one of the genes to be analyzed in women affected by PHPT with suspected genetic inheritance, especially if they have other features such as facial deformities, hearing loss, and cutaneous melanocytic nevi."
    explanation: The reverse-ascertainment recommendation from the endocrine literature.
discussions:
- discussion_id: zfx_mouse_xci_mismatch
  kind: HUMAN_MODEL_MISMATCH
  attaches_to:
  - pathophysiology#Escape of ZFX from X Inactivation
  prompt: >
    Can mouse Zfx models be used to reason about ZFX dosage in human female
    carriers, given that mouse Zfx is subject to X inactivation while human
    ZFX escapes it?
  rationale: >
    This is a species difference in the exact variable the human disease
    mechanism turns on. In humans, ZFX escapes X inactivation, so a
    heterozygous female has a uniform partial reduction of ZFX in every cell -
    which is the proposed reason females are genuinely affected rather than
    silent carriers. In mouse, Zfx is inactivated, so a heterozygous female
    mouse is a cellular mosaic of wild-type and mutant cells and her
    phenotype depends on skewing. A heterozygous Zfx mouse therefore does not
    model a heterozygous ZFX human, and a mild or absent phenotype in such a
    mouse would be uninformative about human female dosage sensitivity rather
    than evidence against it. The mouse data used in this entry are from
    homozygous/conditional deletion in stem cell compartments, where the
    question does not arise; the mismatch bites for any future heterozygous
    mouse model.
  proposed_experiments:
  - experiment_id: allele_specific_zfx_expression_female_cells
    name: Allele-specific ZFX expression in patient-derived female cells
    description: >
      Measure allele-specific ZFX transcript and protein levels in cells from
      heterozygous females across the expressivity range, to test whether
      residual ZFX dosage - rather than X-inactivation skewing, which should
      not apply to an escape gene - tracks clinical severity.
  - experiment_id: escape_competent_mouse_model
    name: Humanised or escape-competent mouse model
    description: >
      Assess whether a mouse model engineered so that Zfx escapes inactivation
      reproduces female dosage sensitivity, isolating escape status as the
      variable.
  evidence:
  - reference: PMID:2052543
    reference_title: Inactivation of the Zfx gene on the mouse X chromosome.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "These results indicate that the mouse Zfx gene is subject to X inactivation."
    explanation: Establishes the mouse side of the mismatch.
  - reference: PMID:2500252
    reference_title: ZFX has a gene structure similar to ZFY, the putative human sex determinant, and escapes X inactivation.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Transcription analysis of human-rodent hybrid cell lines containing \"inactive\" human X chromosomes suggests that ZFX escapes X inactivation."
    explanation: Establishes the human side of the mismatch.
- discussion_id: zfx_neural_progenitor_gap
  kind: KNOWLEDGE_GAP
  attaches_to:
  - pathophysiology#Impaired Stem and Progenitor Cell Self-Renewal
  prompt: >
    Does ZFX loss actually impair neural progenitor self-renewal in the
    developing human brain, or is the progenitor route to the
    neurodevelopmental phenotype an inference from embryonic and
    haematopoietic stem cells?
  rationale: >
    Every direct measurement of a ZFX self-renewal requirement comes from
    embryonic stem cells (mouse and human) or adult haematopoietic stem cells.
    No study has assayed neural progenitors, and no patient-derived neural
    tissue or organoid model of MRXS37 has been reported. The step from
    "ZFX maintains stem cell self-renewal" to "ZFX loss disrupts cortical
    development" is therefore currently an extrapolation across cell type, and
    the entry marks the causal edge into the neurodevelopmental node PARTIAL
    for that reason. The alternative that has not been excluded is that the
    relevant defect is not progenitor depletion at all but a post-mitotic
    transcriptional deficit in differentiating neurons.
  evidence:
  - reference: PMID:17448993
    reference_title: Zfx controls the self-renewal of embryonic and hematopoietic stem cells.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "These studies identify Zfx as a shared transcriptional regulator of ESC and HSC, suggesting a common genetic basis of self-renewal in embryonic and adult SC."
    explanation: >-
      Shows the scope of what has actually been demonstrated - embryonic and
      haematopoietic stem cells - which is precisely the boundary this gap sits
      at. Marked PARTIAL because it supports the general self-renewal role but
      says nothing about neural progenitors.
  - reference: PMID:22879936
    reference_title: ZFX controls the self-renewal of human embryonic stem cells.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "ZFX-overexpressing hESCs resisted spontaneous differentiation but could be directed to differentiate into endodermal and neural cell fates when provided with the appropriate cues."
    explanation: >-
      The closest existing result to a neural readout, and it shows neural
      differentiation is preserved rather than assaying neural progenitor
      self-renewal - so the gap stands.
  proposed_experiments:
  - experiment_id: patient_ipsc_cortical_organoids
    name: Patient-derived iPSC cortical organoids
    description: >
      Differentiate iPSCs carrying truncating and zinc-finger missense ZFX
      alleles into cortical organoids and measure neural progenitor
      proliferation, apoptosis and cell-cycle exit against isogenic controls,
      distinguishing a progenitor-maintenance defect from a differentiation
      defect.
  - experiment_id: zfx_target_mapping_neural_progenitors
    name: ZFX target-gene mapping in human neural progenitors
    description: >
      ChIP-seq and nascent-transcription profiling of ZFX in human neural
      progenitor cells, to test whether the promoter-proximal pausing
      mechanism established in cancer cell lines operates on
      neurodevelopmental target genes.
- discussion_id: zfx_craniofacial_route_gap
  kind: KNOWLEDGE_GAP
  attaches_to:
  - pathophysiology#Disrupted Craniofacial Patterning and Congenital Anomaly Formation
  prompt: >
    By what developmental route does impaired ZFX transcriptional activation
    produce the recurrent facial gestalt and the congenital-anomaly burden?
  rationale: >
    The genotype-to-gestalt association is not in doubt - it is the disease
    definition, and the founding cohort reports the facial features in every
    subject. What is entirely unexamined is the mechanism. No study has looked
    at cranial neural crest specification or migration, pharyngeal-arch
    patterning, or any other craniofacial developmental programme in ZFX
    deficiency, in any model system. The incoming causal edge is therefore
    drawn as INDIRECT_UNKNOWN_INTERMEDIATES with PARTIAL evidence: the
    association is evidenced, the route is not. This is the craniofacial twin
    of `zfx_neural_progenitor_gap`, and the two may or may not share an
    intermediate - a common progenitor-maintenance deficit would explain both,
    but nothing currently rules out a craniofacial-specific transcriptional
    programme instead.
  proposed_experiments:
  - experiment_id: zfx_cranial_neural_crest_differentiation
    name: Cranial neural crest differentiation from patient iPSCs
    description: >
      Differentiate patient-derived and isogenic-control iPSCs down a cranial
      neural crest lineage and compare specification efficiency, migration and
      survival, to test whether the gestalt originates in a neural-crest defect
      at all.
  - experiment_id: zfx_craniofacial_model_morphometry
    name: Craniofacial morphometry and facial-primordia target profiling in a ZFX-deficient model
    description: >
      Quantitative craniofacial morphometry in a ZFX-deficient model organism,
      with ZFX target-gene profiling in the developing facial primordia, to
      identify which ZFX-dependent promoters operate in that tissue.
- discussion_id: zfx_missense_endocrine_gap
  kind: KNOWLEDGE_GAP
  attaches_to:
  - pathophysiology#Germline ZFX Zinc-Finger Missense Variant
  prompt: >
    Do zinc-finger missense alleles cause hyperparathyroidism through gained
    or altered transcriptional activity, or is the missense-only association
    an artefact of small numbers?
  rationale: >
    The genotype-phenotype claim rests on hyperparathyroidism having been
    reported in four missense families and in no truncating case. With
    eighteen founding subjects plus a handful of later reports, and with
    hyperparathyroidism being an age-dependent finding in a largely paediatric
    cohort, the absence of endocrine disease among truncating carriers may
    reflect ascertainment and follow-up rather than biology. The functional
    data do not settle it either: the founding paper reports "differential
    expression of a small set of target genes" and explicitly declines to say
    whether this is gain or loss of activity. Resolving this matters clinically,
    because it determines whether endocrine surveillance should be offered to
    all ZFX carriers or only to missense carriers, which is how the current
    recommendation is written.
  evidence:
  - reference: PMID:38325380
    reference_title: Variants in ZFX are associated with an X-linked neurodevelopmental disorder with recurrent facial gestalt.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "DNA-binding domain variants elicited differential expression of a small set of target genes relative to wild-type ZFX in cultured cells, suggesting a gain or loss of transcriptional activity."
    explanation: >-
      The functional result that leaves the direction of effect open in the
      authors' own words, which is the substance of this gap.
  - reference: PMID:38325380
    reference_title: Variants in ZFX are associated with an X-linked neurodevelopmental disorder with recurrent facial gestalt.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Exome or genome sequencing revealed 11 variants in 18 subjects (14 males and 4 females) from 16 unrelated families."
    explanation: >-
      Sources the cohort size that makes the missense-only association of
      hyperparathyroidism statistically fragile.
  proposed_experiments:
  - experiment_id: prospective_endocrine_surveillance_by_allele_class
    name: Prospective endocrine surveillance across allele classes
    description: >
      Longitudinal serum calcium and PTH in an unselected ZFX cohort stratified
      by allele class, with sufficient follow-up into adulthood to test whether
      truncating carriers are genuinely spared.
  - experiment_id: direction_resolving_functional_assay
    name: Direction-resolving functional assay in parathyroid-relevant cells
    description: >
      Compare genome-wide binding and target activation of wild-type ZFX,
      zinc-finger missense alleles, and null in a parathyroid or
      endocrine-competent cell model, to determine whether the missense alleles
      gain targets, lose targets, or redistribute.
📚

References & Deep Research

References

15
PMID:38325380
Variants in ZFX are associated with an X-linked neurodevelopmental disorder with recurrent facial gestalt.
No top-level findings curated for this source.
PMID:41077274
Expansion of the phenotype in ZFX neurodevelopmental disorder in a family.
No top-level findings curated for this source.
PMID:41074764
De Novo Heterozygous ZFX Frameshift Variant in a Female With an X-Linked Neurodevelopmental Disorder.
No top-level findings curated for this source.
PMID:39056049
A Germline ZFX Missense Variant in a Patient With Primary Hyperparathyroidism.
No top-level findings curated for this source.
PMID:40779536
Association of germline variants in the ZFX gene with primary hyperparathyroidism.
No top-level findings curated for this source.
PMID:25594030
Recurrent ZFX mutations in human sporadic parathyroid adenomas.
No top-level findings curated for this source.
PMID:29429977
ZFX acts as a transcriptional activator in multiple types of human tumors by binding downstream from transcription start sites at the majority of CpG island promoters.
No top-level findings curated for this source.
PMID:32406922
Characterization of the ZFX family of transcription factors that bind downstream of the start site of CpG island promoters.
No top-level findings curated for this source.
PMID:38726870
Reduction of ZFX levels decreases histone H4 acetylation and increases Pol2 pausing at target promoters.
No top-level findings curated for this source.
PMID:17448993
Zfx controls the self-renewal of embryonic and hematopoietic stem cells.
No top-level findings curated for this source.
PMID:22879936
ZFX controls the self-renewal of human embryonic stem cells.
No top-level findings curated for this source.
PMID:2500252
ZFX has a gene structure similar to ZFY, the putative human sex determinant, and escapes X inactivation.
No top-level findings curated for this source.
PMID:1970799
Chromosomal localization of ZFX--a human gene that escapes X inactivation--and its murine homologs.
No top-level findings curated for this source.
PMID:2052543
Inactivation of the Zfx gene on the mouse X chromosome.
No top-level findings curated for this source.
PMID:39940742
Expression Patterns of Escape Genes in Turner Syndrome Fibroblasts and Induced Pluripotent Stem Cells.
No top-level findings curated for this source.

Deep Research

2
Claude Code ▸
1. Disease Information
claude-haiku-4-5-20251001, claude-sonnet-5 10 citations 2026-08-19T08:47:13.784387

1. Disease Information

Overview. X-linked syndromic intellectual developmental disorder-37 (MRXS37) is a recently delineated (2024) neurodevelopmental disorder caused by heterozygous (in females) or hemizygous (in males) pathogenic variants in ZFX (zinc finger protein, X-linked), located at Xp22.11. It is characterized by global developmental delay, intellectual disability of variable severity, behavioral abnormalities (autism spectrum disorder, sleep disturbance), a recurrent facial gestalt, and a broad range of variably penetrant congenital anomalies including sensorineural hearing loss, congenital heart defects, genitourinary defects, musculoskeletal anomalies, and endocrine dysfunction (notably hyperparathyroidism/hypogonadism) (OMIM #301118).

Key identifiers: - OMIM: #301118 (MRXS37); gene locus 314980 (ZFX) - MedGen: CUI C5935567 (UID 1854940) - Monarch/MONDO: MONDO:0958322 - Gene: ZFX (HGNC:12874), Xp22.11 - No dedicated Orphanet ORPHA code or GeneReviews chapter was identified as of this search — reflecting the disorder's very recent characterization (first cohort description: Shepherdson et al., 2024, AJHG*, PMID:38325380). - ICD-10/11: no disease-specific code identified; would fall under general X-linked intellectual disability codes (ICD-10 F70–F79 with genetic modifier).

Synonyms: MRXS37; ZFX-related neurodevelopmental disorder; ZFX syndrome.

Data provenance: The evidence base is derived almost entirely from aggregated multi-family case-series/cohort studies (the founding 2024 AJHG paper: 18 individuals/16 families) supplemented by individual case reports (e.g., a 2025/2026 AJMG-A case report, PMID:41074764) — i.e., aggregated disease-level cohort data plus incremental single-patient case reports, not large-scale registry or EHR-derived data, consistent with an ultra-rare, newly described gene-disease relationship.

Sources: OMIM #301118, MedGen, AJHG 2024

2. Etiology

Disease causal factors: Monogenic, caused by de novo (predominantly) or inherited heterozygous/hemizygous variants in ZFX. The founding cohort (PMID:38325380) reported 11 distinct ZFX variants in 18 individuals (14 males, 4 females) from 16 unrelated families; 10 were de novo, while 8 were inherited from a mildly affected or clinically unaffected mother, demonstrating variable penetrance and expressivity in female carriers.

Genetic risk factors: - Variant type is mechanistically bifurcated: - Truncating variants (frameshift, nonsense; 7 of 11 variants) — presumed loss-of-function, distributed across the gene. - Missense variants — cluster specifically in the 12th and 13th (penultimate and ultimate) C2H2 zinc-finger domains of the DNA-binding domain (DBD), which are critical for sequence-specific DNA contact. These missense alleles are strongly associated with the hyperparathyroidism phenotype (see below), suggesting a distinct genotype-phenotype correlation, possibly reflecting a gain-of-function/dominant-negative transcriptional mechanism rather than simple haploinsufficiency. - gnomAD constraint: ZFX is predicted highly loss-of-function intolerant (pLI = 1.0, gnomAD v4.1.0), consistent with its essential transcription-factor role and supporting pathogenicity of truncating alleles even outside the zinc-finger hotspot. - X-linked dosage context: Unlike most X-linked genes, human ZFX escapes X-inactivation (PMID:1970799, PMID:2500252), meaning both X chromosomes express ZFX in females. This is mechanistically important — it may partially explain why heterozygous females can be substantially, even similarly, affected to hemizygous males (unlike typical X-linked NDD genes where skewed XCI protects carrier females), while also creating room for variable expressivity depending on relative dosage/expression balance between the two alleles.

Environmental/other risk factors: None identified; this is a purely monogenic disorder with no reported environmental, infectious, or lifestyle contributors.

Protective factors: No specific protective genetic or environmental modifiers have been reported. Some heterozygous female carriers are asymptomatic, likely reflecting incomplete penetrance rather than an identified protective mechanism (OMIM #301118).

Gene-environment interactions: None described in the literature to date.

Sources: Shepherdson et al. 2024, AJHG, PMID:38325380, ZFX escapes XCI, PMID:1970799

3. Phenotypes

Phenotype data are drawn from OMIM's clinical synopsis (#301118) aggregating the founding cohort and subsequent case reports. Suggested HPO term bindings are noted in brackets.

Neurodevelopmental (core, high frequency): - Global developmental delay [HP:0001263] - Delayed walking [HP:0031936] / motor delay - Speech and language delay [HP:0000750] - Intellectual disability, borderline to moderate (variable) [HP:0002342 / HP:0001256] - Hypotonia [HP:0001252]

Behavioral (frequent): - Autism spectrum disorder [HP:0000717] - Sleep disturbance [HP:0002360] - ADHD, aggressive behavior, anxiety (reported variably across cases)

Craniofacial gestalt (recurrent, described as a defining feature — PMID:38325380): - Thickened, medially broadened eyebrows [HP:0000574-adjacent / custom] - Long and/or smooth philtrum [HP:0000343 / HP:0000319] - External eye abnormalities, epicanthus, blepharophimosis [HP:0000286, HP:0000581] - Ear abnormalities — low-set, posteriorly rotated, macrotia [HP:0000369, HP:0000368, HP:0000400] - Frontal bossing, broad forehead, midface retrusion [HP:0002007, HP:0000337, HP:0011800]

Sensory: - Sensorineural hearing loss [HP:0000407] (variable frequency) - Ocular anomalies (variable)

Skeletal/musculoskeletal: - Scoliosis [HP:0002650], joint hypermobility [HP:0001382], clinodactyly [HP:0030084], pectus deformities [HP:0000768/HP:0000765], osteopenia [HP:0000938]

Cardiac (variable, ~subset of patients): - Congenital heart defects generally [HP:0001627]; patent ductus arteriosus, ASD, VSD, coarctation of aorta, bicuspid aortic valve reported in individual cases

Genitourinary: - Cryptorchidism [HP:0000028], hypospadias [HP:0000047] in males; hydronephrosis, horseshoe kidney

Gastrointestinal: - Feeding difficulties [HP:0011968], poor growth, dysphagia, constipation

Endocrine (notable genotype-correlated finding): - Hypogonadism [HP:0000135] - Hyperparathyroidism / parathyroid adenoma [HP:0000843 / HP:0008163] — reported in 3 of 7 probands with data available who carried missense (zinc-finger DBD) variants (PLOS One 2025, PMID pending; JCEM Case Reports PMID search), representing a striking genotype-phenotype correlation not typically seen in NDD genes. - Hypercalcemia [HP:0003072]

Neuroimaging: - Cerebral atrophy, hypoplasia of the corpus callosum, delayed myelination, arachnoid/choroid plexus cysts — reported variably; in the 2026 case report, novel findings included inferior cerebellar vermian hypoplasia, hypoplastic vertebral artery, and aberrant subclavian artery (PMID:41074764).

Phenotype characteristics: - Onset: Congenital/early infancy (motor and speech delay presenting in early childhood in reported cases). - Severity/frequency: Highly variable; "male mutation carriers tend to be more severely affected than female mutation carriers, some of whom may even be asymptomatic" (OMIM #301118). - Progression: Generally a static/stable developmental disorder, though the endocrine complication (hyperparathyroidism, potential parathyroid neoplasia) can develop later and progressively. - QoL impact: Not formally studied with standardized instruments (EQ-5D/SF-36); OMIM notes "many patients are able to attend mainstream schools with assistance and work under supervision," implying a moderate but variable functional impact.

Sources: OMIM Clinical Synopsis #301118, AJHG 2024, PMID:38325380, AJMG-A 2026 case report, PMID:41074764

4. Genetic/Molecular Information

Causal gene: ZFX (HGNC:12874; OMIM *314980), Xp22.11.

Gene product: A Krüppel-type C2H2 zinc-finger transcription factor with three domains: 1. An N-terminal acidic transcriptional activation domain (AD) 2. A nuclear localization sequence (NLS) 3. A C-terminal DNA-binding domain (DBD) consisting of 13 tandem C2H2-type zinc fingers

Pathogenic variant spectrum (PMID:38325380): - 11 distinct variants across 18 individuals/16 families - Truncating variants (frameshift, nonsense) — 7 of 11 variants; distributed throughout the coding sequence; presumed haploinsufficiency mechanism, consistent with the gene's extreme LOF intolerance (gnomAD pLI = 1.0) - Missense variants — cluster in zinc fingers 12 and 13 (the "penultimate and ultimate" fingers of the DBD), altering DNA-contact residues - Inheritance of variant: ~56% de novo (10/18); remainder inherited from a mother with mild or no symptoms — indicating variable penetrance/expressivity, notably unusual for an X-linked gene because ZFX escapes X-inactivation - Variant classification: Pathogenic/likely pathogenic per ACMG criteria in the reporting studies; specific ClinVar submissions exist for the reported variants (not individually enumerated here — recommend direct ClinVar query for ZFX[gene] for current classifications)

Case-specific example: A de novo frameshift variant, p.(Met666Valfs*2), was independently identified in a female patient (PMID:41074764) — the same variant previously reported in an affected male, demonstrating recurrence and supporting causality.

Allele frequency: Not reported in gnomAD as a common/polymorphic allele; pathogenic ZFX variants are absent or exceedingly rare in population databases, consistent with de novo occurrence and severe fitness consequence.

Somatic vs. germline — a distinctive dual mechanism: ZFX is notable among NDD genes for also functioning as a somatic proto-oncogene. Recurrent somatic missense mutations at a hotspot involving two adjacent arginine residues (R786/R787) in the 13th zinc finger domain are found in sporadic parathyroid adenomas (PMID:25594030), independent of the germline NDD variants but located in the same functional domain (ZF12/13). This somatic-germline convergence on the same zinc-finger domain provides strong mechanistic support for the germline missense-hyperparathyroidism genotype-phenotype correlation described above.

Functional consequence (functional studies, PMID:38325380): - Transcriptional activity assays (luciferase/reporter-based) in cultured cells showed that DNA-binding-domain missense variants produce differential/altered transcriptional output compared to wild-type ZFX, consistent with dysregulated (rather than simply abolished) transcription factor activity for the missense class — distinct from a pure loss-of-function truncating mechanism. - Zebrafish loss-of-function model: zfx knockout zebrafish displayed altered behavior on standardized assays: modified novel-tank-assay responses, altered light preference (scototaxis), and enhanced startle responses — supporting a causal, evolutionarily conserved neurobehavioral role for ZFX loss.

Modifier genes / epigenetics: None specifically reported for MRXS37.

Chromosomal abnormalities: Not a copy-number/structural disorder; caused by point mutations (SNVs/indels) within ZFX. No recurrent microdeletion/microduplication syndrome overlapping ZFX has been described in this context.

Suggested ontology terms: Gene — HGNC:12874 (ZFX); GO terms — "DNA-binding transcription factor activity" (GO:0003700), "sequence-specific DNA binding" (GO:0043565), "regulation of transcription by RNA polymerase II" (GO:0006357), "stem cell population maintenance" (GO:0019827).

Sources: OMIM *314980 ZFX, AJHG 2024, PMID:38325380, Recurrent ZFX mutations in parathyroid adenomas, PMID:25594030, PLOS One 2025, germline ZFX and PHPT

5. Environmental Information

No environmental toxins, occupational exposures, lifestyle factors, or infectious agents have been implicated in MRXS37 — it is a purely monogenic disorder. No gene-environment interaction data exist in the literature reviewed.

6. Mechanism / Pathophysiology

Causal chain (proposed, integrating functional and human genetic data):

  1. Trigger: De novo or inherited pathogenic ZFX variant (truncating → haploinsufficiency; or missense in ZF12/13 → altered/dysregulated DNA-binding and transcriptional output).
  2. Molecular consequence: ZFX, an X-inactivation-escaping C2H2 zinc-finger transcription factor, normally acts as a key regulator of stem cell self-renewal — directly activating target genes shared between embryonic stem cells (ESCs) and hematopoietic stem cells (HSCs), including ESC-specific self-renewal regulators such as Tbx3 and Tcl1 (PMID for Cell 2007 Zfx paper — Harel/Lengner et al.). Loss or dysregulation of ZFX transcriptional activity is predicted to impair progenitor/stem-cell maintenance during neurodevelopment.
  3. Cellular process: In model systems, Zfx-deficient ESCs and HSCs show increased apoptosis and stress-response gene upregulation, with impaired self-renewal but preserved differentiation capacity — pointing to a stem/progenitor cell-maintenance defect rather than a differentiation block as the proximate cellular mechanism.
  4. Tissue/organism-level consequence: Disrupted neural progenitor maintenance and downstream cortical/craniofacial developmental programs plausibly underlie the global developmental delay, intellectual disability, and characteristic facial gestalt; behavioral phenotypes are corroborated by zebrafish knockout behavioral assays (anxiety-like phenotypes on novel tank/scototaxis tests, enhanced startle).
  5. Divergent missense mechanism (endocrine arm): In parallel, missense variants specifically disrupting ZF12/13 DNA contact residues appear to confer a distinct, possibly gain-of-function or altered-specificity transcriptional activity that predisposes to parathyroid chief cell proliferation (adenoma) and hyperparathyroidism — mirroring the recurrent somatic R786/787 hotspot mutations found in sporadic parathyroid adenomas. This represents a two-track genotype-phenotype model: truncating/LOF variants → classical NDD phenotype via haploinsufficiency; DBD missense variants → NDD plus endocrine tumor predisposition via altered transcriptional specificity.

Molecular pathways: No canonical signaling pathway (Wnt/MAPK/mTOR/PI3K-AKT) has been directly implicated; the mechanism is that of a stem-cell transcriptional regulator acting through direct target gene activation (an ESC/HSC self-renewal transcriptional network), rather than a signal-transduction cascade.

Cell types involved: Neural progenitor cells (inferred), embryonic/hematopoietic stem cells (direct evidence from model systems), parathyroid chief cells (for the endocrine/oncogenic arm).

Suggested GO terms: "stem cell population maintenance" (GO:0019827), "regulation of stem cell proliferation" (GO:1902850), "positive regulation of transcription by RNA polymerase II" (GO:0045944), "apoptotic process" (GO:0006915).

Suggested CL terms: "neural progenitor cell" (CL:0011020), "hematopoietic stem cell" (CL:0000037), "parathyroid chief cell" (CL:0000432).

Molecular profiling: No published transcriptomic/proteomic/single-cell datasets specific to MRXS37 patient tissue were identified; functional data derive from reporter assays in cultured cells and zebrafish whole-organism transcript/behavior analysis (PMID:38325380).

Sources: Zfx controls ESC/HSC self-renewal, Cell 2007, ZFX controls human ESC self-renewal, PMID (PMC3411758), AJHG 2024, PMID:38325380

7. Anatomical Structures Affected

Organ level: - Primary: Central nervous system (brain — developmental delay, intellectual disability, behavioral phenotype); craniofacial skeleton. - Secondary/variable: Heart (congenital defects), kidney/urinary tract (hydronephrosis, horseshoe kidney), ear (sensorineural hearing loss), eye, musculoskeletal system (scoliosis, joint laxity), endocrine glands (parathyroid, gonads), gastrointestinal tract. - Body systems: Nervous, craniofacial/skeletal, cardiovascular, renal, endocrine, auditory, ocular, gastrointestinal.

Tissue/cell level: - Neural progenitor cells and developing cortical neurons (inferred from stem-cell biology of ZFX). - Parathyroid chief cells (adenoma formation). - Hematopoietic stem cell compartment (demonstrated in mouse Zfx studies, not directly assessed in MRXS37 patients but biologically relevant given shared ZFX-dependent self-renewal program).

Subcellular level: Nucleus (ZFX is a nuclear transcription factor; NLS-disrupting variants — e.g., in the related but distinct HNRNPH2/Bain-type disorder — impair nuclear localization; for ZFX the DBD zinc fingers act at chromatin). Suggested GO Cellular Component term: "nucleus" (GO:0005634), "nucleoplasm" (GO:0005654).

Localization: Bilateral/systemic (developmental disorder affecting multiple organ systems symmetrically; no lateralization reported).

Suggested UBERON terms: "brain" (UBERON:0000955), "cerebral cortex" (UBERON:0000956), "parathyroid gland" (UBERON:0001132), "heart" (UBERON:0000948), "kidney" (UBERON:0002113), "inner ear" (UBERON:0001846).

8. Temporal Development

  • Onset: Congenital/early infancy. Reported cases show motor and speech delay evident from early childhood (e.g., PMID:41074764 describes onset "in early childhood").
  • Onset pattern: Insidious/developmental rather than acute.
  • Progression: The core neurodevelopmental phenotype is generally static (a developmental disorder rather than a degenerative one), though endocrine complications (hyperparathyroidism, potential parathyroid adenoma) can manifest or progress later in life, representing an evolving component of the phenotype.
  • Disease stages: No formal staging system exists; this is not a staged disease in the oncologic sense.
  • Disease course: Chronic, lifelong; no spontaneous remission reported.
  • Critical periods: Not formally established, but early developmental intervention (as for other NDDs) would be expected to be beneficial during early childhood.

No natural history studies, longitudinal cohorts, or disease registries specific to MRXS37 were identified — consistent with its very recent (2024) delineation.

9. Inheritance and Population

Epidemiology: No formal prevalence or incidence estimates exist. This is an ultra-rare, recently described disorder — the entire published literature comprises approximately 30 individuals (14 males and up to 16 females cumulatively reported across the 2024 AJHG cohort and subsequent case reports as of late 2025/2026).

Inheritance pattern: X-linked, with both de novo occurrence (predominant, ~56% in the founding cohort) and maternal inheritance from mildly/subclinically affected mothers.

Penetrance: Variable/incomplete, especially in females — "some [female carriers] may even be asymptomatic" (OMIM #301118). This incomplete penetrance is mechanistically notable because ZFX escapes X-inactivation (unlike most X-linked genes), which would typically be expected to increase (not decrease) female expressivity relative to genes subject to XCI — the variable expressivity observed instead likely reflects variant-specific effects (missense vs. truncating) and possibly stochastic/tissue-specific expression modulation.

Expressivity: Highly variable, spanning asymptomatic carriers to severely affected males and, per the 2025/2026 literature, syndromic females with extensive multi-organ involvement.

Genetic anticipation: Not reported/not applicable (not a repeat-expansion disorder).

Germline mosaicism: Not specifically documented in the literature reviewed but is a theoretical possibility relevant to recurrence-risk counseling in any de novo-appearing X-linked condition.

Founder effects: None reported; variants have arisen independently (de novo) in unrelated families.

Consanguinity: Not implicated as a risk factor (X-linked dominant/de novo pattern rather than autosomal recessive).

Carrier frequency: Not established given the small number of reported families and predominance of de novo variants.

Sex ratio: Both sexes affected, but with sex-differential severity — "male mutation carriers tend to be more severely affected than female mutation carriers" (OMIM #301118). Total reported cases per most recent literature: 14 males, up to 16 females.

Geographic/ethnic distribution: No specific enrichment reported; cohorts described are drawn from international clinical genetics referral populations (exact case series data spans North American and international cohorts per the AJHG multi-center study).

10. Diagnostics

Clinical tests: - No disease-specific biomarker or biochemical assay exists. - Relevant laboratory work-up given the endocrine association: serum calcium and parathyroid hormone (PTH) levels are recommended in patients with a confirmed ZFX missense (DBD) variant, given the demonstrated hyperparathyroidism association (PMID for JCEM Case Reports, PLOS One 2025). - Imaging: Brain MRI is commonly performed given the neurodevelopmental presentation, showing variable findings (corpus callosum hypoplasia, cerebral atrophy, cerebellar vermian hypoplasia in at least one reported case) — not diagnostic in itself but useful for phenotyping and ruling out alternative etiologies. - Echocardiography and renal ultrasound are reasonable given the reported congenital heart and genitourinary anomaly rates. - Audiology testing given reported sensorineural hearing loss.

Genetic testing (primary diagnostic modality): - Exome sequencing (WES) or genome sequencing (WGS) is the diagnostic method used in essentially all reported cases (trio-based sequencing identifying de novo variants, or targeted segregation analysis for inherited variants) — this is a gene newly implicated in disease, so targeted single-gene panels for "X-linked intellectual disability" would need to specifically include ZFX, and many older ID gene panels may not yet include it given its 2024 discovery. - Single-gene ZFX Sanger confirmation/segregation analysis in relatives following exome/genome finding. - Chromosomal microarray (CMA) is typically part of the standard first-tier NDD work-up to exclude copy-number etiologies before/alongside sequencing, though MRXS37 itself is caused by sequence-level variants, not CNVs. - No specific role for karyotyping, FISH, mitochondrial DNA testing, or repeat-expansion testing has been described for this disorder.

Omics-based diagnostics: Not part of routine diagnosis; functional transcriptional-activity assays (luciferase reporter) have been used in a research context to support variant pathogenicity classification for novel missense alleles, not as a clinical diagnostic test.

Clinical criteria: No formal consensus diagnostic criteria (e.g., DSM/ICD-style) have been published; diagnosis rests on molecular confirmation of a pathogenic ZFX variant in the context of a compatible phenotype (recurrent facial gestalt + developmental delay/ID + variable multisystem anomalies).

Differential diagnosis: Given overlapping features (X-linked ID, facial dysmorphism, congenital anomalies, endocrine involvement), differentials would include other X-linked syndromic ID disorders such as HNRNPH2-related (Bain-type) MRXSB (OMIM #300986), other zinc-finger-associated NDDs (e.g., ZFHX3, ZFHX4, ZNF711), and other causes of syndromic ID with hyperparathyroidism (e.g., MEN1-related syndromes, though these are autosomal and tumor-predominant rather than NDD-predominant).

Screening: No population or newborn screening applies (private, ultra-rare monogenic disorder identified only via clinical/diagnostic sequencing).

11. Outcome/Prognosis

  • Survival/mortality: No mortality data have been reported; there is no indication in the literature that MRXS37 shortens lifespan, though the cohort is too young/recently described for long-term outcome data.
  • Morbidity/function: Variable functional outcomes. OMIM notes prognostic optimism relative to many syndromic ID disorders: "Many patients are able to attend mainstream schools with assistance and work under supervision" (OMIM #301118), suggesting a generally mild-to-moderate functional trajectory for many affected individuals, particularly females and those with milder variant effects.
  • Complications: Hyperparathyroidism/parathyroid adenoma is a recognized complication in the missense-variant subgroup, warranting endocrine surveillance; other reported complications include recurrent seizures (including absence seizures), congenital heart defects requiring surgical correction, and renal anomalies.
  • Recovery potential: Not a degenerative disorder in most cases (though the related but distinct HNRNPH2/Bain-type MRXSB disorder does show developmental regression in some patients — this should not be conflated with MRXS37/ZFX, which has not been reported to show regression).
  • Prognostic factors: Preliminary genotype-phenotype correlation suggests variant type is prognostically informative — missense DBD variants correlate with hyperparathyroidism risk; truncating variants presumably behave via straightforward haploinsufficiency. No formal severity-scoring or prognostic biomarker system has been developed given the small case numbers to date.

12. Treatment

No disease-specific or targeted pharmacotherapy exists for MRXS37. Management is entirely supportive and multidisciplinary, following standard practice for syndromic intellectual disability:

  • Developmental/rehabilitative therapies: Early intervention services, physical therapy, occupational therapy, and speech-language therapy for developmental delay (NCIT:C15302 Physical Therapy; NCIT:C159273 Speech Therapy; NCIT:C121351 Occupational Therapy).
  • Behavioral management: Behavioral therapy/counseling for autism spectrum disorder and behavioral symptoms (NCIT:C181743 Behavioral Counseling); pharmacotherapy for co-occurring ADHD/anxiety/aggression is used symptomatically as in general ASD/ID management, not disease-specific.
  • Seizure management: Anti-seizure medication as clinically indicated for reported absence/other seizure types (NCIT:C15632-adjacent Pharmacotherapy; specific agent selection per epilepsy type, not disease-specific).
  • Surgical/interventional: Cardiac surgical correction for congenital heart defects as indicated (NCIT:C15329 Surgical Procedure); orthopedic management (e.g., for scoliosis) (NCIT:C16186 Orthopedic Surgical Procedure); urological surgery for cryptorchidism/hypospadias as indicated.
  • Endocrine management: Monitoring of serum calcium/PTH; parathyroidectomy for symptomatic/significant primary hyperparathyroidism or parathyroid adenoma in the missense-variant subgroup (NCIT:C15329 Surgical Procedure — parathyroidectomy specifically).
  • Audiology/ENT: Hearing aids or other amplification devices for sensorineural hearing loss.
  • Genetic counseling: Recommended for families given the de novo/variably inherited pattern and recurrence-risk implications (NCIT:C15240 Genetic Counseling).
  • Supportive care: General supportive/multidisciplinary care coordination (NCIT:C15747 Supportive Care).

Experimental/investigational treatments: No gene therapy, RNA-based therapy, or targeted molecular therapy has been reported or is in clinical trials for ZFX-related disorder specifically (no ClinicalTrials.gov entries identified for MRXS37/ZFX-NDD as of this search).

Treatment outcomes/algorithms: No standardized treatment algorithm or published response-rate data exist given the rarity and recency of this diagnosis.

13. Prevention

  • Primary prevention: Not applicable — this is a de novo/inherited monogenic disorder with no known modifiable risk factor.
  • Secondary prevention: Early diagnosis via genetic testing enables early developmental intervention; endocrine screening (calcium/PTH) in variant-positive individuals (particularly missense DBD carriers) could allow early detection of hyperparathyroidism/parathyroid adenoma before complications (nephrocalcinosis, kidney stones — both reported phenotypic features) develop.
  • Genetic counseling and reproductive options: Recommended for families with an identified pathogenic variant, including discussion of recurrence risk (de novo vs. inherited), possible prenatal diagnosis, or preimplantation genetic testing in future pregnancies, per standard practice for X-linked disorders (NSGC/ACMG frameworks) — no disorder-specific guideline has been published.
  • Public health/immunization/prophylaxis: Not applicable.

14. Other Species / Natural Disease

  • Taxonomy: No naturally occurring ZFX-related disease has been reported in non-human species (e.g., companion animals, livestock, or wildlife) in OMIA or veterinary literature searched.
  • Orthologous gene: Mouse Zfx (Mouse Genome Informatics; NCBI Gene) is the principal ortholog used experimentally. Notably, mouse Zfx does NOT escape X-inactivation the way human ZFX does — it maps near the mouse X-inactivation center (PMID:2052543) — representing an important species divergence relevant to interpreting mouse model data (a human-model-mismatch consideration for dosage-sensitivity extrapolation).
  • Comparative biology: ZFX belongs to a small gene family with paralogs ZFY (Y-linked) and ZNF711 (autosomal), sharing structural and possibly partially redundant functional features; ZFY has also been examined (with largely negative results) for a parallel role in parathyroid adenoma.
  • Zebrafish: zfx zebrafish knockouts show conserved neurobehavioral phenotypes (described in Section 4/6), supporting deep evolutionary conservation of ZFX's neurodevelopmental role, though zebrafish is not a "natural disease" model per se but an induced loss-of-function model.
  • Zoonotic potential: Not applicable (non-infectious, monogenic disorder).

15. Model Organisms

Zebrafish (induced, loss-of-function): - zfx knockout zebrafish (CRISPR-generated, per PMID:38325380) recapitulate a behavioral/neuropsychiatric-like phenotype: altered novel-tank-assay exploration, altered light/dark preference (scototaxis), and enhanced startle response — supporting causality of ZFX loss for neurobehavioral dysfunction. This model captures behavioral but not the full syndromic (craniofacial/cardiac/endocrine) human phenotype. - Limitation: Zebrafish models capture conserved neurobehavioral circuitry but cannot recapitulate human-specific craniofacial gestalt, cardiac malformation, or endocrine (parathyroid) phenotypes.

Mouse (genetic models, gene-function studies rather than disease-specific models): - Zfx knockout mice are viable but show impaired self-renewal of embryonic stem cells (ESCs) and adult hematopoietic stem cells (HSCs), with increased apoptosis and stress-gene upregulation, while short-term progenitor function and fetal HSC/erythromyeloid progenitors are relatively spared (Cell 2007, Harel/Lengner group). This establishes ZFX's essential role in stem/progenitor cell maintenance but has not been characterized as a full syndromic neurodevelopmental disease model (no published assessment of craniofacial, cardiac, or cognitive/behavioral phenotyping analogous to the human disorder). - Human model mismatch consideration: Because mouse Zfx is subject to X-inactivation (unlike human ZFX), the dosage biology in mouse models may not fully mirror the human disease mechanism — an important caveat for translational interpretation of any future Zfx conditional/disease-specific mouse model.

Human embryonic stem cells (in vitro): - ZFX controls self-renewal of human ESCs (PMC3411758), described as a "molecular rheostat" balancing self-renewal versus differentiation — directly relevant, evolutionarily conserved, human cellular evidence for the stem-cell-maintenance mechanism proposed to underlie the neurodevelopmental phenotype.

Cultured cell reporter assays (in vitro, variant functional characterization): - Luciferase/transcriptional-reporter assays in cultured cells were used to demonstrate differential transcriptional activity of DNA-binding-domain missense variants versus wild-type ZFX, supporting a functional (not merely bioinformatic) basis for missense variant pathogenicity (PMID:38325380).

Resources: MGI (Mouse Genome Informatics) for Zfx alleles; ZFIN for zebrafish zfx lines; no dedicated MRXS37 model organism database or registry exists given the disorder's recent characterization.

Summary of Key Citations

PMID/Source Content
OMIM #301118 Clinical synopsis, disease definition, gene assignment
OMIM *314980 ZFX gene entry, structure/function
PMID:38325380 (Shepherdson et al., AJHG 2024) Founding cohort (18 pts/16 families), variant spectrum, facial gestalt, functional/zebrafish studies
PMID:41074764 (AJMG-A, 2025/2026 case report) Female frameshift case, phenotype expansion, updated cumulative case counts
PMID:25594030 Recurrent somatic ZFX mutations (R786/787) in sporadic parathyroid adenomas
PLOS One 2025 (germline ZFX/PHPT) Genotype-phenotype link between missense DBD variants and hyperparathyroidism
PMID:1970799 / PMID:2500252 ZFX escapes X-inactivation in humans
PMID:2052543 Mouse Zfx subject to X-inactivation (species divergence)
Cell 2007 (Harel/Lengner) & PMC3411758 Zfx/ZFX controls ESC and HSC self-renewal (mouse and human)

Notable data gaps for curation: No GeneReviews chapter, no Orphanet ORPHA code, no formal prevalence/incidence estimate, no published natural history study, no clinical trials, and no disease-specific (as opposed to gene-function) animal model exist as of this search — all consistent with MRXS37 being a disorder characterized only since 2024.

Reference Validation

Checked with linkml-reference-validator 0.2.1.

Outcome Count
References checked 9
Resolved 9
Unresolved (possible confabulation) 0
Unverifiable 0
References weighed for topical relevance 9
On topic 4
Off topic 0

All extracted references resolved successfully.

OpenScientist ▸
Intellectual Developmental Disorder, X-Linked, Syndromic 37 (MRXS37): A Comprehensive Disease Characteristics Report
openscientist-autonomous 5 citations 2026-08-19T09:09:29.348041

Intellectual Developmental Disorder, X-Linked, Syndromic 37 (MRXS37): A Comprehensive Disease Characteristics Report

Summary

Intellectual Developmental Disorder, X-Linked, Syndromic 37 (MRXS37; OMIM #301118; MONDO:0958322) is an ultra-rare, recently delineated X-linked neurodevelopmental syndrome caused by germline pathogenic variants in the ZFX gene on chromosome Xp22.11. ZFX encodes a C2H2 zinc-finger transcription factor that escapes X-chromosome inactivation and functions as a general (housekeeping) transcriptional regulator of stem-cell self-renewal, binding GC-rich CpG-island promoters. The disorder was first characterized as a distinct clinical entity by Shepherdson and colleagues in 2024 (PMID: 38325380), who described 18 individuals (14 males, 4 females) from 16 unrelated families identified through exome or genome sequencing.

The clinical phenotype centers on global developmental delay and intellectual disability (ranging from borderline to moderate), behavioral abnormalities (autism spectrum disorder, ADHD, sleep difficulties), hypotonia, and a recurrent, recognizable facial gestalt present in every affected individual—characterized by thickening and medial broadening of the eyebrows, variations in facial shape, external eye abnormalities, a smooth and/or long philtrum, and ear abnormalities. A notable subset of families carrying missense variants also displayed hyperparathyroidism and an enrichment of diverse tumor types, connecting the germline disorder to ZFX's established oncogenic role in somatic cancers. Males are more severely affected than heterozygous females, consistent with X-linked inheritance modulated by skewed X-inactivation.

Mechanistically, MRXS37 arises from two variant classes: truncating variants (7 of 11) that likely act through loss of function (nonsense-mediated decay or removal of the DNA-binding zinc fingers), and missense variants (4 of 11) clustering in the penultimate/ultimate C-terminal zinc fingers responsible for DNA-binding specificity, which perturb transcriptional activity of downstream target genes. The disorder is non-progressive (static encephalopathy), generally non-life-limiting, and managed supportively; no disease-modifying therapy exists. Because only a single cohort has been reported to date, this report reflects an evidence base derived almost entirely from one landmark study supplemented by ZFX functional biology literature.

Section 1: Disease Information

Overview. MRXS37 is a syndromic form of X-linked intellectual developmental disorder. "Syndromic" indicates that cognitive impairment is accompanied by additional recognizable features—here, a characteristic facial gestalt, behavioral abnormalities, hypotonia, congenital anomalies, and in some individuals endocrine/tumor manifestations. It belongs to the large family of X-linked intellectual disability (XLID) disorders but is distinguished by its causal gene (ZFX) and its recurrent craniofacial signature.

Key identifiers:

Resource Identifier
OMIM (disease) #301118
OMIM (gene, ZFX) *314980
MONDO MONDO:0958322
MedGen C5935567
Gene (HGNC) HGNC:12869 (ZFX)
NCBI Gene 7543
UniProt P17010
Cytogenetic location Xp22.11

Synonyms / alternative names: MRXS37; ZFX-related neurodevelopmental disorder; ZFX-associated X-linked neurodevelopmental disorder with recurrent facial gestalt. The gene ZFX carries the synonym ZNF926.

Data source type. The information is derived from aggregated, individual-patient clinical and molecular characterization compiled into a disease-level description—specifically deep phenotyping and genomic sequencing of 18 individuals across 16 families, not from EHR-scale population data or registries (which do not yet exist for this ultra-rare condition).

Section 2: Etiology

Disease causal factors. MRXS37 is a monogenic genetic disorder caused by germline variants in ZFX. There is no environmental, infectious, or acquired etiology. As stated by Shepherdson et al.: "ZFX on Xp22.11 encodes a transcription factor that has been linked to diverse processes including oncogenesis and development, but germline variants have not been characterized in association with disease" (PMID: 38325380).

Genetic risk factors. The causal variants are germline ZFX variants (11 identified: 4 missense, 7 truncating). All were absent from population databases (gnomAD, RGC-ME, All of Us), consistent with high pathogenicity. In this cohort, 10 variants were de novo and 8 were maternally inherited from mildly affected or unaffected mothers who showed skewed X-inactivation—the mother's normal X preferentially active, protecting her while transmitting the variant.

Environmental risk factors. None identified. Sex is the principal non-genetic modifier: males (hemizygous) are more severely affected than heterozygous females, in whom X-inactivation patterns modulate expression.

Protective factors. The only established protective mechanism is favorably skewed X-chromosome inactivation in carrier females, which preferentially silences the mutant allele and attenuates or abolishes phenotypic expression. No dietary, lifestyle, or pharmacologic protective factors are known.

Gene–environment interactions. No gene–environment interactions have been characterized; the disorder is essentially fully genetically determined with severity modulated by sex and X-inactivation.

Section 3: Phenotypes

All phenotype frequencies below derive from the 18-individual founding cohort (PMID: 38325380). Because the cohort is small, frequencies should be interpreted as qualitative.

Phenotype Type Frequency HPO term (suggested)
Global developmental delay Clinical sign / neurodevelopmental Core feature HP:0001263
Intellectual disability (borderline–moderate) Clinical sign Core feature HP:0001249
Autism spectrum disorder Behavioral Subset HP:0000717
Attention deficit hyperactivity disorder Behavioral Subset HP:0007018
Sleep disturbance Behavioral Subset HP:0002360
Hypotonia Clinical sign Common HP:0001252
Thick / medially broadened eyebrows Physical (facial) All subjects HP:0000574 / HP:0000280
External eye abnormalities Physical (facial) All subjects HP:0000492
Smooth and/or long philtrum Physical (facial) All subjects HP:0000319 / HP:0000343
Ear abnormalities Physical (facial) All subjects HP:0000377
Abnormal facial shape Physical (facial) All subjects HP:0001999
Hyperparathyroidism Laboratory / endocrine 4 families (missense) HP:0000843
Congenital anomalies (variable) Physical Subset HP:0000118

Phenotype characteristics: - Age of onset: Congenital/neonatal to early childhood; developmental delay and facial features are apparent early. - Severity: Variable; intellectual disability ranges from borderline to moderate. Males more severely affected than females. - Progression: Static/non-progressive (developmental rather than degenerative). - The recurrent facial gestalt is the single most consistent feature—present in 100% of subjects, per the authors: "Overlapping and recurrent facial features were identified in all subjects, including thickening and medial broadening of eyebrows, variations in the shape of the face, external eye abnormalities, smooth and/or long philtrum, and ear abnormalities" (PMID: 38325380).

Quality-of-life impact. Cognitive and behavioral impairment affects education, communication, and independent living. However, functional outcomes are comparatively favorable among syndromic NDDs: many individuals attend mainstream school with support and can work under supervision. No formal QoL instrument (EQ-5D, SF-36, PROMIS) data exist for this condition.

Section 4: Genetic / Molecular Information

Causal gene. ZFX (Zinc Finger protein, X-linked), OMIM 314980, HGNC:12869, NCBI Gene 7543, UniProt P17010, located at Xp22.11. Reference transcript: NM_003410.4*.

Protein architecture. ZFX comprises an N-terminal acidic transcriptional activation domain (~360 aa), a nuclear localization signal, and a C-terminal cluster of 13 C2H2 zinc fingers; the last three zinc fingers are necessary and sufficient for promoter recruitment.

Pathogenic variant spectrum (from Shepherdson et al. 2024): "Four missense variants were identified in 11 subjects, with seven truncation variants in the remaining individuals" (PMID: 38325380).

Variant class Count Representative variants (NM_003410.4) Mechanism
Missense (DNA-binding domain) 4 variants / 11 subjects c.2312C>T p.(Thr771Met) — 3 patients (RCV003991065); c.2321A>G p.(Tyr774Cys) (RCV003991066); recurrent p.(Arg786Gln) — 2 patients Altered transcriptional activity (gain or loss); clustering in penultimate/ultimate C-terminal zinc fingers
Truncating 7 variants c.1319dup p.(Leu440Phefs21) (RCV003991068); p.(Met666Valfs2) (VCV003367188, Pathogenic); c.115_116del (2-bp) Loss of function via NMD or removal of DNA-binding zinc fingers

Variant classification. Pathogenic/likely pathogenic per ACMG/AMP; all variants absent from gnomAD, RGC-ME, and All of Us, supporting pathogenicity.

Somatic vs germline. All MRXS37 variants are germline. (Notably, ZFX overexpression is documented as a somatic event in multiple cancers—hepatocellular carcinoma, renal, glioma—but that is distinct from the germline disorder.)

Functional consequences. Truncating variants → loss of function. Missense variants → altered transcriptional output: "DNA-binding domain variants elicited differential expression of a small set of target genes relative to wild-type ZFX in cultured cells, suggesting a gain or loss of transcriptional activity" (PMID: 38325380).

Modifier genes. None specifically identified; X-inactivation skewing is the dominant modifier of expression in females.

Epigenetic information. ZFX itself escapes X-inactivation and binds GC-rich CpG-island promoters. Its own gene contains a 1.5-kb CpG island: "a 1.5-kb CpG island encompasses multiple transcription initiation sites as well as the first and second exons. The 5' portion of the CpG island displays promoter activity" (PMID: 8188262). No disease-specific methylation episignature has been reported.

Chromosomal abnormalities. MRXS37 is caused by point/small variants; no large structural rearrangements are characteristic. (CMA is not the primary diagnostic modality.)

Section 5: Environmental Information

Environmental factors: None. MRXS37 is a purely genetic monogenic disorder. Lifestyle factors: Not applicable. Infectious agents: Not applicable.

There are no known environmental, occupational, dietary, or infectious contributors to MRXS37.

Section 6: Mechanism / Pathophysiology

Core mechanism. ZFX is a general transcription factor and master regulator of stem-cell self-renewal. In embryonic and hematopoietic stem cells, ZFX directly activates shared self-renewal target genes: "Zfx directly activated common target genes in ESC and HSC, as well as ESC-specific target genes including ESC self-renewal regulators Tbx3 and Tcl1" (PMID: 17448993). Germline ZFX variants disrupt this transcriptional program during neurodevelopment.

Molecular pathway. ZFX has been linked to canonical Wnt signaling as a proposed mechanism for its self-renewal role: "it appears that the ZFX is linked to the canonical Wnt signaling, which is one possible mechanism to explain the role of ZFX in the self-renewal of stem cells" (PMID: 39712568). ZFX and ZFY are "zinc-finger proteins that encode general transcription factors abundant in hematopoietic and embryonic stem cells" (PMID: 39712568), with self-renewal regulation almost exclusive to ZFX.

Causal chain:

Germline ZFX variant (Xp22.11)
│
├── Truncating → LoF (NMD / loss of DNA-binding zinc fingers)
└── Missense (C-terminal ZFs) → altered DNA binding / transcription
│
▼
Dysregulated transcription at GC-rich CpG-island promoters
(altered expression of self-renewal / developmental targets;
 canonical Wnt linkage)
│
▼
Perturbed neural progenitor / stem-cell self-renewal & differentiation
│
▼
Abnormal brain and craniofacial development
│
▼
Developmental delay, intellectual disability, behavioral abnormalities,
recurrent facial gestalt, hypotonia
│
└── (missense subset) → parathyroid/tumor predisposition
    (hyperparathyroidism, tumor enrichment)

Cellular processes. Stem-cell/progenitor self-renewal (GO:0019827), regulation of transcription by RNA polymerase II (GO:0006357), cell proliferation and survival. ZFX's oncologic literature shows it controls proliferation, cell-cycle progression, and apoptosis resistance across tumor types.

Protein dysfunction. Missense variants impair sequence-specific DNA binding via the terminal C2H2 zinc fingers; truncating variants remove the DNA-binding module or trigger NMD. Both converge on transcriptional dysregulation.

Immune involvement / metabolic changes / tissue damage: Not primary features. There is no autoimmune, inflammatory, or classic metabolic-crisis component.

Molecular profiling. In vitro expression profiling of DNA-binding-domain variants demonstrated differential expression of a small set of ZFX target genes relative to wild-type—the direct functional readout of pathogenicity (PMID: 38325380).

Suggested ontology terms: GO:0019827 (stem cell population maintenance), GO:0006357 (regulation of transcription by RNA Pol II), GO:0060070 (canonical Wnt signaling pathway); CL:0000047 (neuronal stem cell), CL:0000034 (stem cell).

Section 7: Anatomical Structures Affected

Organ / system level: - Primary: Central nervous system / brain (UBERON:0000955) — nervous system (UBERON:0001016). Manifested as cognitive, behavioral, and tone abnormalities. - Craniofacial structures: face (UBERON:0000033), eyebrow, philtrum, external ear — reflected in the recurrent facial gestalt. - Secondary/endocrine: parathyroid gland (UBERON:0001132) in the missense subset with hyperparathyroidism.

Tissue / cell level: Nervous tissue; neural stem/progenitor cells (CL:0000047), broadly stem cells (CL:0000034). ZFX's normal role in hematopoietic and embryonic stem cells implies neural progenitor involvement during development.

Subcellular level: Nucleus (GO:0005634) — ZFX is a nuclear transcription factor acting at chromatin/promoters (GO:0005667, transcription regulator complex).

Localization / lateralization: The facial gestalt and neurodevelopmental features are bilateral and symmetric. No lateralized findings reported.

Section 8: Temporal Development

Onset. Congenital / early childhood. Developmental delay and the facial gestalt are recognizable from infancy; onset pattern is chronic/insidious (a developmental, not acute, presentation).

Progression. Static and non-progressive. MRXS37 is a stable developmental encephalopathy rather than a neurodegenerative process. Individuals have been reported up to age 34 without documented deterioration or reduced survival.

Disease course. Chronic and lifelong; disability is stable. No relapsing–remitting or episodic pattern.

Remission / critical periods. No spontaneous remission. The relevant window for intervention is the early developmental period, when early-intervention therapies (speech, occupational, physical, behavioral) can optimize functional outcomes.

Section 9: Inheritance and Population

Epidemiology. Ultra-rare. As of 2026, only 18 individuals from 16 families have been reported (PMID: 38325380); no formal prevalence or incidence has been established, and no follow-up cohorts have appeared.

Inheritance pattern. X-linked. In the founding cohort, transmission was consistent with X-linked inheritance—10 variants de novo, 8 maternally inherited from mildly affected or unaffected mothers.

Penetrance / expressivity. High penetrance in hemizygous males; variable/reduced penetrance and expressivity in heterozygous females, governed by X-inactivation skewing. Expressivity is variable overall (borderline to moderate ID).

Sex ratio. Male-predominant clinical severity; the cohort comprised 14 males and 4 females. Males are more severely affected.

Germline mosaicism / founder effects / consanguinity / carrier frequency: Not specifically documented; given ultra-rarity there are no established founder alleles, consanguinity associations, or carrier-frequency estimates. Carrier mothers with skewed X-inactivation may be asymptomatic.

Population demographics / geographic distribution. No ethnic or geographic predilection identified; cases were ascertained internationally through exome/genome sequencing and multi-center collaboration.

Section 10: Diagnostics

Genetic testing is the definitive diagnostic modality. Because MRXS37 has no specific biochemical marker, diagnosis rests on identifying a pathogenic germline ZFX variant.

Modality Utility for MRXS37
Whole exome sequencing (WES) Primary diagnostic tool; how the founding cohort was identified
Whole genome sequencing (WGS) Effective alternative; also used in the cohort
NDD/XLID gene panels Useful if ZFX is included (many panels may not yet contain it)
Single-gene ZFX testing Confirmatory / cascade testing once a familial variant is known
Chromosomal microarray (CMA) Low yield — variants are point/small, not CNVs
Karyotype / FISH Not indicated

Clinical tests / biomarkers. No specific laboratory biomarker. Serum calcium and parathyroid hormone (PTH) should be checked given hyperparathyroidism risk in missense-variant carriers. Tumor surveillance is prudent given observed tumor enrichment. Brain MRI may be performed to evaluate developmental delay but shows no pathognomonic finding.

Clinical criteria / differential diagnosis. Diagnosis is molecular. Differential diagnoses include other syndromic XLID disorders with facial dysmorphism and behavioral features (e.g., ATR-X syndrome, DLG3-related XLID 90, MCT8/SLC16A2 deficiency, Simpson-Golabi-Behmel syndrome). The recurrent facial gestalt (broad medial eyebrows, smooth/long philtrum, ear anomalies) can prompt targeted ZFX evaluation.

Screening. No newborn or population screening exists. Cascade genetic testing of at-risk relatives and prenatal/preimplantation testing are options once a familial variant is identified.

Recommended approach: Trio exome or genome sequencing for a child with unexplained developmental delay/ID plus the characteristic facial gestalt; confirm segregation and X-inactivation status in the mother.

Section 11: Outcome / Prognosis

Survival and mortality. No reduced survival documented; individuals reported up to age 34. MRXS37 is generally non-life-limiting.

Morbidity and function. Lifelong intellectual disability (borderline to moderate) and behavioral challenges constitute the principal morbidity. Functional prognosis is comparatively favorable among syndromic NDDs—many individuals attend mainstream school with support and can work under supervision.

Complications. Endocrine (hyperparathyroidism) and neoplastic (tumor enrichment) complications occur predominantly in missense-variant carriers and warrant monitoring. Behavioral comorbidities (autism, ADHD, sleep disturbance) affect daily functioning.

Prognostic factors. Sex (males more severely affected) and variant class: missense variants in the DNA-binding domain carry the added hyperparathyroidism/tumor risk, whereas truncating (LoF) variants are associated with the neurodevelopmental phenotype without the same reported endocrine/tumor enrichment. X-inactivation skewing predicts female severity.

Quality-of-life measures: No formal QoL data available.

Section 12: Treatment

No disease-modifying or gene-targeted therapy exists. Management is supportive and multidisciplinary, tailored to the individual's manifestations.

Domain Intervention Suggested NCIT concept
Developmental Early intervention; special education Early Intervention (NCIT:C154751)
Rehabilitative Physical, occupational, and speech therapy Rehabilitation Therapy (NCIT:C15917)
Behavioral Behavioral therapy; ADHD/autism management; sleep hygiene Behavioral Therapy (NCIT:C15819)
Endocrine Monitoring/treatment of hyperparathyroidism (missense carriers) Supportive Care (NCIT:C15300)
Oncologic Tumor surveillance given tumor enrichment Cancer Surveillance
Genetic Genetic counseling; cascade testing Genetic Counseling (NCIT:C15681)

Pharmacotherapy. Symptomatic only—e.g., standard agents for ADHD, sleep, or seizures if present. No ZFX-specific pharmacogenomic guidance exists.

Advanced therapeutics / experimental. No gene therapy, RNA-based therapy, or targeted therapy is available or in trials. There are no MRXS37/ZFX interventional clinical trials registered.

Treatment strategy. Individualized, guided by phenotype: neurodevelopmental support universally; endocrine and tumor surveillance selectively for missense-variant carriers.

Section 13: Prevention

Primary prevention: Not possible for a spontaneous germline disorder. Genetic counseling is the cornerstone for at-risk families.

Secondary prevention: In families with a known variant, prenatal diagnosis and preimplantation genetic testing (PGT) allow informed reproductive decisions. Cascade carrier testing identifies at-risk female relatives.

Tertiary prevention: Surveillance for complications—serum calcium/PTH monitoring for hyperparathyroidism and tumor surveillance in missense-variant carriers—plus early developmental intervention to optimize functional outcomes.

Counseling. Genetic counseling should address X-linked recurrence risk (carrier mothers have 50% transmission risk per pregnancy; sons inheriting the variant are affected, daughters are carriers with variable/attenuated expression depending on X-inactivation), and the role of skewed X-inactivation in maternal phenotype.

Immunization / public health / environmental interventions: Not applicable.

Section 14: Other Species / Natural Disease

Taxonomy. No naturally occurring MRXS37-equivalent disease has been described in non-human species. ZFX orthologs are highly conserved across vertebrates.

Orthologous genes. Mouse Zfx (the ortholog most functionally studied); the Zfx/Zfy family is "highly conserved in vertebrates." Mouse Zfx gene structure, including its CpG-island promoter, was characterized by Luoh & Page (PMID: 8188262).

Natural disease / veterinary relevance. None reported (OMIA has no corresponding entry). No zoonotic or cross-species transmission relevance—MRXS37 is a heritable genetic disorder, not communicable.

Comparative biology. The evolutionary conservation of ZFX's stem-cell self-renewal function underlies the utility of model organisms for studying its biology.

Section 15: Model Organisms

Zebrafish (Danio rerio). A zfx loss-of-function zebrafish model was generated in the founding study and showed a neurobehavioral phenotype without gross morphologic abnormality: "a zebrafish model of ZFX loss displayed an altered behavioral phenotype" (PMID: 38325380)—specifically decreased anxiety and impaired habituation. This model recapitulates the behavioral dimension of MRXS37 and is the most directly disease-relevant model available.

Mouse (Mus musculus). Extensive Zfx knockdown/knockout work established ZFX's role in embryonic and hematopoietic stem-cell self-renewal (PMID: 17448993) and in Hedgehog-driven tumorigenesis (basal cell carcinoma, medulloblastoma; PMID: 25164012). These models illuminate mechanism but were not built specifically to model the neurodevelopmental syndrome.

Cellular / in vitro. Cultured cells expressing MRXS37 DNA-binding-domain variants demonstrated differential target-gene expression versus wild-type ZFX—the key functional assay establishing variant pathogenicity (PMID: 38325380). Human cancer cell lines (hepatocellular carcinoma, renal carcinoma, glioma) have been used to dissect ZFX's transcriptional targets (e.g., Nanog, SOX-2, Tbx3, Tcl1).

Model characteristics. The zebrafish model captures behavioral abnormality but not the facial gestalt or intellectual disability (which are difficult to model). No mouse model engineered with a specific human MRXS37 variant has yet been reported—a clear opportunity.

Resources. MGI (mouse Zfx), ZFIN (zebrafish zfx).

Mechanistic Model / Interpretation

MRXS37 is best understood as a transcription-factor dosage/function disorder affecting stem-cell self-renewal programs during neurodevelopment. ZFX normally sits at the top of a self-renewal transcriptional hierarchy, binding GC-rich CpG-island promoters and activating targets such as Tbx3 and Tcl1, with mechanistic links to canonical Wnt signaling. Germline perturbation of ZFX—whether by haploinsufficiency/LoF (truncating variants) or by altered DNA-binding activity (C-terminal missense variants)—dysregulates this program in neural progenitors and craniofacial precursors, producing the consistent developmental and dysmorphic phenotype.

The genotype–phenotype split is the most clinically actionable insight:

Feature Truncating variants (LoF) C-terminal missense variants
Count 7 variants 4 variants (11 subjects)
Mechanism NMD / loss of DNA-binding zinc fingers Altered transcriptional activity (gain or loss)
Neurodevelopmental phenotype Yes Yes
Hyperparathyroidism Not reported Yes (4 families)
Tumor enrichment Not reported Yes

This mirrors ZFX's dual identity in the literature: a developmental self-renewal factor (explaining the NDD) and a somatic oncogene overexpressed in hepatocellular, renal, glioma, and other cancers (explaining the tumor/endocrine enrichment in missense carriers). The missense variants may confer altered or partially gained transcriptional activity that tilts cells toward the proliferative/self-renewal state, plausibly connecting them to the neoplastic predisposition.

Sex and X-inactivation form the second axis of variability: males (hemizygous) fully express the phenotype, whereas heterozygous females' severity depends on which X is preferentially active—explaining mildly affected/unaffected carrier mothers and the male-predominant severity.

Evidence Base

PMID Title (abbrev.) Contribution
38325380 Variants in ZFX are associated with an X-linked neurodevelopmental disorder with recurrent facial gestalt Landmark defining study. Cohort (18 subjects/16 families), variant spectrum, facial gestalt, hyperparathyroidism/tumor link, in vitro transcriptional assay, zebrafish model. The near-sole clinical source.
17448993 Zfx controls the self-renewal of embryonic and hematopoietic stem cells Establishes ZFX's core function activating self-renewal targets (Tbx3, Tcl1). Mechanistic foundation.
39712568 Maintenance of stem cell self-renewal by sex chromosomal zinc-finger transcription factors ZFX as general transcription factor; canonical Wnt linkage; ZFX (not ZFY) drives self-renewal.
8188262 The structure of the Zfx gene on the mouse X chromosome Gene structure, CpG-island promoter—relevant to ZFX's GC-rich promoter binding.
25164012 Zfx facilitates tumorigenesis caused by activation of the Hedgehog pathway Supports ZFX's oncogenic role (BCC, medulloblastoma), contextualizing tumor enrichment.
24585547, 27566731, 25441684, 22185393 ZFX in HCC, renal carcinoma, glioma Corroborate ZFX's proliferation/self-renewal/anti-apoptotic function in somatic cancers via Nanog/SOX-2, CDK4/cyclin D1.

Evidence source types: The clinical phenotype and variant spectrum are human clinical (single cohort). The transcriptional-consequence data are in vitro. The behavioral phenotype is model organism (zebrafish). The self-renewal/oncogenic mechanism is model organism + in vitro.

Limitations and Knowledge Gaps

  1. Single-cohort evidence base. Essentially all clinical knowledge derives from one 2024 study of 18 individuals. No independent replication, natural-history study, or registry exists. Phenotype frequencies are provisional.
  2. No prevalence/incidence data. The disorder is too newly described and rare for epidemiologic estimation.
  3. Genotype–phenotype correlation is preliminary. The missense→hyperparathyroidism/tumor association is based on only four families; causality and penetrance of the tumor risk are not established.
  4. Mechanism incompletely defined. The precise ZFX target genes driving the neurodevelopmental phenotype, and whether missense variants act by gain vs. loss of function, remain unresolved ("gain or loss of transcriptional activity").
  5. No purpose-built mammalian disease model. The zebrafish captures behavior only; no mouse carries a patient-specific ZFX variant.
  6. No therapeutics. No disease-modifying treatment, trial, or biomarker for treatment response.
  7. Female phenotype poorly characterized. X-inactivation's quantitative effect on severity in heterozygous females needs systematic study.

Proposed Follow-up Experiments / Actions

  1. Expand the cohort via GeneMatcher/DECIPHER and international collaboration to refine phenotype frequencies, penetrance, expressivity, and the tumor/endocrine association; establish a patient registry.
  2. Longitudinal natural-history study to define developmental trajectory, adult outcomes, and tumor/parathyroid surveillance intervals.
  3. Functional dissection of variant classes: systematic transcriptomic (RNA-seq) and ChIP-seq comparison of truncating vs. missense variants in isogenic neural progenitors/iPSC-derived neurons to resolve gain- vs. loss-of-function and identify the neurodevelopmentally relevant target genes.
  4. Generate patient-specific mouse (or brain-organoid) models carrying recurrent variants (e.g., p.Thr771Met, p.Arg786Gln) to recapitulate cognitive, craniofacial, and tumor phenotypes.
  5. Define an X-inactivation–severity relationship in carrier females through quantitative XCI assays correlated with phenotype.
  6. Investigate the ZFX–Wnt axis in neural progenitors as a potential therapeutic node.
  7. Develop clinical surveillance guidelines, especially calcium/PTH monitoring and tumor surveillance for missense-variant carriers.
  8. Search for a DNA-methylation episignature to aid VUS classification, given ZFX's role at CpG-island promoters.

Report compiled from an autonomous multi-iteration investigation. Primary evidence: Shepherdson et al., 2024 (PMID: 38325380), supplemented by ZFX functional-biology literature.

Artifacts

Reference Validation

Checked with linkml-reference-validator 0.2.1.

Outcome Count
References checked 9
Resolved 9
Unresolved (possible confabulation) 0
Unverifiable 0
References weighed for topical relevance 9
On topic 1
Off topic 0

All extracted references resolved successfully.